

UPHEALTH GROUP LIMITED
(Formerly known as DON AGRO INTERNATIONAL LIMITED)

2025 ANNUAL REPORT

This annual report has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this annual report, including the correctness of any of the statements or opinions made or reports contained in this annual report. The contact person for the Sponsor is Mr Shervyn Essex, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.

CONTENTS

Contents	2
Chairman's Message	3
Board of Directors	5
Key Management Personnel	7
Financial Review	8
Corporate Information	11
Corporate Governance Report	13
Directors' Statement	45
Independent Auditors' Report	51
Statements of Financial Position	55
Consolidated Statement of Profit or Loss and Other Comprehensive Income	56
Consolidated Statement of Changes in Equity	57
Consolidated Statement of Cash Flows	58
Notes to the Consolidated Financial Statements	60
Additional Information on Directors Seeking Re-election	118
Shareholdings Statistics	127
Notice of Annual General Meeting	129
Proxy Form	137

CHAIRMAN'S MESSAGE

DEAR SHAREHOLDERS,

The Group entered FY2025 as Don Agro International Limited, following the disposal of its agricultural business and operating as a cash company.

Today, this transition has been completed. You are reading the Annual Report of UpHealth Group Limited, a fully operational business following its transformation and a period as a cash company. This marks the successful completion of the Group's shift from agriculture into healthcare.

FY2025 was therefore a year of disciplined transition. The Board remained focused on preserving financial strength, maintaining governance standards and executing the acquisition of medical assets in a structured and controlled manner.

As reflected in the financial statements, the Group reported a net loss of S\$1.4 million for FY2025, compared to S\$22.7 million in FY2024, with losses significantly reduced following the disposal of the agricultural business. The Group maintained a solid financial position, with total equity of S\$67.4 million and cash and cash equivalents of S\$24.7 million as at 31 December 2025.

While the healthcare business has not yet been consolidated into the Group's FY2025 financial results, its operating performance demonstrates the substance of the new business.

In 2025, the Group's oncology clinic network served 13,705 patients, compared to 11,019 patients in 2024, representing an increase of approximately 24% year-on-year ("y-o-y").

In addition, Uni clinic, which came under the Group's management at the beginning of 2025, served 40,329 patients during the year. On a combined basis, the total number of patients treated across the Group's medical assets exceeded 54,000 patients in 2025, representing a several-fold increase compared to the standalone oncology network in the prior year.

These figures reflect both growing demand for specialised healthcare services and the scale of the Group's medical operations.

The acquisition of the healthcare business has now been fully completed, and the Company is no longer classified as a cash company. The Group now operates a network of specialised oncology clinics alongside a multifunctional medical facility, providing a foundation for further development within the healthcare sector.

The Board continues to review opportunities to expand the Group's presence in selected international markets, including Southeast Asia, Central Asia and the Middle East, through both acquisitions of operating healthcare assets and partnerships with leading international healthcare providers and established medical institutions.

At its core, this new direction is grounded in serving people. Access to quality healthcare remains an essential need across all geographies and economic environments. This demand is reflected in the global healthcare services market, which reached US\$8.53 trillion in 2024 and is expected to grow to

Annual Report 2025
UpHealth Group Limited
(Formerly known as Don Agro International Limited)

CHAIRMAN'S MESSAGE

approximately US\$10.75 trillion by 2029, at a compound annual growth rate of 4.7%¹. The Group believes that this structural demand makes healthcare a resilient and scalable business across different geographies. Our objective is to build a responsible, efficient and sustainable healthcare business that improves lives while creating long-term value for shareholders.

Throughout this evolution, our approach has remained consistent: disciplined execution, responsible capital management and a focus on building a sustainable business in a sector characterized by long-term structural demand.

On behalf of the Board, I would like to thank our shareholders for their continued trust and support.

Sincerely,
Evgeny Tugolukov

Executive Chairman
UpHealth Group Limited

14 April 2026

¹ Information obtained from The Business Research Company,
<https://www.thebusinessresearchcompany.com/report/healthcare-service-global-market-report>

BOARD OF DIRECTORS

EVGENY TUGOLUKOV

Executive Chairman

Evgeny Tugolukov (“**Evgeny**”) is our Executive Chairman. He was appointed to our Board on 28 November 2018 and re-elected on 29 April 2024. He is responsible for setting and executing the strategic directions and expansion plans for the growth and development of our Group. He has over 20 years of experience holding top management positions in various financial and industrial groups. Evgeny began his career in 1993 when he joined MDM Bank, one of the largest private banks in Russia, before going on to build up and manage several sizable holdings. In 2005, he formed EMAlliance Public JSC (“**EMAlliance**”) where he served as chairman of the board of directors until 2007, developing it into one of Russia’s largest power machine-building companies. In 2008, he founded Strongbow Investments Pte Ltd (“**Strongbow**”), a Singapore-incorporated international holding company with a diverse range of investments in the areas of high-tech start-ups, entertainment, healthcare, real estate development and agriculture, and a strong geographical focus on Southeast Asia, Russia and Eastern Europe. He has been the managing director of Strongbow since 2012. From 2007 to 2011, Evgeny was a Member of Parliament of the State Duma of the Russian Federation, as well as the Chairman of the State Duma Committee on Natural Resources. He was also an honorary business representative with Enterprise Singapore, promoting bilateral trade and business relations between Singapore and Russia from 2014 to 2018. Evgeny graduated with a Diploma in Economics and Management from the Ural Federal University in 2000.

MARAT DEVLET-KILDEYEV

Chief Executive Officer and Executive Director

Marat Devlet-Kildeev (“**Marat**”) has been with the Group since 2012 in a variety of senior management positions. He became CEO and Executive Director of Uphealth Group Limited (formerly known as Don Agro International Limited) in 2018. Marat brings decades of senior management experience across a spectrum of industries, including commercial and corporate banking, investment banking, insurance, publishing, power machine building, advertising, TV, agriculture, etc. Marat holds an MBA degree from the University of Toronto’s Rotman School of Management (1993).

RAVI CHIDAMBARAM

Lead Independent Director

Ravi Chidambaram (“**Ravi**”) is our Lead Independent Director and was appointed to our Board on 28 June 2019 and re-elected on 29 April 2023. He is currently the president of investment banking firm, TC Capital Pte. Ltd. Ravi started his career as a financial analyst in the investment banking division of Kidder, Peabody & Co. in 1986. In 1989, he left to join Commerzbank AG as a credit officer in the international division, sovereign risk unit where he served until 1991. In 1993, he became an associate in the corporate finance department of Goldman Sachs, a role he held until 1996, when he joined Deutsche Bank as a director in the investment banking group. In 1998, he joined Credit Suisse Securities (Europe) Limited as a director in the European telecommunications investment banking group. In 1999 he became a managing director of Bear Stearns and head of the European technology investment banking group. Ravi left Bear Stearns in 2001 and became the president of TC Capital Pte. Ltd. in 2002. Ravi graduated with a Bachelor of Arts in Political Economy from Duke University in 1985 and was a Fulbright Scholar in Political Science at Kiel University

Annual Report 2025
UpHealth Group Limited
(Formerly known as Don Agro International Limited)

BOARD OF DIRECTORS

from 1985 to 1986. He obtained his Master of Business Administration and Master of Arts degrees at the Wharton School and the Lauder Institute of the University of Pennsylvania in 1993.

GAVIN MARK MCINTYRE

Independent Director

Gavin Mark McIntyre (“**Gavin**”) is our Independent Director and was appointed to our Board on 16 August 2023 and re-elected on 29 April 2024. He is a Certified Practising Accountant from the Australian Society of Certificate Practising Accountants. He is currently co-Founder and director of Aegis Interaktif Asia, a boutique forensic advisory services company, as well as a director and consultant of Equitasasia Pte Ltd, a receivables Management and business process outsourcing firm in Asia. Gavin has more than 30 years of professional financial and commercial experience with various firms including Big 4 companies such as Ernst & Young LLP (Assistant Manager in Advisory), Deloitte (Director in Financial Advisory) where he performed financial reporting, budgeting, capex & project reviews, conducted due diligence, risk assessment and financial monitoring services for banking and non-banking clients for various corporate exercises such as acquisitions, divestments, debt restructuring, asset collateralisation, debt and corporate restructuring assignments. He was a project leader for insolvent administrations, e.g. judicial managements, liquidations, receiverships and bankruptcies, internal audit and risk management advisor. He obtained Bachelor of Business (Accounting) at Curtin University of Technology, Australia in 1989.

TAN POH CHYE ALLAN

Independent Director

Tan Poh Chye Allan (“**Allan**”) is our Independent Director and was appointed to our Board on 17 October 2024 (re-appointed on 30 April 2025). He is a member of Law Society of Singapore / Singapore Academy of Law with more than 30 years professional experience in corporate and commercial law, regulatory compliance, and capital markets. Allan is currently a director of Nine Yards Chambers LLC and heads up its corporate department. From 2020 he is the principal/sole proprietor of Allan Tan Corporate Services. He brings extensive experience advising listed companies on complying with stock exchange rules and regulations. He has an extensive practice in renowned firms such as Shook Lin & Bok, Colin Ng & Partners, and Virtus Law (a formal law alliance with Stephenson Harwood LLP, an international law firm). Allan graduated with a Bachelor of Laws from the University of Buckingham in 1988. He also has several different qualifications such as English barrister-at-law from Gray’s Inn, Master’s Degree (Comparative Business Laws) from London Metropolitan University, Executive Development (Sustainability Strategies and Green Economy Programme) from Singapore Management University and Governance for a Sustainable Future from University of Cambridge. He is an Advocate and Solicitor of Singapore.

KEY MANAGEMENT PERSONNEL

Artur Nazaryan (“**Artur**”) is Group’s Chief Financial Officer and is responsible for the finance, accounting and taxation matters of the Group. Artur has been serving in this office for around 10 years. Artur began his career in 2004 as an accountant in the receivables department of Zaslon LLC, where his responsibilities included controlling accounts receivables ledgers and preparing presentations for potential customers. He moved to CJSC KPMG’s audit department in 2007 as auditor and audit supervisor, where he supervised audit and financial consulting engagements and prepared financial models and financial statements. In 2013, he joined Guardian Glass Rostov LLC, a float glass production company, as head of finance and was in charge of all manner of finance, including taxation, reporting, cash flow and working capital management and the development of management accounting systems. In 2014, he became the chief financial officer of ProdAlliance Limited until 2018. Artur graduated with Specialist Diploma in Organisation Management from the Southern Federal University in 2008. He has also been a member of the Association of Chartered Certified Accountants (ACCA) since 2015.

Vadim Novikov (“**Vadim**”) is the Group’s Chief Operating Officer since 2020 and is responsible for overseeing the entire operations of our Group and has been the General Director of Tetra JSC and Don Agro JSC since 2012 and 2014, respectively. Vadim started his career in 2001 as a legal counsel at Law Firm JSC JurCon, a local Russian law firm specialising in advising corporate clients in the power and energy sectors. He moved to an investment company, JSC Rinaco, as a legal counsel in 2003, and provided legal support in corporate and share capital transactions. In 2005, he joined EMAlliance where he was legal counsel, head of corporate and deputy head of tax and legal. Thereafter, Vadim joined ProdAlliance Limited in 2013 as legal counsel providing legal support for its investment activities until 2018. Vadim obtained his Diploma with Honours in Law from the Ural State Law University (formerly known as Ural State Law Academy) in 2001.

FINANCIAL REVIEW

FINANCIAL PERFORMANCE REVIEW

The Group completed the sale of its agricultural subsidiaries in July 2024 and therefore the financial performance for these subsidiaries from July 2024 onwards were deconsolidated from the consolidated financial statements for the six months and full year ended 31 December 2025. The disposal of discontinued operations has resulted in reductions in the Group's financial result from discontinued operations and its financial positions.

Administrative expenses

The administrative expenses decreased by approximately \$0.7 million or 10.2% from approximately \$6.8 million in FY2024 to approximately \$6.1 million in FY2025. The decrease is mainly attributable to decrease in wages and salaries due to the absence of a payment of the bonus for Key Management personnel of approximately \$3.0 million for comprehensive encouragement for long-term support of an agricultural companies' project from the purchase to sale in July 2024. This was partly offset by an increase in consulting services of approximately \$2.0 million due to (i) the preparation of the sale of shares in Don Agro LLC, Volgo-Agro LLC, Don Agrarian Group JSC and Don Muchnov LLC ("**Target Group**") and (ii) higher transactional service costs related to the sale of shares, including professional fees incurred by Target Group and Volgo-Agro LLC for due diligence and audit services in connection with the proposed acquisition of shares in 812 Capital LLC and Center for Innovative Medical Technologies LLC.

Other operating expenses, net

The other operating expense, net decreased by approximately \$0.3 million from other operating expense of approximately \$0.5 million in FY2024 to other operating expense of approximately \$0.2 million in FY2025. The decrease is mainly attributable to an increase in other income arising from the revaluation of a share at fair value in the amount of 1% in the share capital of 812 Capital LLC in accordance with the rules of SFRS 9.

Finance income

Finance income increased by \$1.7 million or 51.6% from approximately \$3.4 million in FY2024 to approximately \$5.1 million in FY2025. The increase is mainly attributable to (i) increase in interest income from bank deposits of approximately \$0.3 million due to higher interest rates as result of increase in the Key rate of Central Bank Russian Federation ii) increase in interest income from a loan due from an external party of approximately \$0.3 as result of interest accrual for FY2025 whereas last year, interest was accrued from August 2024 ; iii) increase in unwinding interest income from loans due from CIMT LLC of approximately \$0.1 million due to issue an interest-free loan to CIMT LLC and (iv) the increase in foreign exchange income of approximately \$0.9 million, was a result of the appreciation of Russian Ruble against the Singapore Dollar.

Finance costs

Finance cost decreased by \$0.5 million from of approximately \$0.7 million in FY2024 to approximately \$0.2 million in FY2025. The decrease is mainly attributable to the absence of foreign exchange loss of approximately \$0.7 million as a result of appreciation of Russian Ruble previously recorded in FY2024. This was partially offset by an increase in net losses from difference in the fair value of financial assets at initial recognition and its transaction price of approximately \$0.2 million.

Annual Report 2025
UpHealth Group Limited
(Formerly known as Don Agro International Limited)

FINANCIAL REVIEW

Loss from discontinued operations, (net of tax)

Loss from discontinued operations (net of tax) decreased by \$18.1 million from of approximately \$18.1 million in FY2024 to nil in FY2025. In FY2025 there were no loss recorded from discontinued operations following the completion of the disposal of the Group's agriculture business in FY2024.

Foreign currency translation differences arising from foreign operations, at nil tax

The Group recorded a gain arising from foreign currency translation differences arising from foreign operations, at nil tax of \$17 million in FY2025 as compared to a currency translation loss from of approximately \$10.7 million in FY2024 due to the appreciation of Russian Ruble against the Singapore Dollar in FY2025.

Currency translation gain attributed to discontinued operations

In FY2025 there was no currency translation gain attributed to discontinued operations following the completion of the disposal of the Group's agriculture business in FY2024.

Revaluation of property plant and equipment and related tax

In FY2025 there were no revaluation of property plant and equipment and related tax following the completion of the disposal of the Group's agriculture business in FY2024.

BALANCE SHEET REVIEW

The Group completed the sale of its agricultural subsidiaries in July 2024 and therefore the financial performance and position for these subsidiaries from July 2024 onwards were deconsolidated from the balance sheet of the consolidated financial statements for FY2025.

Other investments

Other investments increased by \$0.3 million from of approximately \$0.4 million as at 31 December 2024 to of approximately \$0.7 million on 31 December 2025 due to the revaluation of a share at fair value in the amount of 1% in the share capital of 812 Capital LLC.

Trade and other receivable

Trade and other receivables increased by approximately \$39.0 million, or 818.5%, primarily due to: (i) Advance payments of \$36.1 million remitted to the vendors of Target Group, in accordance with the terms of the Proposed Acquisition; (ii) Loans of \$4.9 million granted to 812 Capital LLC and CIMT LLC to support the acquisition of a group of companies operating polyclinics in Moscow under the Uni Clinica brand; (iii) increase in interest receivable of approximately \$0.8 million; and (iv) increase in value added tax receivable of approximately \$0.1 million as a result of purchase VAT taxable services from advisers and consultants and will refundable during three years in accordance with Russian legislation. These increases were partially offset by the receipt of deferred consideration of \$3.0 million related to the disposal of agricultural businesses received by the Company in FY2025.

Annual Report 2025
UpHealth Group Limited
(Formerly known as Don Agro International Limited)

FINANCIAL REVIEW

Cash and cash equivalents

Cash and cash equivalents comprise bank balances and short-term bank deposits. Cash and cash equivalents decreased by approximately \$23.0 million or 48.5% from \$48.0 million as at 31 December 2024 to \$25.0 million as at 31 December 2025. Please refer to the section entitled “Consolidated Statement of Cash Flows” below for further information.

Trade and other payables

The trade and other payables increased by approximately \$0.7 million or 85.3% from \$0.9 million as at 31 December 2024 to \$1.6 million as at 31 December 2025. The increase was mainly attributable to increase in payables due to slower settlement with consultants and legal advisors on the professional fees which were incurred in FY2025 in relation to the acquisition of the medical business.

CASH FLOW ANALYSIS

Net cash flows from operating activities

Cash flows used in operating activities of \$6.3 million in FY2025 were mainly due to (i) loss during the period amounting to \$1.3 million; (ii) finance income in amount of \$5.1 million; and (iii) total outflow due to changes in a working capital of \$0.2 million.

Net cash flows generated from investing activities

Cash flows generated from investing activities of \$2.8 million were mainly due to: (i) loan granted to 812 Capital LLC and CIMT LLC for the purpose of provision of funds for an acquisition of the group of companies which operates the polyclinic in Moscow in an amount of \$4.9 million; (ii) down payment made to Vendors of 812 Capital LLC and Centre for Innovative Medical Technologies, LLC in amount of \$35.2 million; which was partly offset cash flows from investing activities were mainly due to: (a) deferred consideration received in an amount of \$4.0 million; (b) changes in restricted deposits in an amount of \$35.2 million; (c) receipt of interests of \$3.3 million from the bank deposits and (d) receipt from the return of loan provided to LLC SGC Blagovar of \$0.4 million.

Net cash flows from financing activities

Net cash generated from financing activities amounted to \$Nil.

Annual Report 2025
UpHealth Group Limited
(Formerly known as Don Agro International Limited)

CORPORATE INFORMATION

BOARD OF DIRECTORS	: Evgeny Tugolukov (Executive Chairman) Marat Devlet-Kildeev (Chief Executive Officer and Executive Director) Ravi Chidambaram (Lead Independent and Non-Executive Director) Gavin Mark McIntyre (Independent and Non-Executive Director) Tan Poh Chye Allan (Independent and Non-Executive Director)	
COMPANY SECRETARIES	: Chen Chuanjian, Jason Tan Ching Ching	
REGISTERED OFFICE	: 10 Collyer Quay #10-01 Ocean Financial Centre Singapore 049315	
PRINCIPAL PLACE OF BUSINESS	: Suite 506, 8/1 Gostinichny Proezd, Intra-City Area Municipal District Marfino Moscow, Russian Federation, 127106	:
SHARE REGISTRAR AND SHARE TRANSFER AGENT	: Boardroom Corporate & Advisory Services Pte. Ltd. 1 Harbourfront Avenue #14-07 Keppel Bay Tower Singapore 098632	
SPONSOR	: PrimePartners Corporate Finance Pte. Ltd. 16 Collyer Quay #10-00 Collyer Quay Centre Singapore 049318	

Annual Report 2025
UpHealth Group Limited
(Formerly known as Don Agro International Limited)

CORPORATE INFORMATION

AUDITORS	: Foo Kon Tan LLP 1 Raffles Place #04-61/62 One Raffles Place Tower 2 Singapore 048616 Partner-in-charge: Chin Bo Wui (a member of the Institute of Singapore Chartered Accountants and a public accountant registered with ACRA) Appointed in the financial year ended 31 December 2022.
INTERNAL AUDITORS	JSC MCD Office 123, 4 Lit. A Finlyandsky Pr., Saint-Petersburg, 194044, the Russian Federation
PRINCIPAL BANKERS	: Alfabank JSC 27, Kalanchevskaya Street, Moscow 107078, Russia Sberbank PJSC 19, Vavilova St, Moscow, 117997, Russia DBS Bank Limited 12 Marina Boulevard Marina Bay Financial Centre Tower 3 Singapore 018982

Annual Report 2025
UpHealth Group Limited
(Formerly known as Don Agro International Limited)

CORPORATE GOVERNANCE REPORT

The board of directors (the “**Board**” or “**Directors**”) of UpHealth Group Limited (formerly known as Don Agro International Limited) (the “**Company**” and together with its subsidiaries, the “**Group**”) is committed to maintaining high standards of corporate governance and transparency within the Company and the Group by complying with the principles and guidelines as set out in the Code of Corporate Governance issued by Monetary Authority of Singapore on 6 August 2018 (the “**Code**”). This corporate governance report (“**Report**”) outlines the Company’s corporate governance practices that were in place during the financial year ended 31 December 2025 (“**FY2025**”), with specific reference made to the principles of the Code. For FY2025, the Company has complied with the principles and provisions as set out in the Code and the practice guidance issued by the Monetary Authority of Singapore on 6 August 2018 (the “**Guide**”), where applicable. Appropriate explanations have been provided in the relevant sections below where there are deviations from the provisions of the Code and the Guide.

BOARD MATTERS

BOARD’S CONDUCT OF ITS AFFAIRS

Principle 1: The Company is headed by an effective Board which is collectively responsible and works with Management for the long-term success of the company

Provision 1.1

Board supervises the management of the business and affairs of the Group and holds the management accountable for performance. The Board approves the Group’s corporate and strategic direction, the appointment of Directors and key managerial personnel, major funding and investment proposals, and reviews the financial performance of the Group. The Directors recognise the importance of corporate governance and the offering of high standards of accountability to the shareholders, and use best efforts to implement the good practices recommended in the Code. The principal functions of the Board are:

- Set strategic objectives and business plans of the Group;
- Approval of investment and divestment proposals, mergers and acquisitions and disposals of assets;
- Review and approve the appointment/re-appointments of Directors proposed by the Nominating Committee;
- Appointment or removal of the Company Secretary;
- Appointment and re-appointment of internal and external auditors and Key Management Personnel;
- Ensure good corporate governance practices of the Group to protect the interests of shareholders;
- Establish a framework of prudent and effective internal controls and risk management strategies which enables risk to be assessed and managed, including safeguarding of shareholders’ interests and the Group’s assets;
- Review and monitor the performance of the Management;
- Review and approve half-year and full-year results announcements and annual reports;
- Declaration of interim dividends and proposal of final dividends for shareholders’ approval;

Annual Report 2025
UpHealth Group Limited
(Formerly known as Don Agro International Limited)

CORPORATE GOVERNANCE REPORT

- Monitoring Company's risk of becoming subject to sanctions; and
- Ensuring timely and accurate disclosures to SGX-ST and the relevant authorities should any enquiries be made regarding the Group's dealings with Sanctioned Subject².

The Board acts in good faith and in the best interests of the Company by exercising due care, skills and diligence, and avoiding conflicts of interest. The Directors are cognizant of their fiduciary duties at law. When a potential conflict of interest situation arises, the affected Director will recuse himself or herself from the discussion and decisions involving the areas of potential conflict, unless the Board is of the opinion that his or her participation is necessary. Where such participation is permitted, the conflicted Director excuses himself or herself for an appropriate period during the discussions to facilitate full and frank exchange by the other Directors, and shall in any event recuse himself or herself from the decision-making.

Pursuant to Section 156 of the Companies Act 1967 of Singapore (the “**Companies Act**”), each Director is to declare to the Company his or her interests (direct or indirect) in all transactions with the Company and provide details on the nature of such interests as soon as practicable after the relevant facts have come to his or her knowledge. On an annual basis, each Director is also required to submit details of his or her associates for the purpose of monitoring interested persons transactions.

Provision 1.2

Newly appointed Directors will be given briefings by the Management on the business activities and strategic direction of the Group. There are also induction or orientation programmes to familiarise them with the Group's operations. They will also be provided with a formal letter setting out their duties and obligations. Where appropriate and for first time directors with no prior experience as a director of a listed company in Singapore, the Company will also arrange for them to attend training courses organised by the Singapore Institute of Directors (the “**SID**”) or other professional training institutions as appropriate so as to equip them to discharge their duties effectively. Such training must be completed within one year of the appointment.

As part of training for the Board, Directors are briefed either during Board and Board Committee meetings or at specially convened sessions on changes to regulations and accounting standards, as well as industry related matters. All Directors are encouraged to keep themselves updated on changes to the financial, legal and regulatory requirements or framework and the business environment.

All the directors on the board have completed the mandatory training including the mandatory sustainability training

² “Sanctioned Subjects”: Any individual or entity or government which is: (a) listed or designated on any sanction list(s); and/or (b) owned or controlled by an individual or entity or government listed in (a)

Annual Report 2025
UpHealth Group Limited
(Formerly known as Don Agro International Limited)

CORPORATE GOVERNANCE REPORT

All members of the Board are informed that it is necessary to equip themselves with basic knowledge on sustainability matters. The Directors are also encouraged to keep themselves abreast of the latest developments relevant to the Group and attendance of appropriate courses and seminars will be arranged and funded by the Company. In carrying out their duties and where necessary, Directors individually or as a group may seek independent professional advice where appropriate at the Company's expense.

Provision 1.3

The Board has adopted internal guidelines setting forth the matters reserved for the Board's decision and given clear directions to the Group's management on matters that must be approved by the Board. The approval of the Board is required for matters such as corporate restructuring, mergers and acquisitions, major investments and divestments, material acquisitions and disposals of assets, major corporate policies on key areas of operations, major corporate actions such as share issuance, the release of the Group's half-year and full-year results, annual reports, audited financial statements, declaration of dividends and interested persons transactions.

All other matters are delegated to Board Committees whose actions are reported to and monitored by the Board. The Board does not abdicate its responsibility in such delegations of authority.

Provision 1.4

The Board also monitors and evaluates the Group's operations and financial performance, sets targets and goals, works with and monitors the Management in achieving such targets and goals.

The Board has formed three (3) committees, namely the Audit and Risk Committee (the "ARC"), the Remuneration Committee (the "RC") and the Nominating Committee (the "NC").

The terms of reference of the respective Board Committees, which are reviewed by the Board on a regular basis, as well as other relevant information on the Board Committees can be found in the subsequent sections of this Report.

All the Board Committees are actively engaged and play an important role in ensuring good corporate governance in the Company and within the Group. The Board Committees report its activities regularly to the Board. Minutes of the Board Committees are regularly provided to the Board and are available to all Board members. The Board acknowledges that while these various Board Committees have the authority to examine particular issues and report back to the Board with their decisions and recommendations, the ultimate responsibility on all matters lies with the Board. The Board Committees have explicit authority to investigate any matter within their terms of reference, have full access to and co-operation by Management, have resources to enable them to discharge their functions properly and full discretion to invite any Director or senior management to attend their meetings.

Annual Report 2025
UpHealth Group Limited
(Formerly known as Don Agro International Limited)

CORPORATE GOVERNANCE REPORT

Provision 1.5

The Board meets regularly and convenes ad-hoc meetings as and when warranted by particular circumstances as deemed appropriate by the Board members.

The Company's Constitution permits meetings of Directors to be held by means of telephone conference or other similar means of communications.

The Board holds at least two (2) meetings each year to approve the half-year and full-year results announcement and to oversee the business affairs of the Group. The table below sets out the number of Board and Board Committees meetings held during FY2025 and the attendance of each Directors at these meetings:

	Board		Board Committees					
			Audit and Risk		Nominating		Remuneration	
No. of meetings held	2		2		2		1	
Name of Directors	A	B	A	B	A	B	A	B
Evgeny Tugolukov	2	2	2*	2	1*	1	1*	1
Marat Devlet-Kildeev	2	2	2*	2	1*	1	1*	1
Ravi Chidambaram	2	2	2	2	1	1	1	1
Gavin Mark McIntyre	2	2	2	2	1	1	1	1
Tan Poh Chye Allan	2	2	2	2	1	1	1	1

Notes:

A – represents number of meetings held

B – represents number of attendances

* – By invitation

In FY2025, the Group held two ARC meetings (on 25 February 2025 and 12 August 2025), one NC meeting (on 25 February 2025) and one RC meeting (on 25 February 2025).

All Directors are expected, in the course of carrying out their duties, to act in good faith to provide insights and objectively take decisions in the interest of the Group.

All Directors are required to declare their board representations on an annual basis and as soon as practicable after the relevant facts have come to his knowledge. While some of the Directors have taken on multiple board representations, they have ensured that they are able to accord sufficient time and attention to the affairs of each company.

The Board recognises that setting a prescribed limit on the number of listed company board representations held by Directors may assist in addressing concerns relating to competing time commitments. While the Board has not set a formal limit on the number of such appointments a Director may hold, each Director is mindful of the significant time and commitment required to effectively discharge his or her duties. The Board is of the view that the effectiveness of a Director should not be assessed solely based on the number of board representations held, but rather on

Annual Report 2025
UpHealth Group Limited
(Formerly known as Don Agro International Limited)

CORPORATE GOVERNANCE REPORT

the Director's ability to devote sufficient time and attention to the affairs of the Company, and to contribute meaningfully and effectively to the Board.

The NC and the Board are satisfied that in FY2025, each of the Directors was able to devote sufficient time and attention to the affairs of the Company and has diligently discharged his duties as a Director of the Company.

Provision 1.6

All Directors have unrestricted access to the Company's records and information. From time to time, they are provided with complete, adequate and timely information, on an on-going basis, in order for the Directors to discharge their duties efficiently and effectively.

Management provides the members of the Board with board papers as well as relevant background information or explanatory information and documents relating to items of business to be discussed at a Board meeting before each scheduled meeting. The Board is provided with management reports, and papers containing relevant background or explanatory information required to support the decision-making process on an ongoing basis and in a timely manner. In respect of the annual budgets, the management shall provide any material variance between the budget or projections and actual results to the Board. Management recognises the importance of circulating information on a timely basis to ensure that the Board has adequate time to review the materials to facilitate a constructive and effective discussion during the scheduled meetings. As such, Management endeavours to circulate information at least one week prior to the meetings to allow sufficient time for review by the Directors.

The Company's management, legal advisors and auditors, who can provide additional insight into the matters for discussion are also invited from time to time to attend such meetings. The minutes of meetings of the Board and Board Committees are circulated to all Board or Board Committee members (as applicable) after the respective meetings for their approval.

Provision 1.7

The role of the Company Secretaries is clearly defined and includes the responsibility for ensuring that the Board procedures are followed and that applicable rules and regulations are complied with. The Company Secretaries or their nominee(s) attends all Board and Board Committees meetings. In the event that any Company Secretary is unable to attend a meeting, arrangements will be made for a suitable replacement to be present to ensure that proper minutes are taken and maintained. Under the direction of the Chairman, the Company Secretaries facilitate effective information flow within the Board and the Board Committees, and between Management and Non-Executive Directors. Pursuant to the Company's Constitution, the appointment and removal of the Company Secretaries are matters reserved for the Board as a whole. The Directors have separate and independent access to the Management, the Company Secretaries, and external advisers (where necessary) at the Company's expense.

Annual Report 2025
UpHealth Group Limited
(Formerly known as Don Agro International Limited)

CORPORATE GOVERNANCE REPORT

None of our Directors, Controlling Shareholders or any of their associates has an interest, direct or indirect:

- (a) in any transaction to which our Group was or is to be a party;
- (b) in any entity carrying on the same business or dealing in similar services which competes materially and directly with the existing business of our Group; and
- (c) in any enterprise or company that is our Group's customer or supplier of goods and services.

BOARD COMPOSITION AND GUIDANCE

Principle 2: The Board has an appropriate level of independence and diversity of thought and background in its composition to enable it to make decisions in the best interests of the company.

Provision 2.1

There is presently a strong and independent element on the Board with Independent Directors constituting majority of the Board. The Board considers an Independent Director as one who has no relationship with the Company, its related corporations, its substantial shareholders or its officers that could interfere, or be reasonably perceived to interfere, with the exercise of the Directors' independent business judgment of the Group's affairs.

None of the Independent Directors have been employed by the Company or any of its related corporations for the current or any of the past three financial years, and none of the Independent Directors have an immediate family member who is employed or has been employed by the Company or any of its related corporations for the past three financial years, and whose remuneration is determined by the RC.

None of the Directors are related to each other, our Executive Officers or our substantial shareholders.

The Independent Directors do not have any existing business or professional relationship of a material nature with the Group, the other Directors or the Company's substantial shareholders. None of the Independent Directors sit on the board of our subsidiaries.

The Independent Directors are respected individuals from diverse professional backgrounds, with extensive and complementary core competencies, qualifications, skills and experience. The Board comprises members with expertise in areas including accounting, finance, business, management, industry knowledge and strategic planning. The NC is of the view that the current composition of the Board provides an appropriate balance of skills, experience and knowledge, enabling the Board to function effectively as a whole. Independent Directors play a pivotal role in enhancing corporate accountability. Their presence on the Board provides objective and independent perspectives, enabling balanced and well-considered decision-making. They contribute constructively to Board deliberations and help safeguard the interests of the Company and its

Annual Report 2025
UpHealth Group Limited
(Formerly known as Don Agro International Limited)

CORPORATE GOVERNANCE REPORT

stakeholders, including shareholders, employees, customers, suppliers and the wider community in which the Group operates.

Pursuant to Rule 406(3)(d)(iv) of the Catalist Rules which came into effect on 11 January 2023, an Independent Director who has held his or her position for an aggregate period of more than nine (9) years (whether before or after listing) will cease to be independent thereafter. However, such director may continue to be considered independent until the conclusion of the next annual general meeting (“AGM”) of the Company. As at the date of this report, none of the Independent Directors has served on the Board for more than nine (9) years from the date of his first appointment.

Provisions 2.2, 2.3 and 2.4

As at the date of this Report, the Board comprises five (5) Directors, three (3) of whom are Independent Non-Executive Directors:

Name	Position
Evgeny Tugolukov	Executive Chairman
Marat Devlet-Kildeev	Chief Executive Officer (the “CEO”) and Executive Director
Ravi Chidambaram	Lead Independent Director, Chairman of the RC
Gavin Mark McIntyre	Independent Director, Chairman of the ARC
Tan Poh Chye Allan	Independent Director, Chairman of the NC

As both the Chairman of the Board and the CEO are part of Management, a majority of the Board comprises Independent Non-Executive Directors, ensuring an appropriate level of independence and objectivity in Board deliberations. In line with Provision 3.3 of the Code, the Board has appointed a Lead Independent Director to provide leadership in circumstances where the Chairman is conflicted, and to serve as an alternative point of contact for shareholders where necessary, particularly given that the Chairman is not independent.

The Company’s Board Diversity Policy (“Policy”) is set out to ensure that there is diversity on the composition of the Board.

The Company recognizes the need and benefits of having diversity at the Board level to enhance stewardship and decision-making abilities to meet up to the fast-changing business environment. The Board seeks to achieve an appropriate balance of skills, knowledge and experience to minimise the risk of groupthink and to encourage a broad range of perspectives.

A diverse Board consist of Directors of different age, gender, length of service with varied skills and other relevant qualities considered necessary for the effective governance of the Board. These differences are considered in determining the composition of the Board and where possible, would be balanced appropriately.

The NC reviews and assesses the Board composition on behalf of the Board and recommends the appointment of new directors. All appointments to the Board are based on merit and the NC will

Annual Report 2025
UpHealth Group Limited
(Formerly known as Don Agro International Limited)

CORPORATE GOVERNANCE REPORT

consider diversity factors like skills, knowledge, experience, age, gender, length of service and any other relevant factors.

The current Board members comprise business leaders, professionals with accounting and finance, business, management and legal background. The Board acknowledges that improvements to Board diversity is an ongoing process.

Following the recent completion of the Group's restructuring exercise, the Group's and Board's immediate focus was to ensure continuity, stability and to provide the requisite expertise to support the Company's immediate strategic and operational priorities. Accordingly, the Board will not be setting any diversity targets. Notwithstanding the Board recognises that diversity is an ongoing process and will continue to pursue and, where appropriate, establish targets for Board diversity following the completion of the proposed acquisition and the Company's exit from its cash company status in FY2025.

Accordingly, the Company plans to disclose information on its diversity targets together with the Company's plans to progress towards the targets in the annual report and sustainability report for the financial year ending 31 December 2026.

The NC will review the Policy to assess its relevance and effectiveness will make recommendations to the Board for consideration and approval.

The Board has implemented measures to maintain and enhance its balance and diversity, including an annual review by the NC to assess whether the existing attributes and core competencies of the Board are complementary and support its effective functioning, as well as an annual evaluation by Directors of the skill sets and experience of fellow Board members, with a view to identifying any gaps in expertise. The NC considers the outcomes of these assessments in making recommendations on the appointment of new Directors and the re-appointment of incumbent Directors. In identifying suitable candidates, the Board seeks to achieve an appropriate mix of members with core competencies, including accounting and finance, business acumen, management experience, industry knowledge, strategic planning, customer-focused insights, familiarity with regulatory requirements and risk management expertise.

Provision 2.5

Where appropriate, the Independent Directors meet periodically without the presence of Executive Directors or Management to discuss matters relating to the Group's affairs, including its management and financial performance. Following such discussions, the Independent Directors provide feedback to the Board and/or the Chairman, as appropriate.

During FY2025, the Independent Non-Executive Directors held several informal discussions via teleconference without the presence of Management.

Annual Report 2025
UpHealth Group Limited
(Formerly known as Don Agro International Limited)

CORPORATE GOVERNANCE REPORT

CHAIRMAN AND CHIEF EXECUTIVE OFFICER

Principle 3: There is a clear division of responsibilities between the leadership of the Board and Management, and no one individual has unfettered powers of decision-making.

Provisions 3.1 and 3.2

The functions of the Executive Chairman and CEO in the Company are assumed by different individuals.

Mr. Evgeny Tugolukov is an Executive Chairman. He was appointed to our Board on 28 November 2018 and re-elected on 29 April 2024 and is responsible for setting and executing the strategic directions and expansion plans for the growth and development of our Group.

Mr. Marat Devlet-Kildeev is the CEO. He was appointed to the Board on 28 November 2018 and re-elected as a Director on 30 April 2025. As CEO, he is responsible for directing and controlling the operations of the Group and its key operational subsidiaries.

The roles of the Chairman and the CEO are separated to ensure an appropriate balance of power, increased accountability and greater capacity of the Board for independent decision-making. The Chairman is not related to the CEO.

The clear separation of roles of the CEO and Chairman provides a healthy professional relationship between the Board and Management with clarity of roles and robust deliberations on the business activities of the Group.

Provision 3.3

As the Executive Chairman is part of the Management and therefore not independent, Mr. Ravi Chidambaram has been appointed as the Lead Independent Director, as recommended by the Code, as the principal liaison on Board issues between the Independent Directors, the Chairman and CEO. The responsibilities of the Lead Independent Director include:

- Acting as the principal liaison to address shareholders' and other stakeholders' concerns for which contact through the normal channels of communication with the Executive Chairman or Executive Officer are inappropriate or failed to resolve the concerns in question;
- Chairing Board meetings in the absence of the Executive Chairman;
- Working with the Executive Chairman in leading the Board; and
- Providing a channel to Independent Directors for confidential discussions on any concerns they may have and to resolve conflicts of interest, as and when necessary.

Annual Report 2025
UpHealth Group Limited
(Formerly known as Don Agro International Limited)

CORPORATE GOVERNANCE REPORT

Mr. Ravi Chidambaram can be contacted via the following electronic mail address: ravi@tccapital.com.

BOARD MEMBERSHIP

Principle 4: The Board has a formal and transparent process for the appointment and re-appointment of directors, taking into account the need for progressive renewal of the Board.

Provision 4.1

The NC is responsible for:

- (a) reviewing and recommending the nomination or re-nomination of our Directors having regard to each Director's contribution and performance;
- (b) reviewing succession plans for our Directors, in particular the appointment and/or replacement of the Chairman of our Board, our CEO and Key Management Personnel;
- (c) determining on an annual basis whether or not a Director is independent;
- (d) deciding whether or not a Director is able to and has been adequately carrying out his duties as a director;
- (e) reviewing training and professional development programmes for the Board of Directors;
- (f) reviewing and approving any new employment of related persons and the proposed terms of their employment; and
- (g) undertake such other functions and duties as may be required by statute or the Catalist Rules, and by such amendments made thereto from time to time.

The NC determines the framework and methodology for evaluating the performance of the Board, Board Committees and individual Directors, and proposes objective performance criteria for the Board's approval. Such criteria are designed to assess, inter alia, how the Board has contributed to the long-term success and value creation of the Company, as well as the effectiveness of each Director's contributions to the Board. The Board has established a formal evaluation process, administered by the NC, to assess the effectiveness of the Board as a whole, each Board Committee, and the contribution of individual Directors. Please refer to the "Board Performance" section of this Report for further details.

Each member of our NC does not take part in determining his own renomination or independence and shall abstain from voting on any resolutions in respect of the assessment of his performance or re-nomination as a Director. In the event that any member of the NC has an interest in a matter being deliberated upon by the NC, he abstains from participating in the review and approval process relating to that matter.

Annual Report 2025
UpHealth Group Limited
(Formerly known as Don Agro International Limited)

CORPORATE GOVERNANCE REPORT

Provision 4.2

The NC comprises three (3) Independent Directors (including the Lead Independent Director), namely Mr. Tan Poh Chye Allan (Chairman), Mr. Ravi Chidambaram and Mr. Gavin Mark McIntyre.

Provision 4.3

In the event that a vacancy on the Board arises, the NC may identify suitable candidates for appointment as new director through the business networks of the Board. The NC may consider using third party search firms to identify a broader range of suitable candidates when vacancies in the Board arise in the future.

The NC will assess suitable candidates for appointment to the Board based on the requisite qualification, expertise and experience, will determine of the candidate's independence; and recommend the most suitable candidate to the Board for appointment as Director.

The considerations in assessing the capacity of Directors include the following:

- Expected and/or competing time commitments of Directors, including whether such commitment is a full-time or part-time employment capacity;
- Geographical location of Directors;
- Size and composition of the Board;
- Nature and scope of the Group's operations and size; and
- Capacity, complexity and expectations of the other listed directorships and principle commitments held.

The Company's Constitution states that at each AGM, one-third (or if their number is not three or a multiple of three, the number nearest to but not less than one-third) of the Directors for the time being, shall retire from office and that all Directors shall retire from office at least once in every three (3) years and such retiring Directors shall be eligible for re-election. Each member of the NC has abstained from voting on any resolutions in respect of the assessment of his performance or re-nomination as Director.

The NC assesses and recommends to the Board whether retiring Directors are suitable for re-election.

The NC, in considering the re-appointment of a Director, evaluates such Director's contributions in terms of experience, business perspective and attendance at meetings of the Board and/or Board Committees and pro-activeness of participation in meetings.

The NC recommended that the Directors, Mr. Gavin Mark McIntyre and Mr. Ravi Chidambaram be put forward for re-election and re-appointment accordingly at the forthcoming AGM. The

Annual Report 2025
UpHealth Group Limited
(Formerly known as Don Agro International Limited)

CORPORATE GOVERNANCE REPORT

Board accepted the recommendation and being eligible, Mr. Gavin Mark McIntyre and Mr. Ravi Chidambaram will be offering themselves for re-election and for re-appointment accordingly at the forthcoming AGM. Information on Mr. Gavin Mark McIntyre and Mr. Ravi Chidambaram as required in Appendix 7F of the Catalist Rules under Rule 720(5) of the Catalist Rules are set out in the “Additional Information on Directors Seeking Re-election” section of this annual report for the financial year ended 31 December 2025 (“**Annual Report**”).

Mr. Gavin Mark McIntyre will, upon re-election as a Director, remain as the Chairman of the ARC and Member of the NC and the RC.

Mr. Ravi Chidambaram will, upon re-election as a Lead Independent Director, remain as the Chairman of the RC and Member of the ARC and the NC.

The Board, with the concurrence of the NC, has also considered Mr. Gavin Mark McIntyre and Mr. Ravi Chidambaram to be independent for the purposes of Rule 704(7) of the Catalist Rules.

The academic and professional qualifications and the information on shareholdings in the Company held by each Director are set out in the “Board of Directors” and “Directors’ Statement” sections of this Annual Report respectively.

The Company does not have any alternate directors on the Board currently.

Provision 4.4

The NC conducts an annual review of each Director’s independence and takes into consideration the Provision 2.1 of the Code as well as the relevant Catalist Rules. The Board considers the existence of relationships or circumstances, including those identified by the Code and Catalist Rules, that are relevant to determine whether a Director is independent. In addition, the NC reviews the individual Director’s declaration in their assessment of independence.

The NC has ascertained that all Independent and Non-Executive Directors are considered independent. They have signed the independent confirmation for FY2025. There are no Directors who is deemed independent by the Board, notwithstanding the existence of a relationship that would otherwise deem him not to be independent.

The NC had reviewed the time spent and attention given by each of the Directors to the Company’s affairs, taking into account the multiple directorships and principal commitments of each of the Directors (if any), as set out below, and is satisfied that all Directors were able to diligently discharge their duties and sufficient time and attention has been given to the Group by the Directors in FY2025.

Annual Report 2025
UpHealth Group Limited
(Formerly known as Don Agro International Limited)

CORPORATE GOVERNANCE REPORT

Provision 4.5

Key information regarding the Directors is set out below.

Name of the Director	Date of first Appointment	Date of last re-election	Date of next re-election	Directorship or Chairmanship both present and held over the preceding three (3) years in other listed companies		Other Principal Commitments
				Present	Past Three Years	
Evgeny Tugolukov	28.11.2018	29.04.2024	NA	None	None	1) Non-Executive and Non-Independent Director in MedScan, Joint Stock Company; and 2) Non-Executive Director in Asian American Medical Group Limited.
Marat Devlet-Kildeev	28.11.2018	30.04.2025	NA	None	None	1) Non-Executive Director in Dubultu Krasts, SIA; 2) Executive Director in Rīgas Nukleārās Medicīnas Laboratorija, SIA; 3) Tetra JSC, Indirect member, Director/President; and 4) Happy Cow LLC, Indirect member.
Ravi Chidambaram	28.06.2019	29.04.2023	At the forthcoming AGM of the Company	None	None	1) CeeSuite Pte. Ltd., Director; 2) Datarama Pte. Ltd., Director;

Annual Report 2025
UpHealth Group Limited
(Formerly known as Don Agro International Limited)

CORPORATE GOVERNANCE REPORT

						3) Datarama Technology Pte. Ltd, Director; 4) Oneness Pte. Ltd., Director; 5) TCVN IT Pte. Ltd., Director; 6) TC Capital Pte. Ltd., Director; 7) Watershed Holdings Pte. Ltd., Director; 8) TC Capital Advisory Ltd., Director; 9) TC Capital Partners Ltd, Director; 10) Zen Capital Ltd, Director; 11) Rimm Sustainability Pte Ltd, Director; 12) Ecosphere Partners Ptd Ltd, Director; 13) TNGA Pte Ltd, Director; 14) Amar Terrace Pte Ltd, Director; And 15) Atom8ai Pte Ltd, Director
Gavin Mark McIntyre	16.08.2023	29.04.2024	At the forthcoming AGM of the Company	None	1) Director in Embracing Future Holdings	1) Director in Xihe Holdings Group of Companies (in Liquidation); 2) Director

Annual Report 2025
UpHealth Group Limited
(Formerly known as Don Agro International Limited)

CORPORATE GOVERNANCE REPORT

					Limited (fka Biolidics Ltd); 2) Director in Vcplus Limited; 3) Director in Nico Steel Holdings Limited; and 4) Director in Bromat Holdings Ltd.	in Equitas Financial Services Pte. Ltd; 3) Director in Equitasasia Holdings Pte. Ltd; 4) Director and shareholder in Equitasasia Pte Ltd and 5) Director and shareholder in Aegis Interaktif Asia Pte Ltd.
Tan Poh Chye Allan	17.10.2024	30.04.2025	NA	1) Independent Director in VibroPower Corporation Limited; 2) Lead Independent Director in EcoWise Holdings Limited;	1) Affinity Energy and Health Limited (listed on ASX) - Independent Director; 2) Nico Steel Holdings Limited – Lead Independent Director; and 3) CNMC Goldmine Holdings Limited – Independent Director.	1) Director in Wealthy Genius Private Limited (f.k.a. The Verdure Group Private Limited) (dormant); 2) Director in Resort Marketing Corp Pte. Ltd. (dormant); and 3) Director, Nine Yards Chambers LLC; and 4) Sole Proprietor of Allan Tan Corporate Services.

Annual Report 2025
UpHealth Group Limited
(Formerly known as Don Agro International Limited)

CORPORATE GOVERNANCE REPORT

BOARD PERFORMANCE

Principle 5: The Board undertakes a formal annual assessment of its effectiveness as a whole, and that of each of its board committees and individual directors.

Provisions 5.1 and 5.2

The NC decides how the Board's performance is to be evaluated and proposes objective performance criteria, subject to the Board's approval, which address how the Directors have enhanced long-term shareholders' value.

The assessment of the Board, Board Committees and the Directors are to be carried out once every financial year. Each member of the NC is required to abstain from deliberations and voting on any matter relating to the assessment of his own performance or re-nomination as a Director. The evaluation of Board's and Board Committees' performance shall consider matters on Board composition, information to the Board, Board procedures and Board accountability. The evaluation of individual Directors takes into account their attendance at meetings, discharge of duties and responsibilities, and level of engagement and contribution in Board discussions.

The NC had adopted the following annual assessment forms which required the completion by each Director and respective Board Committees' member:

- Board and Board Committee Performance Evaluation Form; and
- Individual Director Evaluation Form.

The Directors complete the board assessment questionnaire and the results are collated by the Company Secretaries and the summary of the assessment are presented to the Chairman of the Board and the NC for review and collective discussion with other Board members to address or recommend any areas for improvement and follow up actions. The appraisal process focuses on a set of performance criteria for the Board, Board Committees and individual Directors' assessment which includes:

- a) For the Board: the evaluation of the (i) size and composition of the Board, (ii) the Board's access to information, (iii) the Board processes and accountability, (iv) Board performance in relation to discharging its principal responsibilities, (v) communication with Key Management Personnel and (vi) the Directors' standards of conduct; and
- b) For an individual Director: the evaluation of:
 - (i) attendance at Board and Board Committee meetings; (ii) Director's duties such as preparation for Board and Board and Committee meetings, willingness to devote time and effort to participate in events outside the Boardroom, contribution to development of strategy and to risk management, resolution in maintaining own views and resisting pressure from others, compliance with corporate governance requirements; (iii) know-how

Annual Report 2025
UpHealth Group Limited
(Formerly known as Don Agro International Limited)

CORPORATE GOVERNANCE REPORT

such as financial, business, industry and company knowledges; and (iv) interaction on how well does the Director interact with: fellow directors, Key Management Personnel, shareholders and auditors.

NC then makes recommendations to the Board aimed at helping the Board to discharge its duties effectively. The Chairman of the Board act on the results of the performance evaluation and the recommendation of the NC, and where appropriate, in consultation with the NC, new Members may be appointed or resignation of Directors may be sought.

The NC, having reviewed the overall performance of the Board and the Board Committees, as well as the assessment of the individual Director, in terms of its role and responsibilities and the conduct of its affairs as a whole for FY2025, is of the view that the performance of the Board as a whole, Board Committees and contribution by each Director have been satisfactory and that the Board has met its performance objective for FY2025.

The NC did not propose any changes to the performance criteria for FY2025 as compared to the previous financial year as the economic climate, Board composition and the Group's principal business activities remained the same.

No external facilitator was engaged by the Board for the evaluation process in FY2025. The NC has full authority to engage external facilitators to assist the NC to carry out the evaluation process, if the need arises.

REMUNERATION MATTERS

PROCEDURES FOR DEVELOPING REMUNERATION POLICIES

Principle 6: The Board has a formal and transparent procedure for developing policies on director and executive remuneration, and for fixing the remuneration packages of individual directors and key management personnel. No director is involved in deciding his or her own remuneration.

Provision 6.1

The RC was formed to recommend to the Board a framework of remuneration for our Directors and Key Management Personnel, and determine specific remuneration packages for each Director and Key Management Personnel. The recommendations of RC should be submitted for endorsement by the entire Board. All aspects of remuneration, including but not limited to directors' fees, salaries, allowances, bonuses, the options to be issued under the Share Option Scheme (the "ESOS") and other benefits-in-kind shall be covered by our RC. RC reviews the remuneration packages of Directors and Key Management Personnel to ensure that said packages, including termination terms, are fair.

Annual Report 2025
UpHealth Group Limited
(Formerly known as Don Agro International Limited)

CORPORATE GOVERNANCE REPORT

Provision 6.2

The RC comprises three (3) Independent Directors (including the Lead Independent Director), Mr. Ravi Chidambaram (Chairman), Mr. Gavin Mark McIntyre and Mr. Tan Poh Chye Allan.

Provision 6.3

In addition, the RC performs an annual review of the remuneration of employees related to Directors and/or substantial shareholders of the Company to ensure that their remuneration packages are in line with our staff remuneration guidelines and commensurate with their respective job scopes and level of responsibilities. They will also review and approve any bonuses, pay increases and/or promotions for these employees. Each Member of the RC abstains from voting on any resolutions in respect of his remuneration package or that of employees related to him.

Provision 6.4

No remuneration consultants were engaged by the Company in FY2025.

Level and Mix of Remuneration

Principle 7: The level and structure of remuneration of the Board and key management personnel are appropriate and proportionate to the sustained performance and value creation of the company, taking into account the strategic objectives of the company.

Provisions 7.1, 7.2 and 7.3

The Company has entered into respective service agreements (“**Service Agreements**”) with the Executive Chairman, Mr. Evgeny Tugolukov, and the CEO, Mr. Marat Devlet-Kildeev, the Chief Financial Officer (“**CFO**”), Mr. Artur Nazaryan and the Chief Operating Officer (“**COO**”), Mr. Vadim Novikov (each an “**Appointee**”).

The Service Agreements are valid for an initial period of three (3) years with effect from the date of admission of the Company to Catalist (“**Initial Term**”), being 14 February 2020. Upon the expiry of the Initial Term, the employment of the Appointees shall be automatically renewed on a year-on-year basis on such terms and conditions as the parties may agree unless terminated in accordance with the respective Service Agreements.

Each Appointee’s remuneration and annual fixed bonus is a subject to annual review by the RC after the accounts of our Group for the immediate preceding financial year have been audited, in light of their performance and prevailing economic conditions. The Service Agreements provided for, *inter alia*, the salary payable to the Appointees, annual leave, medical benefits, grounds of termination and certain restrictive covenants (including non-compete obligations).

The Executive Chairman, CEO and CFO may terminate their respective Service Agreements at any time by giving to our Company not less than six (6) months’ notice in writing, or in lieu of notice, payment of an amount equivalent to six (6) months’ salary based on their respective last

Annual Report 2025
UpHealth Group Limited
(Formerly known as Don Agro International Limited)

CORPORATE GOVERNANCE REPORT

drawn monthly salary; while the COO may terminate his Service Agreement at any time by giving to our Company not less than three (3) months' notice in writing, or in lieu of notice, payment of an amount equivalent to three (3) months' salary based on his last drawn monthly salary. The parties may by mutual agreement waive or vary the notice requirement.

Pursuant to the respective Service Agreements, the remuneration received by each Appointee in FY2025 is made up of only fixed compensation consisting annual base salary. The variable component of compensation is in the form of the Company's ESOS.

To enhance its remuneration so as to attract, retain and motivate the Directors to provide good stewardship of the Company and Key Management Personnel, the Company has adopted a share option scheme, the ESOS, which was approved at an extraordinary general meeting ("EGM") of our Shareholders held on 4 February 2020. The ESOS serves as a long-term incentive scheme for the Directors and employees of the Company. The ESOS serves to increase the Company's flexibility and effectiveness in its continuing efforts to reward, retain and motivate employees to improve their performance and to align the interests of Directors with the interests of Shareholders. For details about the ESOS, please refer to the Directors' Statement section of this Annual Report.

The Non-Executive Directors do not have Service Agreements with the Company. They are paid fixed Directors' fees, which are determined by the Board appropriate to the level of their contributions, taking into account factors such as the effort and time spent and the responsibilities of each Non-Executive Director.

The Independent Non-Executive Directors' fees are proposed by the RC and recommended by the Board for shareholders' approval at a general meeting of the Company. Non-Executive Directors' fees of S\$180,000 for FY2025 had been approved at the AGM held on 30 April 2025. The RC has reviewed and assessed that the remuneration of the Non-Executive Directors for FY2025 is appropriate, considering the effort, time spent and responsibilities.

DISCLOSURE ON REMUNERATION

Principle 8: The company is transparent on its remuneration policies, level and mix of remuneration, the procedure for setting remuneration, and the relationships between remuneration, performance and value creation.

Provisions 8.1, 8.2 and 8.3

The remuneration (including salary, directors' fees, bonus) paid during FY2025 are set out in the following remuneration bands³

³ Remuneration bands:

Band A" refers to remuneration of up to S\$250,000

Band B" refers to remuneration between S\$250,001 and S\$500,000

Band C" refers to remuneration from S\$500,001 to S\$750,000

Annual Report 2025
UpHealth Group Limited
(Formerly known as Don Agro International Limited)

CORPORATE GOVERNANCE REPORT

FY2025

Directors

Evgeny Tugolukov	Band A
Marat Devlet-Kildeev	Band C
Ravi Chidambaram	Band A
Tan Poh Chye Allan	Band A
Gavin Mark McIntyre	Band A

Executive Officers

Artur Nazaryan	Band A
Vadim Novikov	Band A

The breakdown for the remuneration of the Directors in FY2025 was as follows:

Director's Remuneration

Name	Salary (%)	Bonus (%)	Directors' Fees (%)	Benefits-in-kind (%)	Total (%)	Total (\$)
Between S\$500,001 to S\$750,000	-	-	-	-	-	-
Marat Devlet-Kildeev	100	-	-	-	100	653,470
Below S\$250,000						
Evgeny Tugolukov	100	-	-	-	100	195,158
Ravi Chidambaram	-	-	100	-	100	80,000
Tan Poh Chye Allan	-	-	100	-	100	60,000
Gavin Mark McIntyre	-	-	100	-	100	80,000

The Company, for FY2025, has only two (2) Key Management Personnel. The breakdown for the remuneration of the Company's Key Management Personnel (who are not Directors or the CEO) in FY2025 was as follows:

Name	Salary (%)	Bonus (%)	Directors' Fees (%)	Benefits-in-kind (%)	Total (%)
Below S\$250,000					
Artur Nazaryan	100	-	-	-	100
Vadim Novikov	100	-	-	-	100

The total remuneration paid to the Key Management Personnel in FY2025 was S\$323,043.

There were no termination, retirement and post-employment benefits granted to Directors and Key Management Personnel in FY2025.

In 2024, the duties of three directors were effectively performed by two independent directors, Mr. Ravi and Mr. Gavin, as Mr. Allan was appointed as an independent director on 17 October 2024. Accordingly, the total amount of directors' fees for 2024 amounted to \$132,459, which is

Annual Report 2025
UpHealth Group Limited
(Formerly known as Don Agro International Limited)

CORPORATE GOVERNANCE REPORT

\$47,541 below the total directors' remuneration. On 7 April 2025, Mr. Ravi and Mr. Gavin were each paid an additional \$20,000 for their services rendered in FY2024, which is within the total amount of \$180,000 approved by the board of directors for the remuneration of independent directors for FY2024.

As mentioned under Principle 7 of this Report, the terms of employment as set out in the Service Agreements with the Executive Directors and Key Management Personnel shall commence with effect from the date on which the Company is admitted to the Catalist (the “**Commencement Date**”) and shall continue on the Initial Term. After the Initial Term, the Appointee’s employment shall be automatically renewed on a year-to-year basis on such terms and conditions as the parties may agree.

There were no employees who are substantial shareholders of the Company, or are immediate family members of a Director, the CEO or a substantial shareholder.

Further details on the ESOS can be found in the “Director’s statement” section of this Annual Report.

ACCOUNTABILITY AND AUDIT

RISK MANAGEMENT AND INTERNAL CONTROLS

Principle 9: The Board is responsible for the governance of risk and ensures that Management maintains a sound system of risk management and internal controls, to safeguard the interests of the company and its shareholders.

Provision 9.1

The Board believes in the importance of maintaining a system of risk management and internal controls to safeguard the interests of the shareholders and the Group’s assets.

The Board, with assistance of the ARC, is responsible for the effective design, implementation and monitoring of the Company’s risk management strategy and internal controls. In addition, the Executive Directors and the management regularly review the Group’s business and operational activities to identify areas of significant business risks as well as appropriate measures to control and mitigate these risks. The management reviews significant control policies and procedures, and highlights the significant matters to the Board and the ARC.

The Company is committed to conducting business in full compliance with all applicable laws and regulations related to economic sanctions, export controls, trade embargoes and wider prohibitions and restrictions on international trade and investment related activities, including but not limited to those adopted, administered and enforced by the Government of the United States, the European Union and its member states, the United Nations Security Council, the Government of Australia and the Government of Singapore (“**International Sanctions**”), to the extent they apply to the activities of the Group.

Annual Report 2025
UpHealth Group Limited
(Formerly known as Don Agro International Limited)

CORPORATE GOVERNANCE REPORT

In order to protect the interests of our Group and to reduce the risk of our Group infringing any International Sanctions Laws, our Group has adopted a sanctions compliance policy (“**Sanctions Compliance Policy**”) which sets out enhanced internal control and risk management measures to help our Group monitor and evaluate our business and take measures to protect the interests of our Group from any material risk relating to International Sanctions Laws.

This Sanctions Compliance Policy (including the Sanctions Risk Rating Policy) was reviewed by Hogan Lovells (the “**External Sanctions Counsel**”), and the Board. This Sanctions Compliance Policy is disseminated throughout our domestic operations and overseas offices and branches.

The Sanctions Compliance Policy (including the Sanctions Risk Rating Policy) is reviewed by the External Sanctions Counsel on an annual basis to ensure that they are adequate and effective.

The ARC has the ultimate responsibility for ensuring that the Group complies with International Sanctions Laws and regulations at all times.

The Company’s CEO and COO are responsible for, among other things, monitoring the Company’s exposure to sanctions risks and our implementation of the related internal control procedures, and report to our ARC in relation thereto.

The Group uses the Dow Jones database for sanction’s screening of the new counterparties, including suppliers and customers. There were no new sanctioned companies found as a result of this screening.

The ARC holds at least two (2) meetings each year to monitor our exposure to sanctions risks. The Company’s CEO and/or COO should be familiar with International Sanctions and be able to identify issues, risks and prohibited activities in relation to International Sanctions.

The External Sanctions Counsel has made the following conclusions in the Memorandum of Advice to the Company dated 14 April 2026:

- (a) the Group’s activities during the Period Under Review do not appear to violate or implicate any breaches of the restrictions under International Sanctions;
- (b) the Group’s activities do not constitute “Sanctioned Activities” as that term is defined in the SGX Conditions; and
- (c) the Group’s dealings with any of the parties that may be deemed to be Sanctioned Subjects within the meaning of the SGX Conditions do not violate any International Sanctions laws and regulations.

In making the conclusion of the External Sanctions Counsel and to ensure the Sanctions Compliance Policy is adequate and effective, our External Sanctions Counsel carried out the following measures to review the Company’s compliance with the Sanctions Compliance Policy.

Annual Report 2025
UpHealth Group Limited
(Formerly known as Don Agro International Limited)

CORPORATE GOVERNANCE REPORT

The External Sanctions Counsel reviewed the Group's responses to the "International Sanctions Due Diligence Checklist" dated 2 July 2025 (the "**Sanctions DD Checklist**"), prepared by Hogan Lovells, and updated responses by e-mail correspondence on and around 12 April 2026. The Group's responses to the Sanctions DD Checklist included disclosure of all counterparties with whom the Group transacted during FY2025, the Group's transactions with the counterparties from the countries, where international sanctions are applicable, with the parties which are included in various list of restricted parties, such as the List of Specially Designated Nationals and Blocked Persons, the Sectoral Sanctions Identification List, maintained by the U.S. Department of the Treasury's Office of Foreign Asset Control and other lists of restricted or sanctioned subjects, entities and organizations maintained by the United States, European Union, the United Nations or other jurisdictions or controlled by persons or entities from such lists. The Group's responses to the Sanctions DD Checklist have included documents and information that relate to the subject matter of the Sanctions DD Checklist. Based on a review of the Company's responses, the External Sanction Counsel assessed the Company's compliance with the Sanctions Compliance Policy and the Company's carrying out of compliance measures as part of the assessment of the adequacy and effectiveness of the Sanctions Compliance Policy. There was no update to the Sanctions Compliance Policy in FY2025.

Management has overseen an external audit and conducted a review of sanction compliance in FY2025. As such, the Board remains confident in the Group's implementation of adequate and effective internal controls (including financial, operational, compliance and information technology controls), risk management systems and sanctions risks management to safeguard the interest of the Group and its shareholders in FY2025.

Based on the internal controls established and maintained by the Company, work performed by the internal and external auditors, and reviews performed by management, other committees of the Board and the Board, with the concurrence of the Audit and Risk Committee, is of the opinion that the Company's internal controls (including financial, operational, compliance and information technology controls), and risk management systems were adequate and effective as at 31 December 2025.

Provision 9.2

The Board has received assurance from the CEO and CFO in respect of FY2025 that:

- (a) the financial records have been properly maintained and the financial statements give true and fair view of the Company's operations and finances; and
- (b) the Company's risk management and internal controls system are adequate and effective.

AUDIT AND RISK COMMITTEE ("ARC")

Principle 10: The Board has an Audit and Risk Committee which discharges its duties objectively.

Provision 10.1

Annual Report 2025
UpHealth Group Limited
(Formerly known as Don Agro International Limited)

CORPORATE GOVERNANCE REPORT

The written terms of reference of the ARC have been approved and adopted.

The ARC performs the following functions:

- (a) review the relevance and consistency of the accounting standards, the significant financial reporting issues, recommendations and judgements made by the external auditors so as to ensure the integrity of the financial statements of our Group and any announcements relating to our Group's financial performance;
- (b) review and report to the Board, at least annually, the adequacy and effectiveness of our Group's internal controls, including financial, operational, compliance and information technology controls (such review can be carried out internally or with the assistance of any competent third parties), and risk management systems;
- (c) review the assurance from the CEO and the CFO on the financial records and financial statements;
- (d) review the adequacy, effectiveness, independence, scope and results of the external audit and our Group's internal audit function;
- (e) make recommendations to the Board on the proposals to the shareholders on the appointment, reappointment and removal of the external auditors, and on the remuneration and terms of engagement of the external auditors;
- (f) review the system of internal controls and management of financial risks with our internal and external auditors;
- (g) review the co-operation given by our management to external auditors and internal auditors, where applicable;
- (h) review the Group's compliance with such functions and duties as may be required under the relevant statutes or the Catalist Rules, including such amendments made thereto from time to time;
- (i) review and approve interested person transactions and review procedures thereof;
- (j) review potential conflicts of interest (if any) and to set out a framework to resolve or mitigate any potential conflicts of interests;
- (k) review risk management framework, with a view to providing an independent oversight on Group's financial reporting, the outcome of such review to be disclosed in the annual reports or, where the findings are material, announced immediately via SGXNet;
- (l) investigate any matters within its terms of reference;

Annual Report 2025
UpHealth Group Limited
(Formerly known as Don Agro International Limited)

CORPORATE GOVERNANCE REPORT

- (m) review the policy and arrangements concerns about possible improprieties in financial reporting or other matters to be safely raised, independently investigated and appropriately followed up on;
- (n) review the adequacy of and approve procedures put in place related to our Group's policy for entering into any future hedging transactions;
- (o) review the sanctions-related risks of our Group including transactions and business dealings with our customers, suppliers and bankers and assess whether there is a need to obtain independent legal advice and/or appoint a compliance adviser with respect to the applicable sanctions risks faced by our Group;
- (p) monitor the Group's measures and procedures to manage sanctions-related risks and review the Sanctions Compliance Policy and the adequacy of safeguards in relation to potential sanctions-related risks to the Group;
- (q) review the utilisation of funds (including any material deviation from such utilisation) raised from the Placement and any secondary fund-raising post-Listing to ensure that they are solely for the purposes disclosed in the listing document and to the SGX-ST, and not to benefit any Sanctioned Subject;
- (r) provide their views (which will be stated in our annual report) on whether they concur with our Board's comment on whether the Company has adequate and effective internal controls (including internal controls related to cash flows) and risk management systems to safeguard the interests of the Group and the shareholders, in particular with respect to sanctions risks;
- (s) continuously monitor the written undertakings which our Group has provided to SGX-ST and ensure timely and accurate disclosures to SGX-ST and the relevant authorities should any enquiries be made regarding our Group's dealings with Sanctioned Subjects; and
- (t) undertake such other functions and duties as may be required by statute or the Catalist Rules, and by such amendments made thereto from time to time.

Apart from the duties listed above, the ARC shall commission and review the findings of internal investigations into matters where there is any suspected fraud or irregularity, or failure of internal controls or suspected infringement of any Singapore law, rule or regulation which has or is likely to have a material impact on Group's operating results and/or financial position. In the event that a member of our ARC is interested in any matter being considered by ARC, he will abstain from reviewing and deliberating on that particular transaction or voting on that particular resolution.

Provisions 10.2 and 10.3

The ARC comprises three (3) Independent Directors, namely Mr. Gavin Mark McIntyre (Chairman), Mr. Ravi Chidambaram (Lead Independent Director) and Mr. Tan Poh Chye Allan.

Annual Report 2025
UpHealth Group Limited
(Formerly known as Don Agro International Limited)

CORPORATE GOVERNANCE REPORT

The members of the ARC are appropriately qualified to discharge their responsibilities and have relevant accounting and related financial management experience and expertise. None of the ARC members were previous partners or directors of the Company's external auditor, Foo Kon Tan LLP (the "**External Auditors**"), within the last two years or hold any financial interest in the external auditor.

Provision 10.4

Internal audit

The Company has engaged JSC MCD (the largest auditing firm in St. Petersburg, Russia) as its internal auditors ("**Internal Auditors**"). The internal auditor reports directly to the ARC and administratively to the Management. The internal audit work to be carried out is guided by the International Standards for Professional Practice of Internal Auditing (IIA Standards) laid down in the International Professional Practices Framework issued by the IIA.

The internal audit plan was approved by the Management and the ARC.

Pursuant to current the Company's status as cash company following the completion of Proposed Disposals (as defined in announcement dated 29 April 2024), the Internal Auditors performed audit procedures in relation to cash and bank management for FY2025 in JSC Tetra. The Company ceased to be a cash company on 12 February 2026. For further details, please refer to the Company's announcement dated 12 February 2026.

The ARC, in consultation with the management, approves the appointment, removal, evaluation and compensation of the Internal Auditors. The internal auditors have unfettered access to ARC and all the documents, records, properties, and personnel of the Group.

The ARC reviews, on an annual basis, the independence, adequacy and effectiveness of the internal audit function and the internal audit reports.

The ARC is satisfied that the internal audit function is independent, effective and adequately resourced to perform its functions for FY2025.

External audit

The ARC reviews the independence of the External Auditors on an annual basis. The ARC has received the audit report from the External Auditors, which includes details of the audit fees charged for FY2025.

Foo Kon Tan LLP ("**FKT**"), which is registered with the Accounting and Corporate Regulatory Authority of Singapore, will be able to meet the audit requirements of the Group.

Annual Report 2025
UpHealth Group Limited
(Formerly known as Don Agro International Limited)

CORPORATE GOVERNANCE REPORT

The aggregate amount of fees paid/payable to the external auditor of the Company for FY2025 are as follow:

	Audit fee (S\$'000)	Reporting Account fee (S\$'000)⁴	Non-audit fee (S\$'000)
FKT	72	300	-

The ARC is satisfied that the provision of non-audit services does not affect the independence of the External Auditors.

Accordingly, the ARC has recommended to the Board that FKT be nominated for re-appointment as the External Auditors of the Company at the forthcoming AGM.

JSC Beterra was the component auditor of all the foreign incorporated subsidiaries of the Company, namely (a) LLC Happy Cow and (b) JSC Tetra for the purpose of group reporting to the Company's principal auditors. The Group continues to engage LLC Stolichnaya Audit Company as the statutory auditor of JSC Tetra. The Board and ARC are satisfied that the appointment would not compromise the standard and effectiveness of the audit of the Company.

Accordingly, the Board confirms that Rules 712,715 and 716 of the Catalist Rules have been complied with.

No former partner or director of the Company's existing auditing firm has acted as a member of the ARC.

Provision 10.5

The ARC has met with the External Auditors and Internal Auditors at least once in the absence of Management in FY2025 and FY2026 respectively.

Whistle-blowing

The ARC is responsible for the oversight and monitoring of whistle-blowing matters and has reviewed the whistle-blowing policy that the Group has established. The ARC serves as an independent function to investigate whistleblowing reports made in good faith. The whistle-blowing policy provides mechanisms which ensure a secure and confidential channel that allows employees and external parties to report possible improprieties and disclose any wrongdoings such as fraud, misconduct, breach of any laws or any other illegal acts directly to the ARC Chairman. Reports can be lodged via email to whistleblower@donagroint.com. In addition, there are policies and reporting mechanisms for employees and customers to raise concerns to the management, who will escalate significant issues to the Board as required. Employees making the report in good faith and without malice are protected from reprisals, unfair treatment or

⁴ it refers to review fee arising from review work conducted by FKT in connection to the Group's Circular dated 30 December 2025.

Annual Report 2025
UpHealth Group Limited
(Formerly known as Don Agro International Limited)

CORPORATE GOVERNANCE REPORT

victimization. The ARC is satisfied that arrangements are in place to ensure independent investigation of such matters and for appropriate follow-up actions to be taken. There was no whistle-blowing report received via the whistle-blowing channels in FY2025.

SHAREHOLDER RIGHTS AND ENGAGEMENT

Shareholder Rights and conduct of general meetings

Principle 11: The company treats all shareholders fairly and equitably in order to enable them to exercise shareholders' rights and have the opportunity to communicate their views on matters affecting the company. The company gives shareholders a balanced and understandable assessment of its performance, position and prospects.

Provision 11.1

The Group's corporate governance practices promote fair and equitable treatment of all shareholders. All shareholders should equally and on a timely basis be informed of all major developments that impact the Group via SGXNet. The Group recognises that the release of timely and relevant information is central to good corporate governance and enables shareholders to make informed decisions in respect of their investments in the Company.

Shareholders are informed of general meetings through announcements released on the SGXNet and notices contained in the annual reports or circulars sent to all shareholders. The rules, including the voting procedures, will be clearly explained by the scrutineers at such general meetings. All shareholders are entitled to attend the general meetings and are provided the opportunity to participate in the general meetings. Shareholders are advised to refer to the Company's announcement on SGXNet on the notice of AGM which will be released in due course.

Provision 11.2

The Company takes note that there should be separate resolutions at general meetings on each substantially separate issue and to avoid bundling resolutions. Where the resolutions are "bundled" for issues which are interdependent and linked so as to form one significant proposal, the Company explains the reasons and material implications in the notice of meeting.

The Company typically ensures that there are separate resolutions at general meetings on each distinct issue. Detailed information on each item in the AGM/EGM agenda is provided in the explanatory notes to the Notice of AGM/EGM in the Annual Report.

Provision 11.3

General meetings of the Company are typically chaired by the Chairman of the Board and are also attended by other Directors, including the Chairmen of the NC, the RC and the ARC, as well as Management, the Company Secretaries and where appropriate, the External and Internal auditors. All Directors are present at all general meetings, unless of exigencies. At such meetings,

Annual Report 2025
UpHealth Group Limited
(Formerly known as Don Agro International Limited)

CORPORATE GOVERNANCE REPORT

shareholders are given the opportunity to raise questions and express their views, and to engage directly with the Directors, including the Chairmen of the Board Committees, on matters relating to the Company. Where appropriate, the External Auditors are also present to assist the Board in addressing shareholders' queries on the conduct of the audit, as well as the preparation and content of the auditor's report and other audit-related matters.

All Directors attended the AGM for the Company's financial year ended 31 December 2024 held on 30 April 2025 at 1 North Bridge, #13-06, High Street Centre, Singapore 179094 and by way of electronic means.

Provision 11.4

Voting in absentia and by electronic mail may only be possible following careful study to ensure integrity of the information and authentication of the identity of shareholder through the web is not compromised and is also subject to legislative amendment to recognise electronic voting.

Provision 11.5

The Company Secretary prepares minutes of general meetings that include substantial and relevant comments or queries from shareholders relating to the agenda of the meeting, and responses from the Board and Management, and the minutes of general meetings will be made available on SGXNet within one (1) month from the date of the general meetings.

Provision 11.6

The Company currently does not have a fixed dividend policy. Nonetheless, Key Management Personnel will review, *inter alia*, the Group's performance in the relevant financial period, projected capital needs and working capital requirements and make appropriate recommendations to the Board on dividend declaration.

There is no final dividend declared or recommended for FY2025 due to the Group's plans to conserve cash, improving working capital for potential further expansion of the Group, including the acquisition a medical business. Any dividend payments will be clearly communicated to shareholders via announcements on SGXNet.

ENGAGEMENT WITH SHAREHOLDERS

Principle 12: The company communicates regularly with its shareholders and facilitates the participation of shareholders during general meetings and other dialogues to allow shareholders to communicate their views on various matters affecting the company.

Provision 12.1

The Company is committed to disclose to its Shareholders the information in a timely and fair manner via announcements on SGXNet.

Annual Report 2025
UpHealth Group Limited
(Formerly known as Don Agro International Limited)

CORPORATE GOVERNANCE REPORT

The Board will support and encourage active shareholders' participation at AGMs as it believes that general meetings serve as an opportune forum for shareholders to meet the Board and key management, and to interact with them. General meetings have been and are still the principal forum for dialogue with the shareholders. They offer opportunities for the Board to interact with shareholders, understand their views, gather feedback as well as address concerns. Enquiries by shareholders are dealt with as promptly as practicably possible.

The Company does not practice selective disclosure. Results and annual reports are announced or issued within the mandatory period.

The Board is mindful of the obligation to provide regular, effective and fair communication with shareholders. Information is communicated to the shareholders on a timely basis through:

- annual reports that are prepared and sent to all shareholders. The Board makes every effort to ensure that the annual report includes all relevant information about the Group, including future developments and other disclosures required by the Companies Act and the relevant accounting standards;
- half-yearly and full-yearly announcements containing a summary of the financial information;
- notices of AGMs and EGMs;
- press releases on major developments of the Group;
- disclosures to the SGX-ST; and
- the Group's website at www.donagroint.com, at which shareholders can access information on the Group. The website provides, *inter alia*, products information and profile of the Group.

Provision 12.2

The Group does not have a formal investor relations policy but considers advice from its corporate lawyers and professionals before publishing press statements and financial results on the Company's website and SGXNet. All shareholders should be informed simultaneously in an accurate and comprehensive manner regarding all material developments that impact the Group via SGXNet on an immediate basis, in line with the Group's disclosure obligations pursuant to the Catalist Rules of the SGX-ST and the Companies Act.

The investor relations role is currently performed by Management who actively engages and promotes regular, effective and fair communication with shareholders. The Board would consider establishing an investor relations policy at the appropriate time and the appointment of a professional investor relations officer to manage the investor relations role should the need arise.

Annual Report 2025
UpHealth Group Limited
(Formerly known as Don Agro International Limited)

CORPORATE GOVERNANCE REPORT

Provision 12.3

Shareholder may contact the Group with questions, and the manner in which the Group may respond to such questions, including inter alia, through announcements made on the SGXNet, the Company's website, the Company's AGM and EGMs.

ENGAGEMENT WITH STAKEHOLDERS

Principle 13: The Board adopts an inclusive approach by considering and balancing the needs and interests of material stakeholders, as part of its overall responsibility to ensure that the best interests of the company are served.

Provision 13.1

The Company has identified stakeholders as those who are impacted by the Group's business and operations as well as those who have a material impact on the Group's business and operations. Such stakeholders include employees, contractors and suppliers, government and regulators, community, and shareholders and investors.

The Company engages its stakeholders through various channels (announcements via the SGXNet, general meetings and presentations to engage with these material stakeholders, company's website) to ensure that the business interests of the Group are balanced against the needs and interests of its stakeholders.

All shareholders receive the Company's annual report and notice of general meetings. The Board welcomes questions from Shareholders who wish to raise issues, either informally or formally before or during the general meetings.

To ensure that all shareholders have the opportunity to participate effectively in and vote at general meetings, voting at general meetings of the Company is conducted by poll where shareholders are accorded voting rights proportionate to their shareholding and all votes are counted and announced immediately at the meeting. The Company puts all resolutions to vote by poll at general meetings and the detailed results of the total number and percentage of votes cast for and against each resolution will be announced via SGXNet after the conclusion of the general meeting on the same day.

Provision 13.2

The Company has identified stakeholders as those who are impacted by the Group's business and operations as well as those who have a material impact on the Group's business and operations. Such stakeholders include employees, contractors and suppliers, government and regulators, community, and shareholders and investors.

Annual Report 2025
UpHealth Group Limited
(Formerly known as Don Agro International Limited)

CORPORATE GOVERNANCE REPORT

Provision 13.3

The Group maintains a current corporate website, www.donagroint.com, through which shareholders are able to access up to date information on the Group. The website provides annual reports, financial information, profiles of the Group and contact details of the investor relations of the Group.

DEALING IN SECURITIES

In accordance with the requirements of Rule 1204(19) of the Catalist Rules, the Company and its officers should not deal in the Company's securities during the period commencing one month before the announcement of the Company's half year and full year financial results, and ending on the date of announcement of the relevant results. The restriction extends to the issue of shares or other convertible securities by the Company, and the sale or purchase of shares or other convertible securities by its officers. Under the Securities and Futures Act 2001 ("SFA"), officers should note that it is an offence to deal in the Company's securities (as well as securities of other listed companies) while in possession of unpublished material price-sensitive information. They are also discouraged from dealing in the Company's securities on short-term considerations.

INTERESTED PERSON TRANSACTIONS

The Group has not obtained a general mandate from shareholders for recurrent interested person transactions. In FY2025 there were no interested person transactions.

NON-SPONSOR FEES

The total amount of non-sponsor fees paid/payable to the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd., for FY2025 was S\$400,000.

SUSTAINABILITY REPORTING

In July 2024, the Company became a cash company following the completion of the Proposed Disposals (as defined in announcement dated 29 April 2024) as defined under Rule 1017 of the Catalist Rules. Given the current cash company status of the Company, the Company will not be publishing its Sustainability Report for FY2025. The Company has made the announcement for non-issuance of sustainability report on 6 April 2026.

MATERIAL CONTRACTS

There were no material contracts entered into by the Group involving the interest of any Director or controlling shareholder of the Company, either subsisting at the end of the financial year, or if not then subsisting, entered into since the end of the previous financial year.

Annual Report 2025
UpHealth Group Limited
(Formerly known as Don Agro International Limited)

DIRECTORS' STATEMENT

The directors are pleased to present their statement to the members of UpHealth Group Limited (formerly known as Don Agro International Limited) (the “**Company**”) together with the audited consolidated financial statements of the Company and its subsidiaries (collectively the “**Group**”) and statement of financial position of the Company for the financial year ended 31 December 2025.

In our opinion:

- (a) the consolidated financial statements of the Group and the statement of financial position of the Company are drawn up so as to give a true and fair view of the financial position of the Group and of the Company as at 31 December 2025 and of the financial performance, changes in equity and cash flows of the Group for the financial year ended on that date, in accordance with the provisions of the Singapore Companies Act 1967 (the “**Act**”) and Singapore Financial Reporting Standards (International); and
- (b) at the date of this statement, there are reasonable grounds to believe that the Company will be able to pay its debts as and when they fall due.

The Board of Directors has, on the date of this statement, authorised these financial statements for issue.

Name of directors

The Directors of the Company in office at the date of this statement are as follows:

Evgeny Tugolukov
Marat Devlet-Kildeev
Ravi Chidambaram
Gavin Mark McIntyre
Tan Poh Chye Allan

Change of name

On 30 January 2026, the Company changed its name from Don Agro International Limited to UpHealth Group Limited.

Arrangements to enable directors to acquire benefits by means of the acquisition of shares or debentures

Neither at the end of, nor at any time during the financial year, was the Company a party to any arrangement whose objects are, or one of whose objects is, to enable the directors of the Company to acquire benefits by means of the acquisition of shares in or debentures of the Company or any other body corporate, other than as disclosed in this statement.

Annual Report 2025
UpHealth Group Limited
(Formerly known as Don Agro International Limited)

DIRECTORS' STATEMENT

Directors' interests in shares or debentures

According to the Register of Directors' Shareholdings kept by the Company under Section 164 of the Act, none of the directors who held office at the end of the financial year had any interest in the shares or debentures of the Company or its related corporations, except as follows:

	<u>Shareholdings registered in the name of Directors</u>		<u>Shareholdings in which directors are deemed to have an interest</u>	
	<u>As at 1.1.2025</u>	<u>As at 31.12.2025</u>	<u>As at 1.1.2025</u>	<u>As at 31.12.2025</u>
The Company	<u>Number of ordinary shares</u>			
Evgeny Tugolukov	117,500,000	117,500,000	6,585,000	6,585,000
Marat Devlet-Kildeev	7,500,000	7,500,000	-	-

In accordance with the continuing listing requirements of the Singapore Exchange Securities Trading Limited ("SGX-ST"), the Directors of the Company state that, according to the Register of the Directors' Shareholdings, the Directors' interests as at 21 January 2026 in the shares or debentures of the Company have not changed from those disclosed as at 31 December 2025.

Share options

In conjunction with our listing on the Catalist Board of Singapore Exchange Securities Trading Limited ("Catalist") we have adopted an employee share option scheme ("ESOS") which was approved at an Extraordinary General Meeting of our Shareholders held on 4 February 2020. The ESOS shall continue in operation for a maximum duration of 10 years commencing on the date on which the ESOS was adopted by our Company in the general meeting and may be continued for any further period thereafter with the approval of our Shareholders. No options were issued under the ESOS.

Summary of the ESOS

The following is a summary of the rules of the ESOS:

(1) Participants

Confirmed Group Employees (including Executive Directors) and Non-Executive Directors (including Independent Directors) who have attained the age of twenty-one (21) years on or prior to the relevant Offer Date and are not undischarged bankrupts and have not entered into a composition with their respective creditors, shall be eligible to participate in the ESOS at the absolute discretion of the Committee.

DIRECTORS' STATEMENT

Summary of the ESOS (Cont'd)

(1) Participants (Cont'd)

Confirmed Group Employees (including Executive Directors) and Non-Executive Directors (including Independent Directors) who are also Controlling Shareholders or Associates of a Controlling Shareholder are also eligible to participate in the ESOS provided that (a) the participation of, and (b) the terms of any Options to be granted and the actual number of Shares to be granted under the ESOS, to a Participant who is a Controlling Shareholder or an Associate of a Controlling Shareholder shall be approved by the independent Shareholders in separate resolutions for each such person.

(2) Administration

The ESOS shall be administered by the Committee with powers to determine, *inter alia*, the following:

- (a) persons to be granted Options;
- (b) number of Options to be granted; and
- (c) recommendations for modifications to the ESOS.

The Committee will consist of Directors who are in the Remuneration Committee (including Directors or persons who may be participants of the ESOS). A member of the Committee who is also a participant of the ESOS must not be involved in any deliberation or decision in respect of Options granted or to be granted to him.

(3) Size of the ESOS

The total number of Shares over which the Committee may grant Options on any date, when added to the number of Shares issued and issuable in respect of (a) all Options granted under the ESOS; and (b) all outstanding options or awards granted under such other share-based incentive schemes of the Company, shall not exceed 15.0% of the number of issued Shares (including treasury shares, as defined in the Act) on the day immediately preceding the Offer Date of the Option. Our Directors believe that this limit gives us sufficient flexibility to decide upon the number of Option Shares to offer to our existing and new employees. The number of eligible participants is expected to grow over the years. Our Company, in line with its goal of ensuring sustainable growth, is constantly reviewing its position, and considering the expansion of its talent pool which may involve employing new employees. The employee base, and thus the number of eligible participants will increase as a result. If the number of Options available under the ESOS is limited, our Company may only be able to grant a small number of Options to each eligible participant which may not be a sufficiently attractive incentive. Our Company is of the opinion that it should have sufficient number of Options to offer to new employees as well as to existing ones. The number of Options offered must also be significant to serve as a meaningful reward for contributions to our Group. However, it does not necessarily mean that the Committee will definitely issue Option Shares up to the prescribed limit. The Committee shall exercise its discretion in deciding the number of Option Shares to be granted to each employee which will depend on the performance and value of the employee to our Group.

Annual Report 2025
UpHealth Group Limited
(Formerly known as Don Agro International Limited)

DIRECTORS' STATEMENT

Summary of the ESOS (Cont'd)

(4) Maximum entitlements

The aggregate number of Shares comprised in any Option to be offered to a participant under the ESOS shall be determined at the absolute discretion of the Committee, which shall take into account (where applicable) criteria such as rank, past performance, years of service, potential for future development of that participant. The aggregate number of Shares in respect of which Options may be granted to the Controlling Shareholders or Associates of the Controlling Shareholders under the ESOS shall not exceed 25.0% of the total number of Shares available under the ESOS. The aggregate number of Shares in respect of which Options may be granted to any individual Controlling Shareholders or Associates of the Controlling Shareholders under the ESOS shall not exceed 10.0% of the total number of Shares available under the ESOS.

(5) Options, exercise period and exercise price

The Options that are granted under the ESOS may have exercise prices that are, at the Committee's discretion, set at a price (the "**Market Price**") equal to the average of the last dealt prices for the Shares on the Official List of Catalist for the five (5) consecutive Market Days immediately preceding the relevant date of grant of the relevant Option; or at a discount to the Market Price (subject to a maximum discount of 20.0%). Options which are fixed at the Market Price ("**Market Price Option**") may be exercised after the first anniversary of the date of grant of that Option while Options exercisable at a discount to the Market Price ("**Discounted Option**") may only be exercised after the second anniversary from the date of grant of the Option. Options granted under the ESOS will expire upon the tenth anniversary of the date of grant of that Option (or, in the case of Options granted to a Non-Executive Director, upon the fifth anniversary of the date of grant of that Option).

During the financial year, there were:

- (i) no options granted by the Company or its subsidiaries to any person to take up unissued shares in the Company or its subsidiaries; and
- (ii) no shares issued by virtue of any exercise of options to take up unissued shares of the Company or its subsidiaries.

At the end of the year, there were no unissued shares of the Company or its subsidiaries under options granted by the Company or its subsidiaries as at the end of year.

Audit and Risk Committee ("ARC")

The ARC at the date of this statement comprises the following members, all of whom are Independent Directors:

Gavin Mark McIntyre (Chairman)
Ravi Chidambaram
Tan Poh Chye Allan

DIRECTORS' STATEMENT

Audit and Risk Committee ("ARC") (Cont'd)

The ARC has carried out its functions in accordance with Section 201B(5) of the Act, including reviewing the following, where relevant, with the Executive Directors, external auditor and internal auditor of the Company:

- (a) review the relevance and consistency of the accounting standards, the significant financial reporting issues, recommendations and judgements made by the external auditors so as to ensure the integrity of the financial statements of our Group and any announcements relating to our Group's financial performance;
- (b) review and report to the Board, at least annually, the adequacy and effectiveness of our Group's internal controls, including financial, operational, compliance and information technology controls (such review can be carried out internally or with the assistance of any competent third parties), and risk management systems;
- (c) review the assurance from the Chief Executive Officer and the Chief Financial Officer on the financial records and financial statements;
- (d) review the adequacy, effectiveness, independence, scope and results of the external audit and our Group's internal audit;
- (e) make recommendations to the Board on the proposals to the shareholders on the appointment, reappointment and removal of the external auditors, and on the remuneration and terms of engagement of the external auditors;
- (f) review the system of internal controls and management of financial risks with our internal and external auditors;
- (g) review the co-operation given by our management to external auditors and internal auditors, where applicable;
- (h) review the Group's compliance with such functions and duties as may be required under the relevant statutes or the Catalist Rules, including such amendments made thereto from time to time;
- (i) review and approve interested person transactions and review procedures thereof;
- (j) review potential conflicts of interest (if any) and to set out a framework to resolve or mitigate any potential conflicts of interests;
- (k) review risk management framework, with a view to providing an independent oversight on Group's financial reporting, the outcome of such review to be disclosed in the annual reports or, where the findings are material, announced immediately via SGXNet;
- (l) investigate any matters within its terms of reference;
- (m) review the policy and arrangements concerns about possible improprieties in financial reporting or other matters to be safely raised, independently investigated and appropriately followed up on;
- (n) review the adequacy of and approve procedures put in place related to our Group's policy for entering into any future hedging transactions;
- (o) review the sanctions-related risks of our Group including transactions and business dealings with our customers, suppliers and bankers and assess whether there is a need to obtain independent legal advice and/or appoint a compliance adviser with respect to the applicable sanctions risks faced by our Group;

Annual Report 2025
UpHealth Group Limited
(Formerly known as Don Agro International Limited)

DIRECTORS' STATEMENT

Audit and Risk Committee (“ARC”) (Cont’d)

- (p) monitor the Group’s measures and procedures to manage sanctions-related risks and review the Sanctions Compliance Policy and the adequacy of safeguards in relation to potential sanctions-related risks to the Group;
- (q) review the utilisation of funds (including any material deviation from such utilisation) raised from the Placement and any secondary fund-raising post-Listing to ensure that they are solely for the purposes disclosed in the listing document and to the SGX, and not to benefit any Sanctioned Subject;
- (r) provide their views (which will be stated in our annual report) on whether they concur with our Board’s comment on whether the Company has adequate and effective internal controls (including internal controls related to cash flows) and risk management systems to safeguard the interests of the Group and the shareholders, in particular with respect to sanctions risks;
- (s) continuously monitor the written undertakings which our Group has provided to SGX-ST and ensure timely and accurate disclosures to SGX-ST and the relevant authorities should any enquiries be made regarding our Group’s dealings with Sanctioned Subjects; and
- (t) undertake such other functions and duties as may be required by statute or the Catalist Rules, and by such amendments made thereto from time to time.

The ARC has full access to and has the co-operation of management and has been given the resources required for it to discharge its function properly. It also has full discretion to invite any Director and executive officer to attend its meetings. The external and internal auditor have unrestricted access to the ARC.

In appointing the auditors for the Company and its subsidiaries, we have complied with the Catalist Rules 712 and 715 of the SGX-ST Listing Manual.

Full details of the ARC are disclosed in the Corporate Governance Report.

Independent auditor

The independent auditor, Foo Kon Tan LLP, Public Accountants and Chartered Accountants, has expressed its willingness to accept re-appointment.

On behalf of the Directors

.....
EVGENY TUGOLUKOV

.....
MARAT DEVLET-KILDEYEV

Dated: 14 April 2026

Annual Report 2025
UpHealth Group Limited
(Formerly known as Don Agro International Limited)

INDEPENDENT AUDITORS' REPORT

Report on the Audit of the Financial Statements

Opinion

We have audited the financial statements of UpHealth Group Limited (formerly known as Don Agro International Limited) (the “**Company**”) and its subsidiaries (the “**Group**”), which comprise the consolidated statement of financial position of the Group and the statement of financial position of the Company as at 31 December 2025, and the consolidated statement of profit or loss and other comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows of the Group for the year then ended, and notes to the financial statements, including material accounting policy information.

In our opinion, the accompanying consolidated financial statements of the Group and the statement of financial position of the Company are properly drawn up in accordance with the provisions of the Companies Act 1967 (the “**Act**”) and Singapore Financial Reporting Standards (International) (“**SFRS(I)s**”) so as to give a true and fair view of the consolidated financial position of the Group and the financial position of the Company as at 31 December 2025, and of the consolidated financial performance, consolidated changes in equity and consolidated cash flows of the Group for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with Singapore Standards on Auditing (“**SSAs**”). Our responsibilities under those standards are further described in the *Auditor’s Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Group in accordance with the Accounting and Corporate Regulatory Authority (“**ACRA**”) *Code of Professional Conduct and Ethics for Public Accountants and Accounting Entities* (“**ACRA Code**”), as applicable to audits of financial statements of public interest entities, together with the ethical requirements that are relevant to audits of the financial statements of public interest entities in Singapore. We have also fulfilled our other ethical responsibilities in accordance with these requirements and the ACRA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Emphasis of Matter

We draw attention to Note 31 of the financial statements, which describes the geopolitical uncertainties and economic impact on the Group arising from the ongoing armed conflict between Russia and Ukraine. Our opinion is not modified in respect of this matter.

Key Audit Matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

We have determined that there are no key audit matters to communicate in our report.

Annual Report 2025
UpHealth Group Limited
(Formerly known as Don Agro International Limited)

INDEPENDENT AUDITORS' REPORT

Other Information

Management is responsible for the other information. The other information comprises the information included in the annual report, but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and Directors for the Financial Statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the provisions of the Act and SFRS(I)s, and for devising and maintaining a system of internal accounting controls sufficient to provide a reasonable assurance that assets are safeguarded against loss from unauthorised use or disposition; and transactions are properly authorised and that they are recorded as necessary to permit the preparation of true and fair financial statements and to maintain accountability of assets.

In preparing the financial statements, management is responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The directors' responsibilities include overseeing the Group's financial reporting processes.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SSAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SSAs, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

INDEPENDENT AUDITORS' REPORT

Auditor's Responsibilities for the Audit of the Financial Statements (Cont'd)

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls.
- Obtain an understanding of internal controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Plan and perform the group audit to obtain sufficient appropriate audit evidence regarding the financial information of the entities or business units within the Group as a basis for forming an opinion on the group financial statements. We are responsible for the direction, supervision and review of the audit work performed for purposes of the group audit. We remain solely responsible for our audit opinion.

We communicate with the directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide the directors with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, actions taken to eliminate threats or safeguards applied.

From the matters communicated with the directors, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Annual Report 2025
UpHealth Group Limited
(Formerly known as Don Agro International Limited)

INDEPENDENT AUDITORS' REPORT

Report on Other Legal and Regulatory Requirements

In our opinion, the accounting and other records required by the Act to be kept by the Company have been properly kept in accordance with the provisions of the Act.

The engagement partner on the audit resulting in this independent auditor's report is Chin Bo Wui.

Foo Kon Tan LLP
Public Accountants and
Chartered Accountants

Singapore,

14 April 2026

STATEMENTS OF FINANCIAL POSITION AS AT 31 DECEMBER 2025

		The Group		The Company	
	Note	2025	2024	2025	2024
		\$'000	\$'000	\$'000	\$'000
ASSETS					
Non-Current Assets					
Property, plant and equipment	3	—	—	—	—
Right-of-use assets	4	—	—	—	—
Investments in subsidiaries	5	—	—	14,007	15,945
Goodwill	6	—	—	—	—
Biological assets	7	—	—	—	—
Other investments	8	662	385	—	—
		662	385	14,007	15,945
Current Assets					
Biological assets	7	—	—	—	—
Other receivables	9	43,726	4,763	2,628	1,912
Cash and bank balances	10	24,679	47,886	153	38
		68,405	52,649	2,781	1,950
Total assets		69,067	53,034	16,788	17,895
EQUITY AND LIABILITIES					
Capital and Reserves					
Share capital	11	40,667	40,667	40,911	40,911
Capital reserve	12	(10,450)	(10,450)	(21,270)	(21,270)
Foreign currency translation reserve	12	10,268	(6,730)	—	—
Retained earnings/ (accumulated losses)		26,885	28,253	(4,437)	(2,485)
Total equity		67,370	51,740	15,204	17,156
Non-Current Liabilities					
Deferred tax liabilities	13	—	—	—	—
		—	—	—	—
Current Liabilities					
Other payables	14	1,572	850	1,584	739
Provisions	15	39	380	—	—
Current tax liabilities		86	64	—	—
		1,697	1,294	1,584	739
Total liabilities		1,697	1,294	1,584	739
Total equity and liabilities		69,067	53,034	16,788	17,895

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

	Note	2025 \$'000	2024 \$'000
Continuing operations			
Administrative expenses	18	(6,101)	(6,792)
Other operating expenses, net	19	(194)	(519)
Loss from operating activities		(6,295)	(7,311)
Finance income	20	5,122	3,378
Finance costs	20	(195)	(688)
Net finance income	20	4,927	2,690
Loss before tax		(1,368)	(4,621)
Tax expense	21	—	—
Loss from continuing operations		(1,368)	(4,621)
Discontinued operations			
Loss from discontinued operations, net of tax	23	—	(18,102)
Loss for the year		(1,368)	(22,723)
Other comprehensive income/(loss) after tax:			
<i>Items that may be reclassified subsequently to profit or loss:</i>			
Foreign currency translation differences arising from foreign operations, at nil tax		16,998	(10,689)
Foreign currency translation reserve reclassified to profit or loss upon disposal of discontinued operations	23	—	24,033
		16,998	13,344
<i>Items that will not be reclassified subsequently to profit or loss:</i>			
Revaluation of property, plant and equipment	3	—	4,793
Related income tax	13	—	(959)
		—	3,834
Other comprehensive income for the year, net of tax		16,998	17,178
Total comprehensive income/(loss) for the year		15,630	(5,545)
Loss for the year attributable to:			
Owners of the Company		(1,368)	(22,722)
Non-controlling interests		—	(1)
		(1,368)	(22,723)
Total comprehensive income/(loss) for the year attributable to:			
Owners of the Company		15,630	(5,544)
Non-controlling interests		—	(1)
		15,630	(5,545)
Loss per share			
Basic and diluted loss per share (cents)	24	(0.91)	(15.12)
Loss per share – Continuing operations			
Basic and diluted loss per share (cents)	24	(0.91)	(3.08)

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

	Share capital \$'000	Capital reserve \$'000	Revaluation reserve \$'000	Foreign currency translation reserve \$'000	Retained earnings \$'000	Equity attributable to owners of the Company \$'000	Non- controlling interests \$'000	Total equity \$'000
At 1 January 2024	40,667	(10,450)	25,451	(20,074)	21,690	57,284	45	57,329
Loss for the year	–	–	–	–	(22,722)	(22,722)	(1)	(22,723)
Other comprehensive income/(loss)								
Foreign currency translation differences arising from foreign operations, at nil tax	–	–	–	(10,689)	–	(10,689)	–	(10,689)
Revaluation of property, plant and equipment (Note 3)	–	–	4,793	–	–	4,793	–	4,793
Related income tax (Note 13)	–	–	(959)	–	–	(959)	–	(959)
Foreign currency translation reserve reclassified to profit or loss upon disposal of discontinued operations (Note 23)	–	–	–	24,033	–	24,033	–	24,033
Transfer of revaluation of freehold land and related income tax, upon disposal of discontinued operations	–	–	(29,285)	–	29,285	–	–	–
Total comprehensive income/(loss) for the year	–	–	(25,451)	13,344	6,563	(5,544)	(1)	(5,545)
Changes in ownership interests in subsidiaries								
Disposal of discontinued operations with non-controlling interests (Note 23)	–	–	–	–	–	–	(44)	(44)
	–	–	–	–	–	–	(44)	(44)
At 31 December 2024	40,667	(10,450)	–	(6,730)	28,253	51,740	–	51,740
At 1 January 2025	40,667	(10,450)	–	(6,730)	28,253	51,740	–	51,740
Loss for the year	–	–	–	–	(1,368)	(1,368)	–	(1,368)
Other comprehensive income/(loss)								
Foreign currency translation differences arising from foreign operations, at nil tax	–	–	–	16,998	–	16,998	–	16,998
Total comprehensive income/(loss) for the year	–	–	–	16,998	(1,368)	15,630	–	15,630
At 31 December 2025	40,667	(10,450)	–	10,268	26,885	67,370	–	67,370

CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

	Note	2025 \$'000	2024 \$'000
Cash Flows from Operating Activities			
Loss for the year		(1,368)	(22,723)
<i>Adjustments for:</i>			
Depreciation of property, plant and equipment and right-of-use assets	3, 4	–	1,643
Finance costs	20	195	1,465
Finance income	20	(5,122)	(3,424)
Gain from change in fair value of other investments	19	(141)	–
Gain on disposal of property, plant and equipment	19	–	(88)
Loss from change in fair value of biological assets	7	–	9,801
Loss on disposal of discontinued operations	23	–	8,048
Write-down of inventories	17	–	22
Reversal of provision for inventory obsolescence	19	–	(272)
(Reversal of provision)/provision made, net	15	(128)	587
Tax expense	21	–	62
Operating loss before working capital changes		(6,564)	(4,879)
Changes in inventories		–	5,976
Changes in trade and other receivables		(68)	(1,546)
Changes in biological assets		–	(8,777)
Changes in trade and other payables and provisions		312	(2,267)
Changes in deferred income		–	(38)
Cash used in operations		(6,320)	(11,531)
Income tax paid		–	(178)
Net cash used in operating activities		(6,320)	(11,709)
Cash Flows from Investing Activities			
Changes in restricted deposits		35,243	(31,717)
Deferred consideration received on disposal of subsidiaries		3,969	–
Interest received		3,354	3,421
Purchase of property, plant and equipment	3	–	(439)
Proceeds from disposal of property, plant and equipment		–	192
Investment acquired		–	(457)
Loan due from a third party		–	(1,429)
Loans granted to 812 Capital LLC and CIMT LLC		(4,876)	–
Repayment of loans from a third party		397	–
Advance payments for proposed acquisition of 812 Capital LLC and Center for Innovative Medical Technologies LLC (“CIMT LLC”)		35,243	–
Disposal of discontinued operations, net of cash disposed of	23	–	60,593
Net cash from investing activities		2,844	30,164
Cash Flows from Financing Activities			
Interest paid	Note A	–	(752)
Proceeds from borrowings	Note A	–	7,493
Repayment of borrowings	Note A	–	(2,449)
Repayment of lease liabilities	Note A	–	(63)
Net cash from financing activities		–	4,229
Net (decrease)/increase in cash and cash equivalents		(3,476)	22,684
Cash and cash equivalents at beginning of year		21,097	2,349
Effects of exchange rate fluctuations on cash held		7,058	(3,936)
Cash and cash equivalents at end of year	10	24,679	21,097

CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

Note A:

The table below details changes in the Group's liabilities arising from financing activities, including both cash and non-cash changes. Liabilities arising from financing activities are those for which cash flows were, or future cash flows will be, classified in the Group's consolidated statement of cash flows as cash flows from financing activities.

	Secured bank loans \$'000	Lease liabilities \$'000	Total \$'000
At 1 January 2024	5,910	4,258	10,168
Cash flows:			
- Proceeds from borrowings	7,493	–	7,493
- Repayment of borrowings	(2,449)	–	(2,449)
- Repayment of lease liabilities	–	(63)	(63)
- Interest paid	(559)	(193)	(752)
	4,485	(256)	4,229
Non-cash changes:			
- Finance costs	568	209	777
- Finance income	–	(3)	(3)
- Modification of right-of-use assets	–	21	21
- Additions to right-of-use assets	–	215	215
- Payment-in-kind	–	(156)	(156)
- Disposal of discontinued operations (Note 23)	(10,769)	(4,150)	(14,919)
	(10,201)	(3,864)	(14,065)
Effect on movement in exchange rates	(194)	(138)	(332)
At 31 December 2024	–	–	–

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

1 General Information

1.1 The Company

The consolidated financial statements of the Group and statement of financial position of the Company for the year ended 31 December 2025 were authorised for issue in accordance with a resolution of the directors on the date of the Directors' statement.

The Company was incorporated as Don Agro International Private Limited on 16 October 2018 and is domiciled in the Republic of Singapore. The Company was a private company limited by shares with an issued and paid-up share capital of \$100 comprising 100 shares of which 6% and 94% are held by Mr Marat Devlet-Kildeev and Mr Evgeny Tugolukov, respectively. On 4 February 2020, the Company was converted into a public company limited by shares and changed its name to Don Agro International Limited. The Company's registered address is 10 Collyer Quay, #10-01, Ocean Financial Centre, Singapore 049315.

The Company was listed on the Catalist Board of Singapore Exchange Securities Trading Limited on 14 February 2020.

In February 2022, following the recognition of republics of Donetsk and Lugansk and the commencement of military operations in Ukraine by the Russian Federation, additional sanctions were introduced by the United States of America, the European Union and some other countries against Russia. Moreover, there is an increased risk that even further sanctions may be introduced. This may have significant adverse impact on Russia's economy. These events have led to depreciation of the Russian rouble, increased volatility of financial markets and significantly increased the level of economic uncertainty in the Russian business environment.

The Group was previously involved in the agriculture businesses in the Russian Federation in relation to growing, processing and distribution of agricultural and dairy products, mainly grain and milk at farms located in the Rostov Region, until the agriculture businesses were disposed in July 2024.

On 30 January 2026, the Company changed its name from Don Agro International Limited to UpHealth Group Limited.

On 9 February 2026, the Group completed the acquisition of healthcare business in Russian Federation, which comprise the following:

- Euroonco operates a network of expert oncology clinics across three major cities, focusing on the treatment of advanced-stage cancer. The clinics include inpatient facilities, intensive care units and operating rooms, with total inpatient capacity exceeding 60 beds.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

1 General Information (Cont'd)

1.1 The Company (Cont'd)

- Uni Medica operates a large multifunctional medical facility with a gross floor area of approximately 7,000 square metres. Uni Medica combines outpatient and inpatient services and currently operates around 30 inpatient beds, intensive care units, operating rooms and an outpatient infrastructure comprising 70 fully equipped medical rooms.

The consolidated financial statements reflect management's assessment of the impact of the Russian business environment on the operations and the financial position of the Group. The future business environment may differ from management's assessment.

1.2 The restructuring exercise ("Restructuring Exercise")

Pursuant to a share swap agreement dated 21 November 2019 entered into between the Company and Vallerd Investments Limited, the Company acquired from Vallerd Investments Limited, the entire issued and paid-up share capital of Tetra JSC held by it, comprising an aggregate of 62,403,000 ordinary shares for a total consideration of \$35,741,000 based on the unaudited Net Tangible Assets ("NTA") of Tetra JSC and its subsidiaries as at 30 June 2019. The purchase consideration was satisfied by the issue and allotment of an aggregate of 9,999,900 shares in the capital of the Company ("**Consideration Shares**") credited as fully paid-up and was arrived at on a willing buyer, willing seller basis.

The Restructuring Exercise was accounted for as a combination of businesses under common control by Mr. Evgeny Tugolukov and Mr. Marat Devlet-Kildeev, as they control the entities within the Group before and after the Restructuring Exercise. The presentation reflects the economic substance of the combining entities, which were under common control throughout the relevant periods, as a single economic enterprise, notwithstanding that the Restructuring Exercise was completed during 2020.

1.3 Transfer of entities under common control

The Restructuring Exercise is considered to be an acquisition of equity interests by entities under common control and therefore the entities acquired by the Group pursuant to the restructuring have been accounted for in a manner similar to the pooling-of-interest method. Accordingly, the assets and liabilities of these entities have been included in the consolidated financial statements at their historical carrying amounts. Although the share swap agreement was entered on 21 November 2019, the consolidated financial statements present the financial condition, results of operations and cash flows as if the restructuring had occurred as of the beginning of the earliest period presented.

1.4 Subsidiaries

The consolidated financial statements of the Group have been prepared to reflect the operations of the Company and the subsidiaries as a single economic enterprise and consist of those companies under common control during the years ended 31 December 2025 and 2024.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

1 General Information (Cont'd)

1.5 Discontinued operations

In July 2024, the Group completed the disposal of all of its agricultural businesses. The disposal meets the definition of discontinued operations in accordance with SFRS(I) 5 *Non-current Assets Held for Sale and Discontinued Operations*. As a consequence of the disposal of discontinued operations of the Group, the Group does not have any operating businesses following the completion of the disposal and the Company has become a cash company as defined under Rule 1017 of the Catalist Rules.

On 9 February 2026, the Group completed the acquisition of healthcare business in Russian Federation and ceased to be a cash company.

2(a) Basis of preparation

The financial statements have been prepared in accordance with Singapore Financial Reporting Standards (International) (“**SFRS(I)s**”) including related Interpretations.

The financial statements have been prepared under the historical cost convention, except as disclosed in the accounting policies below.

The financial statements are presented in Singapore dollars (“\$”). The functional currency of the Company is the Singapore dollars. Assets and liabilities of foreign subsidiaries are translated from the respective functional currency to \$ at rates of exchange ruling at the respective reporting date. All equity items are translated at historical rates. The results for the respective years are translated using the average rate. Resultant exchange differences are recognised directly in equity, in the foreign currency translation reserve. All financial information presented in \$ has been rounded to nearest thousand, unless otherwise stated.

The accounting policies have been applied consistently to all years presented in these financial statements.

Critical accounting judgements and key sources of estimation uncertainty

The preparation of the financial statements in conformity with SFRS(I)s requires the use of judgements, estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the financial period. Although these estimates are based on management’s best knowledge of current events and actions, actual results may differ from those estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected.

The critical accounting estimates and assumptions used in applying accounting policies and areas involving a high degree of judgement are described below.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

2(a) Basis of preparation (Cont'd)

(a) Significant judgements used in applying accounting policies

In the process of applying the Group's accounting policies, management has made the following judgements which have the most significant effect on the amounts recognised in the consolidated financial statements:

Identification of functional currency

The functional currency of each entity in the Group is the currency of the primary economic environment in which it operates. Determination of the functional currency involves significant judgement and other companies may make different judgements based on similar facts. Management reconsiders the functional currency if there is a change in the underlying transactions, events and conditions which determines its primary economic environment.

The determination of functional currency affects the carrying amount of the non-current assets included in the statements of financial position and, as a consequence, the depreciation of those assets included in the consolidated statement of profit or loss and other comprehensive income. It also impacts the exchange gains and losses included in the consolidated statement of profit or loss and other comprehensive income.

(b) Key sources of estimation uncertainty

Management is of the opinion that there are no significant accounting estimates and judgements that have the most significant effect on the amounts recognised in these financial statements.

The geopolitical uncertainties arising from the ongoing Russian-Ukraine war could have a significant impact on the Group's assets and liabilities.

2(b) Adoption of new and amended standards and interpretations

The Group and the Company have adopted all the new and revised SFRS(I)s, SFRS(I) interpretations ("SFRS(I) INT") and amendments to SFRS(I)s, effective for the current financial period that are relevant to them. The adoption of these new and revised SFRS(I) pronouncements does not result in significant changes to the Group's and the Company's accounting policies and has no material effect on the amounts or the disclosures reported for the current reporting periods.

Reference	Description	Effective date (Annual periods beginning on or after)
Amendments to SFRS(I) 1-21	<i>Lack of Exchangeability</i>	1 January 2025

The application of these amendments to standards and interpretations does not have a material effect on the financial statement.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

2(c) Standards issued but not yet effective

At the date of authorisation of these financial statements, the Group and the Company have not adopted the new and revised SFRS(I)s, SFRS(I) INT and amendments to SFRS(I)s that have been issued but are not yet effective.

Reference	Description	Effective date (Annual periods beginning on or after)
Amendments to SFRS(I) 9 and SFRS(I) 7	Classification and Measurement of Financial Instruments	1 January 2026
Amendments to SFRS(I) 9 and SFRS(I) 7	Contracts Referencing Nature- dependent Electricity	1 January 2026
Annual Improvements to SFRS(I)	Volume 11	1 January 2026
SFRS(I) 18	Presentation and Disclosure in Financial Statements	1 January 2027
SFRS(I) 19	Subsidiaries without Public Accountability: Disclosures	1 January 2027
Amendments to SFRS(I) 1- 21	Translation to a Hyperinflationary Presentation Currency	1 January 2027
Amendments to SFRS(I) 10 and SFRS(I) 1-28	Sale or Contribution of Assets between an Investor and its Associate or Joint Venture	Yet to be determined

Management anticipates that the adoption of these new and revised SFRS(I) pronouncements in future periods will not have a material impact on the Group's financial statements in the period of their initial application, except for the following:

SFRS(I) 18 *Presentation and Disclosure in Financial Statements*

SFRS(I) 18 replaces SFRS(I)1-1 *Presentation of Financial Statements*, introducing new requirements that will help to achieve comparability of the financial performance of similar entities and provide more relevant information and transparency to users.

SFRS(I) 18 introduces new requirements for presentation within the statement of profit or loss, including specified totals and subtotals. In particular, entities are required to classify all income and expenses within the statement of profit or loss into one of five categories: operating, investing, financing, income taxes and discontinued operations. In addition, SFRS(I) 18 requires disclosure of newly prescribed management-defined performance measures and includes new requirements for aggregation and disaggregation of financial information based on the identified 'roles' of the primary financial statements and the notes to the financial statements.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

2(c) Standards issued but not yet effective (Cont'd)

SFRS(I) 18 *Presentation and Disclosure in Financial Statements* (Cont'd)

Furthermore, narrow scope amendments are made to SFRS(I) 1-7 *Statement of Cash Flows*, which include changing the starting point for determining cash flows from operations under the indirect method, from 'profit or loss' to 'operating profit or loss' and removing the optionality around classification of cash flows from dividends and interest. There are also amendments to several other standards.

SFRS(I) 18, and the consequential amendments to the other standards, is effective for annual reporting periods beginning on or after 1 January 2027. Early application is permitted. SFRS(I) 18 is applied retrospectively with specific transition provisions.

The Group is currently assessing the impact of SFRS(I) 18. It is currently impracticable to disclose any further information on the known or reasonably estimable impact to the financial statements in the period of initial application.

2(d) Material accounting policy information

Basis of consolidation

Business combinations

Business combinations are accounted for using the acquisition method in accordance with SFRS(I) 3 *Business Combinations* as at the date of acquisition, which is the date on which control is transferred to the Group.

In determining whether a particular set of activities and assets is a business, the Group assesses whether the set of assets and activities acquired includes, at a minimum, an input and substantive process and whether the acquired set has the ability to produce outputs.

The Group has an option to apply a 'concentration test' that permits a simplified assessment of whether an acquired set of activities and assets is not a business. The optional concentration test is met if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets.

The Group measures goodwill at the date of acquisition as:

- the consideration transferred (generally measured at fair value); plus
- the recognised amount of any NCI in the acquiree; plus
- if the business combination is achieved in stages, the fair value of the pre-existing equity interest in the acquiree,

over the net recognised amount (generally measured at fair value) of the identifiable assets acquired and liabilities assumed. Any goodwill that arises is tested annually for impairment.

The consideration transferred does not include amounts related to the settlement of pre-existing relationships. Such amounts are generally recognised in profit or loss.

**NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS FOR THE FINANCIAL YEAR ENDED 31
DECEMBER 2025**

2(d) Material accounting policy information (Cont'd)
Basis of consolidation (Cont'd)

Business combinations (Cont'd)

Any contingent consideration payable is recognised at fair value at the date of acquisition and included in the consideration transferred. If the contingent consideration that meets the definition of a financial instrument is classified as equity, it is not remeasured and settlement is accounted for within equity. Otherwise, other contingent consideration is remeasured at fair value at each reporting date and subsequent changes to the fair value of the contingent consideration are recognised in profit or loss.

Non-controlling interests that are present ownership interests and entitle their holders to a proportionate share of the acquiree's net assets in the event of liquidation, are measured either at fair value or at the non-controlling interests' proportionate share of the recognised amounts of the acquiree's identifiable net assets, at the date of acquisition. The measurement basis taken is elected on a transaction-by-transaction basis. All other non-controlling interests are measured at acquisition-date fair value, unless another measurement basis is required by SFRS(I)s.

Costs related to the acquisition, other than those associated with the issue of debt or equity securities, that the Group incurs in connection with a business combination are expensed as incurred.

Changes in the Group's interest in a subsidiary that do not result in a loss of control are accounted for as transactions with owners in their capacity as owners and therefore no adjustments are made to goodwill and no gain or loss is recognised in surplus or deficit. Adjustments to non-controlling interests arising from transactions that do not involve the loss of control are based on a proportionate amount of the net assets of the subsidiary.

Subsidiaries

Subsidiaries are entities controlled by the Group. The Group controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date that control commences until the date that control ceases.

The accounting policies of subsidiaries have been changed when necessary to align them with the policies adopted by the Group. Losses applicable to the non-controlling interests in a subsidiary are allocated to the non-controlling interests even if doing so causes the non-controlling interests to have a deficit balance.

In the Company's separate financial statements, investments in subsidiaries are stated at cost less allowance for any impairment losses on an individual subsidiary basis.

**NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS FOR THE FINANCIAL YEAR ENDED 31
DECEMBER 2025**

2(d) Material accounting policy information (Cont'd)

Basis of consolidation (Cont'd)

Acquisitions from entities under common control

Business combinations arising from transfers of interests in entities that are under the control of the shareholder that controls the Group are accounted for as if the acquisition had occurred at the beginning of the earliest comparative year presented or, if later, at the date that common control was established; for this purpose comparatives are restated. The assets and liabilities acquired are recognised at the carrying amounts recognised previously in the Group controlling shareholder's consolidated financial statements. The components of equity of the acquired entities are added to the same components within Group equity and any gain/loss arising is recognised directly in equity.

Loss of control

Upon the loss of control, the Group derecognises the assets and liabilities of the subsidiary, any non-controlling interests and the other components of equity related to the subsidiary. Any surplus or deficit arising on the loss of control is recognised in profit or loss. If the Group retains any interest in the previous subsidiary, then such interest is measured at fair value at the date that control is lost. The fair value of any interest retained in the former subsidiary at the date when control is lost is regarded as the fair value on initial recognition for subsequent accounting under SFRS(I) 9 *Financial Instruments* when applicable, or the cost on initial recognition of an investment in an associate or a joint venture.

Transactions eliminated on consolidation

Intra-group balances and transactions, and any unrealised income and expenses arising from intra-group transactions, are eliminated in preparing the consolidated financial statements. Unrealised gains arising from transactions with equity-accounted investees are eliminated against the investment to the extent of the Group's interest in the investee. Unrealised losses are eliminated in the same way as unrealised gains, but only to the extent that there is no evidence of impairment.

Foreign currency

Foreign currency transactions

Transactions in foreign currencies are translated to the respective functional currencies of Group entities at exchange rates at the dates of the transactions.

Monetary assets and liabilities denominated in foreign currencies at the reporting date are translated to the functional currency at the exchange rate at that date. The foreign currency gain or loss on monetary items is the difference between amortised cost in the functional currency at the beginning of the year, adjusted for effective interest and payments during the year, and the amortised cost in foreign currency translated at the exchange rate at the end of the year.

Non-monetary assets and liabilities denominated in foreign currencies that are measured at fair value are translated to the functional currency at the exchange rate at the date that the fair value was determined. Non-monetary items in a foreign currency that are measured in terms of historical cost are translated using the exchange rate at the date of the transaction. Foreign currency differences arising on retranslation are recognised in profit or loss.

**NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS FOR THE FINANCIAL YEAR ENDED 31
DECEMBER 2025**

2(d) Material accounting policy information (Cont'd)
Foreign Currency (Cont'd)

Foreign operations

The assets and liabilities of foreign operations, excluding goodwill and fair value adjustments arising on acquisition, are translated to Singapore dollars at exchange rates at the reporting date. The income and expenses of foreign operations are translated to Singapore dollars at exchange rates at the dates of the transactions.

Foreign currency differences are recognised in other comprehensive income, and presented in the foreign currency translation reserve (“translation reserve”) in equity. However, if the foreign operation is a non-wholly-owned subsidiary, then the relevant proportionate share of the translation difference is allocated to the non-controlling interests. When a foreign operation is disposed of in such that control, significant influence or joint control is lost, the cumulative amount in the translation reserve related to that foreign operation is reclassified to profit or loss as part of the gain or loss on disposal. When the Group disposes of only part of its interest in a subsidiary that includes a foreign operation while retaining control, the relevant proportion of the cumulative amount is reattributed to non-controlling interests. When the Group disposes of only part of its investment in an associate or joint venture that includes a foreign operation while retaining significant influence or joint control, the relevant proportion of the cumulative amount is reclassified to profit or loss.

When the settlement of a monetary item receivable from or payable to a foreign operation is neither planned nor likely to occur in the foreseeable future, foreign exchange gains and losses arising from such a monetary item that are considered to form part of a net investment in a foreign operation are recognised in other comprehensive income, and are presented in the foreign currency translation reserve in equity.

Property, plant and equipment

Recognition and measurement

Items of property, plant and equipment are measured at either cost less accumulated depreciation and accumulated impairment losses, except for land which is measured using revaluation model.

Any revaluation increase arising from the revaluation of freehold land is recognised in other comprehensive income and accumulated in revaluation reserve, except to the extent that it reverses a revaluation decrease for the same asset previously recognised in profit or loss, in which case the increase is credited to profit or loss to the extent of the decrease previously charged to profit or loss. A decrease in carrying amount arising on the revaluation of freehold land is charged to profit or loss to the extent that it exceeds the balance, if any, held in the revaluation reserves relating to a previous revaluation of that asset.

On the subsequent sale or retirement of freehold land, the attributable revaluation surplus remaining in the revaluation reserve is transferred directly to retained profits. No transfer is made from the revaluation reserve to retained profits except when the asset is derecognised.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

2(d) Material accounting policy information (Cont'd)

Property, plant and equipment (Cont'd)

Recognition and measurement (Cont'd)

Cost includes expenditure that is directly attributable to the acquisition of the asset. The cost of self-constructed assets includes:

- the cost of materials and direct labour;
- any other costs directly attributable to bringing the assets to a working condition for their intended use;
- when the Group has an obligation to remove the asset or restore the site, an estimate of the costs of dismantling and removing the items and restoring the site on which they are located; and
- capitalised borrowing costs.

Purchased software that is integral to the functionality of the related equipment is capitalised as part of that equipment.

When parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment.

The gain or loss on disposal of an item of property, plant and equipment (calculated as the difference between the net proceeds from disposal and the carrying amount of the item) is recognised in profit or loss.

Subsequent costs

The cost of replacing a component of an item of property, plant and equipment is recognised in the carrying amount of the item if it is probable that the future economic benefits embodied within the component will flow to the Group, and its cost can be measured reliably. The carrying amount of the replaced component is derecognised. The costs of the day-to-day servicing of property, plant and equipment are recognised in profit or loss as incurred.

Depreciation

Depreciation is based on the cost of an asset less its residual value. Significant components of individual assets are assessed and if a component has a useful life that is different from the remainder of assets, that component is depreciated separately.

Depreciation is recognised as an expense in profit or loss on a straight-line basis over the estimated useful lives of each component of an item of property, plant and equipment, unless it is included in the carrying amount of another asset. Leased assets are depreciated over the shorter of the lease term and their useful lives unless it is reasonably certain that the Group will obtain ownership by the end of the lease term.

Freehold land and properties under construction in progress are not depreciated.

Depreciation is recognised from the date that the property, plant and equipment are installed and are ready for use, or in respect of internally constructed assets, from the date that the asset is completed and ready for use.

**NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS FOR THE FINANCIAL YEAR ENDED 31
DECEMBER 2025**

2(d) Material accounting policy information (Cont'd)

Property, plant and equipment (Cont'd)

Depreciation (Cont'd)

The estimated useful lives for the current and previous years are as follows:

Buildings : 7 - 50 years

Plant and equipment : 3 - 12 years

Motor vehicles : 3 - 10 years

Depreciation methods, useful lives and residual values are reviewed at the end of each reporting period and adjusted if appropriate.

Leases

As a lessee

The Group recognises a right-of-use asset and a lease liability at the lease commencement date. The right-of-use asset is initially measured at cost, and subsequently at cost less any accumulated depreciation and impairment losses, and adjusted for certain remeasurements of the lease liability.

The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the end of the lease term, unless the lease transfers ownership of the underlying asset to the Group by the end of the lease term or the cost of the right-of-use asset reflects that the Group will exercise a purchase option.

In that case, the right-of-use asset will be depreciated over the useful life of the underlying asset which is determined on the same basis as those of property, plant and equipment. In addition, the right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain remeasurements of the lease liability.

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Group's incremental borrowing rate. Generally, the Group uses its incremental borrowing rate as the discount rate.

The Group determines its incremental borrowing rate by obtaining interest rates from various external financing sources and makes certain adjustments to reflect the terms of the lease and type of the asset leased.

The lease liability is subsequently increased by the interest cost on the lease liability and decreased by lease payment made. It is remeasured when there is a change in future lease payments arising from a change in an index or rate, a change in the estimate of the amount expected to be payable under a residual value guarantee, or as appropriate, changes in the assessment of whether a purchase or extension option is reasonably certain to be exercised or a termination option is reasonably certain not to be exercised.

When the lease liability is remeasured in this way, a corresponding adjustment is made to the carrying amount of the right-of-use asset, or is recorded in profit or loss if the carrying amount of the right-of-use asset has been reduced to zero.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

2(d) Material accounting policy information (Cont'd) Leases (Cont'd)

As a lessee (Cont'd)

In accordance with SFRS(I) 16 *Leases*, variable payments which do not depend on index or rate, i.e. do not reflect changes in market rental rates, should not be included in the calculation of lease liability. In respect of municipal (or federal) land leases where the lease payments are based on cadastral value of the land plot and do not change until the next potential revision of that value or payments (or both) by the authorities, the Group determined that these lease payments are not considered as either variable (that depend on an index or rate or reflect changes in market rental rates) or in-substance fixed, and therefore these payments are not included in the measurement of the lease liability.

The Group leases a number of land plots under lease agreements that typically run for a period of 1 to 17 years, with an option to renew the lease after expiration. The Group determined the lease term as a contract term.

For majority of lease agreements, rent is established as a payment in-kind in a form of agricultural produce harvested by the Group. At the commencement date, the Group measures the lease liability at the present value of the payments in-kind that are not paid at that date. The following payments are not included in the measurement of lease liability: plowing services, ritual services, and reimbursement of land tax to the lessor.

The Group has applied judgement to determine the lease term for some lease contracts in which it is a lessee that include renewal options. The assessment of whether the Group is reasonably certain to exercise such options impacts the lease term, which significantly affects the amount of lease liabilities and right-of-use assets recognised.

Short-term leases and leases of low-value assets

The Group has elected not to recognise right-of-use assets and lease liabilities for leases of low-value assets and short-term leases. The Group recognises the lease payments associated with these leases as an expense on a straight-line basis over the lease term.

Impairment of non-financial assets

The carrying amounts of the Group's non-financial assets, other than biological assets, inventories and tax assets, are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated. An impairment loss is recognised if the carrying amount of an asset or its related cash-generating unit (CGU) exceeds its estimated recoverable amount.

**NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS FOR THE FINANCIAL YEAR ENDED 31
DECEMBER 2025**

2(d) Material accounting policy information (Cont'd)

Impairment of non-financial assets (Cont'd)

The recoverable amount of an asset or CGU is the greater of its value in use and its fair value less costs to sell. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or CGU. For the purpose of impairment testing, assets that cannot be tested individually are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or CGUs.

Impairment losses are recognised in profit or loss. Impairment losses recognised in respect of CGUs are allocated first to reduce the carrying amount of any goodwill allocated to the CGU (group of CGUs), and then to reduce the carrying amounts of the other assets in the CGU (group of CGUs) on a *pro rata* basis.

Impairment loss recognised in prior periods are assessed at each reporting date for any indications that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortisation, if no impairment loss had been recognised.

Biological assets and agricultural produce

Biological assets of the Group consist of unharvested crops (grain crops and other plant crops) permanent grass and livestock (dairy cows which are able to produce milk (mature livestock), heifers and calves, being raised to produce milk in the future (immature livestock)). Bearer livestock and permanent grass are classified as non-current assets and unharvested crops are classified as current assets in the statement of financial position of the Group.

Crops are measured at fair value less costs to sell, which include all costs that would be necessary to sell the assets. Permanent grass is stated at cost less accumulated depreciation and accumulated impairment losses.

The fair value of agricultural produce at the point of harvest is based on the market price less costs to sell.

Upon harvest, grain crops and other plant crops are included into inventory for further processing or for sale and are initially measured at their fair value less cost to sell at the date of harvest. A gain or loss arising on initial recognition of agricultural produce at fair value less estimated point-of-sale costs is recognised in profit or loss in the period in which it arises.

Livestock is measured at their fair value less estimated point-of-sale costs. The fair value of livestock is based on cash flows model discounted using a pre-tax rate that reflects current market assessment of the time value of money and risks specific to the asset.

**NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS FOR THE FINANCIAL YEAR ENDED 31
DECEMBER 2025**

2(d) Material accounting policy information (Cont'd)

Biological assets and agricultural produce (Cont'd)

All the gross gains or loss arising from initial recognition of biological assets and from changes in fair value less costs to sell of biological assets are included as a separate line “gain/(loss) from change in fair value of biological assets” above the gross profit line.

Cost to sell include all costs that would be necessary to sell the assets.

Inventories

Inventories are recorded at the lower of cost and net realisable value. Cost of inventory is determined on the weighted average basis, and includes expenditure incurred in acquiring the inventories, production or conversion costs and other costs incurred in bringing them to their existing location and condition. The cost of finished goods and work in progress comprises raw material, direct labour, other direct costs and related production overheads (based on normal operating capacity).

The cost of agricultural produce transferred from biological assets is its fair value less costs to sell at the date of harvest.

Net realisable value is the estimated selling price in the ordinary course of business, less the estimated cost of completion and estimated costs necessary to make the sale.

Financial instruments

Financial instruments carried on the statements of financial position include financial assets and financial liabilities. The particular recognition methods adopted are disclosed in the individual policy statements associated with each item. These are recognised on the Group's and the Company's statement of financial position when the Group and the Company become a party to the contractual provisions of the instrument.

Disclosures of the Group's and the Company's financial risk management objectives and policies are provided in Note 28.

Financial assets and financial liabilities are offset and the net amount presented on the statements of financial position when, and only when, the Group and the Company currently has a legally enforceable right to set off the recognised amounts, and intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

**NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS FOR THE FINANCIAL YEAR ENDED 31
DECEMBER 2025**

2(d) Material accounting policy information (Cont'd)

Financial assets (Cont'd)

Initial recognition and measurement

Financial assets are classified, at initial recognition, and subsequently measured at amortised cost, fair value through other comprehensive income ("FVOCI"), or fair value through profit or loss ("FVTPL").

The classification of financial assets at initial recognition depends on the financial asset's contractual cash flow characteristics and the Group's and the Company's business model for managing them. With the exception of trade receivables that do not contain a significant financing component or for which the Group and the Company have applied the practical expedient, the Group and the Company initially measure a financial asset at its fair value plus, in the case of financial asset not at fair value through profit or loss, transaction costs.

Trade receivables are measured at the amount of consideration to which the Group and the Company expect to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third party if the trade receivables do not contain a significant financing component at initial recognition.

In order for a financial asset to be classified and measured at amortised cost or FVOCI, it needs to give rise to cash flows that are "solely payments of principal and interest" ("SPPI") on the principal amount outstanding. This assessment is referred to as the SPPI test and is performed at an instrument level.

The Group's and the Company's business model for managing financial assets refer to how it manages its financial assets in order to generate cash flows. The business model determines whether cash flows will result from collecting contractual cash flows, selling the financial assets, or both.

Subsequent measurement

For purposes of subsequent measurement, financial assets are classified in four categories:

- Financial assets at amortised cost (debt instruments);
- Financial assets at FVOCI with recycling of cumulative gains and losses (debt instruments);
- Financial assets designated at FVOCI with no recycling of cumulative gains and losses upon derecognition (equity instruments); or
- Financial assets at FVTPL.

The Group and the Company do not hold any financial assets at FVOCI.

Financial assets at amortised cost

Subsequent measurement of debt instruments depends on the Group's and the Company's business model with the objective to hold financial assets in order to collect contractual cash flows and the contractual cash terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal and interest on the principal amount outstanding of the asset.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

2(d) Material accounting policy information (Cont'd)

Financial assets (Cont'd)

Financial assets at amortised cost (Cont'd)

Financial assets that are held for the collection of contractual cash flows where those cash flows represent SPPI are measured at amortised cost. Financial assets are measured at amortised cost using the effective interest method, less impairment. Gains and losses are recognised in the consolidated statement of profit or loss and other comprehensive income when the assets are derecognised or impaired, and through the amortisation process.

The Group's and the Company's financial assets at amortised cost comprise trade and other receivables (excluding advances paid to suppliers, current tax assets and value-added tax ("VAT") receivables) and cash and bank balances.

Financial assets at FVTPL

All financial assets not classified as measured at amortised cost or FVOCI as described above are measured at FVTPL. Changes in fair values and interest income are recognised in profit or loss in the period in which it arises and presented in "finance income or costs".

The Group's financial assets at FVTPL comprises other investments.

Impairment of financial assets

The Group recognises loss allowances for expected credit losses ("ECLs") on financial assets measured at amortised costs.

Loss allowance for the Group is measured on either of the following bases:

- 12-month ECLs: these are ECLs that result from default events that are possible within the 12-months after the reporting date (or for a shorter period if the expected life of the instrument is less than 12 months); or
- Lifetime ECLs: these are ECLs that result from all possible default events over the expected life of a financial instrument or contract asset.

Simplified approach

The Group applies the simplified approach to provide for ECLs for all trade receivables. The simplified approach requires the loss allowance to be measured at an amount equal to lifetime ECLs.

General approach

The Group applies the general approach to provide for ECLs on all other financial assets. Under the general approach, the loss allowance is measured at an amount equal to 12-month ECLs at initial recognition.

At each reporting date, the Group assesses whether the credit risk of a financial instrument has increased significantly since initial recognition. When credit risk has increased significantly since initial recognition, loss allowance is measured at an amount equal to lifetime ECLs.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

2(d) Material accounting policy information (Cont'd) **Financial assets (Cont'd)**

When determining whether the credit risk of a financial asset has increased significantly since initial recognition and when estimating ECLs, the Group considers reasonable and supportable information that is relevant and available without undue cost or effort. This includes both quantitative and qualitative information and analysis, based on the Group's historical experience and informed credit assessment and includes forward-looking information.

If credit risk has not increased significantly since initial recognition or if the credit quality of the financial instruments improves such that there is no longer a significant increase in credit risk since initial recognition, loss allowance is measured at an amount equal to 12-month ECLs.

The Group considers a financial asset to be in default when:

- the borrower is unlikely to pay its credit obligations to the Group in full, without recourse by the Group to actions such as realising security (if any is held); or
- the financial asset is more than 90 days past due.

The maximum period considered when estimating ECLs is the maximum contractual period over which the Group is exposed to credit risks.

Measurement of ECLs

ECLs are probability-weighted estimates of credit losses. Credit losses are measured at the present value of all cash shortfalls (i.e. the difference between the cash flows due to the entity in accordance with the contract and the cash flows that the Group expects to receive). ECLs are discounted at the effective interest rate of the financial asset.

Credit-impaired financial assets

At each reporting date, the Group assesses whether financial assets carried at amortised cost are credit-impaired. A financial asset is 'credit-impaired' when one or more events that have a detrimental impact on the estimated future cash flows of the financial asset have occurred.

Evidence that a financial asset is credit-impaired includes the following observable data:

- significant financial difficulty of the borrower or issuer;
- a breach of contract such as a default or being more than 90 days past due;
- the restructuring of a loan or advance by the Group on terms that the Group would not consider otherwise;
- it is becoming probable that the borrower will enter bankruptcy or other financial reorganisation; or
- the disappearance of an active market for a security because of financial difficulties.

Presentation of allowance for ECLs in the statements of financial position

Loss allowances for financial assets measured at amortised cost are deducted from the gross carrying amount of these assets.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

2(d) Material accounting policy information (Cont'd) **Financial assets (Cont'd)**

Write-off

The gross carrying amount of a financial asset is written off (either partially or in full) to the extent that there is no realistic prospect of recovery. This is generally the case when the Group determines that the debtor does not have assets or sources of income that could generate sufficient cash flows to repay the amounts subject to the write-off. However, financial assets that are written off could still be subject to enforcement activities in order to comply with the Group's procedures for recovery of amounts due.

Value-added tax

Revenue, expenses and assets are recognised net of the amount of value-added tax ("VAT"), except where the VAT incurred on a purchase of assets or services is not recoverable from the taxation authorities, in which case the VAT is recognised as part of the cost of acquisition of the asset or as part of the expense item as applicable, and except that trade receivables and trade payables are recorded with the amount of VAT included. The net amount of VAT recoverable from or payable to the taxation authorities are included as part of other receivables or other payables in the statements of financial position.

Cash and cash equivalents

In the statements of financial position, cash and bank balances comprise cash (i.e. cash on hand and demand deposits) and cash equivalents. Cash equivalents are short-term (generally with original maturity of three months or less), highly liquid investments that are readily convertible to a known amount of cash and which are subject to an insignificant risk of changes in value. Cash equivalents are held for the purpose of meeting short-term cash commitments rather for investment or other purposes.

Bank balances for which use by the Group is subject to third party contractual restrictions are included as part of cash unless the restrictions result in a bank balance no longer meeting the definition of cash. If the contractual restrictions to use the cash extend beyond 12 months after the reporting date, the related amounts are classified as non-current in the statements of financial position. For the purposes of the consolidated statement of cash flows, cash and cash equivalents consist of cash and cash equivalents as defined.

Share capital

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of ordinary shares are recognised as a deduction from equity, net of any tax effects.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

2(d) Material accounting policy information (Cont'd)

Dividends

Final dividends proposed by the directors are not accounted for in shareholders' equity as an appropriation of retained profit, until they have been approved by the shareholders in a general meeting. When these dividends have been approved by the shareholders and declared, they are recognised as a liability.

Interim dividends are simultaneously proposed and declared, because of the regulation of constitution of the Company that grants the directors the authority to declare interim dividends. Consequently, interim dividends are recognised directly as a liability when they are proposed and declared.

Financial liabilities

Initial recognition and measurement

The Group and the Company determine the classification of its financial liabilities at initial recognition. All financial liabilities are recognised initially at fair value plus in the case of financial liabilities not at FVTPL, directly attributable transaction costs.

Borrowings to be settled within the Group's normal operating cycle are considered as "current". Other borrowings due to be settled more than 12 months after the reporting date are included in "non-current" borrowings in the statements of financial position. Borrowings are recognised initially at fair value of proceeds received less attributable transaction costs, if any. Borrowings are subsequently stated at amortised cost which is the initial fair value less any principal repayments.

Any difference between the proceeds (net of transaction costs) and the redemption value is taken to the consolidated statement of profit or loss and other comprehensive income over the period of the borrowings using the effective interest method. The interest expense is chargeable on the amortised cost over the period of borrowing using the effective interest method.

Subsequent measurement

After initial recognition, financial liabilities that are not carried at FVTPL are subsequently measured at amortised cost using the effective interest method. Gains and losses are recognised in the consolidated statement of profit or loss and other comprehensive income when the liabilities are derecognised, and through the amortisation process.

Derecognition

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as a derecognition of the original liability and the recognition of a new liability, and the difference in the respective carrying amounts is recognised in the consolidated statement of profit or loss and other comprehensive income.

**NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS FOR THE FINANCIAL YEAR ENDED 31
DECEMBER 2025**

2(d) Material accounting policy information (Cont'd)

Provisions

A provision is recognised if, as a result of a past event, the Group has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. The unwinding of the discount is recognised as finance costs.

Revenue

Revenue from sale of crops and dairy milk and services in the ordinary course of business is recognised when the Group satisfies a performance obligation (PO) by transferring control of a promised crop or dairy milk or flour or service to the customer. The amount of revenue recognised is the amount of the transaction price allocated to the satisfied PO.

The transaction price is allocated to each PO in the contract on the basis of the relative stand-alone selling prices of the promised crop or dairy milk or flour or services. The individual standalone selling price of a crop or dairy milk or service that has not previously been sold on a stand-alone basis, or has a highly variable selling price, is determined based on the residual portion of the transaction price after allocating the transaction price to crop, dairy milk and/or services with observable stand-alone selling prices. A discount or variable consideration is allocated to one or more, but not all, of the performance obligations if it relates specifically to those performance obligations.

The transaction price is the amount of consideration in the contract to which the Group expects to be entitled in exchange for transferring the promised crop or dairy milk or flour or services. The transaction price may be fixed or variable and is adjusted for time value of money if the contract includes a significant financing component. Consideration payable to a customer is deducted from the transaction price if the Group does not receive a separate identifiable benefit from the customer. When consideration is variable, the estimated amount is included in the transaction price to the extent that it is highly probable that a significant reversal of the cumulative revenue will not occur when the uncertainty associated with the variable consideration is resolved.

Revenue may be recognised at a point in time or over time following the timing of satisfaction of the PO. If a PO is satisfied over time, revenue is recognised based on the percentage of completion reflecting the progress towards complete satisfaction of that PO.

Finance costs

Finance costs comprise interest expense on loans and borrowings, and lease liabilities. Interest expense is recognised using the effective interest method.

Borrowing costs that are not directly attributable to the acquisition, construction or production of a qualifying asset are recognised in profit or loss using the effective interest method.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

2(d) Material accounting policy information (Cont'd)

Finance costs (Cont'd)

Foreign currency gains and losses on financial assets and financial liabilities are reported on a net basis as either finance income or finance cost depending on whether foreign currency movements are in a net gain or net loss position.

Government grants

A conditional government grant related to property, plant and equipment are recognised initially as “deferred income” at fair value when there is reasonable assurance that they will be received and the Group will comply with the conditions associated with the grant. These grants are presented at gross presentation basis in the consolidated financial statements. These grants are then recognised in profit or loss as “other operating income” on a systematic basis over the useful life of the asset. Grants that compensate the Group for finance cost incurred are recognised in profit or loss as reduction in “finance costs” on a systematic basis in the same periods in which the finance costs are recognised.

Employee benefits

Defined contribution plans

A defined contribution plan is a post-employment benefit plan under which an entity pays fixed contributions into a separate entity and will have no legal or constructive obligation to pay further amounts. Obligations for contributions to defined contribution pension plans are recognised as an employee benefit expense in profit or loss in the periods during which related services are rendered by employees.

Short-term employee benefits

Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided. A liability is recognised for the amount expected to be paid under short-term cash bonus if the Group has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee, and the obligation can be estimated reliably.

Income taxes

Tax expense comprises current and deferred tax. Current tax and deferred tax are recognised in profit or loss except to the extent that it relates to a business combination, or items recognised directly in equity or in other comprehensive income.

Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to tax payable in respect of previous years. The amount of current tax payable or receivable is the best estimate of the tax amount expected to be paid or received that reflects uncertainty related to income taxes; if any.

Current tax assets and liabilities are offset only if certain criteria are met.

**NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS FOR THE FINANCIAL YEAR ENDED 31
DECEMBER 2025**

2(d) Material accounting policy information (Cont'd)
Income taxes (Cont'd)

Deferred tax is recognised in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes.

Deferred tax is not recognised for:

- temporary differences on the initial recognition of assets or liabilities in a transaction that is not a business combination and, at the time of the transaction (i) affects neither accounting nor taxable profit or loss and (ii) does not give rise to equal taxable and deductible temporary differences; and
- temporary differences related to investments in subsidiaries to the extent that the Group is able to control the timing of the reversal of the temporary difference and it is probable that they will not reverse in the foreseeable future.

The measurement of deferred taxes reflects the tax consequences that would follow the manner in which the Group expects, at the reporting date, to recover or settle the carrying amount of its assets and liabilities. Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date.

Deferred tax assets and liabilities are recognised on transactions that, on initial recognition, give rise to equal amounts of deductible and taxable temporary differences, arising from leases.

Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realised simultaneously.

Deferred tax assets are recognised for unused tax losses, unused tax credits and deductible temporary differences to the extent that it is probable that future taxable profits will be available against which they can be used. Future taxable profits are determined based on the reversal of relevant taxable temporary differences. If the amount of taxable temporary differences is insufficient to recognise a deferred tax asset in full, then future taxable profits, adjusted for reversals of existing temporary differences, are considered, based on the business plans for individual subsidiaries in the Group.

Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realised; such reductions are reversed when the probability of future taxable profits improves.

Unrecognised deferred tax assets are reassessed at each reporting date and recognised to the extent that it has become probable that future taxable profits will be available against which they can be used.

**NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS FOR THE FINANCIAL YEAR ENDED 31
DECEMBER 2025**

2(d) Material accounting policy information (Cont'd)
Income tax (Cont'd)

In determining the amount of current and deferred tax, the Group takes into account the impact of uncertain tax positions and whether additional taxes and interest may be due. The Group believes that its accruals for tax liabilities are adequate for all open tax years based on its assessment of many factors, including interpretations of tax law and prior experience. This assessment relies on estimates and assumptions and may involve a series of judgements about future events. New information may become available that causes the Group to change its judgement regarding the adequacy of existing tax liabilities; such changes to tax liabilities will impact tax expense in the period that such a determination is made.

Discontinued operations

A discontinued operation is a component of the Group that either has been disposed of, or that is classified as held-for-sale and:

- represents a separate major line of business or geographical area of operations;
- is part of a single co-ordinated plan to dispose of a separate major line of business or geographical area of operations; or
- is a subsidiary acquired exclusively with a view to resale.

Classification as a discontinued operation occurs at the earlier of disposal or when the operation meets the criteria to be classified as held for sale. When an operation is classified as a discontinued operation, the comparative statement of profit or loss is re-presented as if the operation had been discontinued from the start of the comparative year.

Related parties

A related party is defined as follows:

- (a) A person or a close member of that person's family is related to the Company and the Group if that person:
 - (i) has control or joint control over the Company;
 - (ii) has significant influence over the Company; or
 - (iii) is a member of the key management personnel of the Company or the Group or of a parent of the Company.

**NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS FOR THE FINANCIAL YEAR ENDED 31
DECEMBER 2025**

2(d) Material accounting policy information (Cont'd)

Related parties (Cont'd)

- (b) An entity is related to the Company and the Group if any of the following conditions applies:
- (i) the entity and the Company are members of the same group (which means that each parent, subsidiary and fellow subsidiary is related to the others);
 - (ii) one entity is an associate or joint venture of the other entity (or an associate or joint venture of a member of a group of which the other entity is a member);
 - (iii) both entities are joint ventures of the same third party;
 - (iv) one entity is a joint venture of a third entity and the other entity is an associate of the third entity;
 - (v) the entity is a post-employment benefit plan for the benefit of employees of either the Company or an entity related to the Company. If the Company is itself such a plan, the sponsoring employers are also related to the Company;
 - (vi) the entity is controlled or jointly controlled by a person identified in (a);
 - (vii) a person identified in (a) (i) has significant influence over the entity or is a member of the key management personnel of the entity (or of a parent of the entity); or
 - (viii) the entity, or any member of a group of which it is a part, provides key management personnel services to the reporting entity or to the parent of the reporting entity.

Fair value measurement

A number of the Group's accounting policies and disclosures require the measurement of fair values, for both financial and non-financial assets and liabilities.

The Group has an established control framework with respect to the measurement of fair value. This includes a finance team that has overall responsibility for all significant fair value measurements, including Level 3 fair values, and report directly to the Chief Financial Officer.

The finance team regularly reviews significant unobservable inputs and valuation adjustments. If third party information, such as source documents, is used to measure values, then the valuation team assesses and documents the evidence obtained from the third parties to support the conclusion that these valuations meet the requirement of SFRS(I)s, including the level in fair value hierarchy in which the valuations should be classified. Significant valuation issues are reported to the Board of directors.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

2(d) Material accounting policy information (Cont'd)

Fair value measurement (Cont'd)

When measuring the fair value of an asset or a liability, the Group uses observable market data as far as possible. Fair values are categorised into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows:

- *Level 1:* quoted prices (unadjusted) in active markets for identical assets or liabilities.
- *Level 2:* inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
- *Level 3:* inputs for the asset or liability that are not based on observable market data (unobservable inputs).

If the inputs used to measure the fair value of an asset or a liability fall into different levels of the fair value hierarchy, then the fair value measurement is categorised in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement (with Level 3 being the lowest).

The Group recognises transfers between levels of the fair value hierarchy as at the end of the reporting period during which the change has occurred.

Earnings per share

The Group presents basic and diluted earnings per share data for its ordinary shares. Basic earnings per share is calculated by dividing the profit or loss attributable to ordinary shareholders of the Company by the weighted-average number of ordinary shares outstanding during the year, adjusted for own shares held. Diluted earnings per share is determined by adjusting the profit or loss attributable to ordinary shareholders and the weighted-average number of ordinary shares outstanding, adjusted for own shares held, for the effects of all dilutive potential ordinary shares.

Segment reporting

An operating segment is a component of the Group that engages in business activities from which it may earn revenues and incur expenses, including revenues and expenses that relate to transactions with any of the Group's other components. All operating segments' operating results are reviewed regularly by the Group's Chief Executive Officer (the chief operating decision maker) to make decisions about resources to be allocated to the segment and to assess its performance, and for which discrete financial information is available.

Segment results that are reported to the Directors of the Company include items directly attributable to a segment as well as those that can be allocated on a reasonable basis. Unallocated items comprise mainly corporate assets, head office expenses and tax assets and liabilities.

Segment capital expenditure is the total cost incurred during the year to acquire property, plant and equipment.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

3 Property, plant and equipment

	At valuation	----- At cost -----				
The Group	Land	Buildings	Plant and equipment	Motor vehicles	Construction in progress	Total
	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000
<u>Cost</u>						
At 1 January 2024	30,585	6,706	15,328	1,418	56	54,093
Additions	89	251	88	—	11	439
Disposals/written-off	(14)	(115)	(156)	(13)	—	(298)
Revaluation	4,793	—	—	—	—	4,793
Disposal of discontinued operations	(34,468)	(6,622)	(14,764)	(1,333)	(64)	(57,251)
Effect on movements in exchange rates	(985)	(220)	(496)	(50)	(3)	(1,754)
At 31 December 2024, 1 January 2025 and 31 December 2025	—	—	—	22	—	22
<u>Accumulated depreciation and impairment loss</u>						
At 1 January 2024	—	2,173	10,115	922	—	13,210
Depreciation	—	220	955	85	—	1,260
Disposals/written-off	—	(70)	(120)	(4)	—	(194)
Disposal of discontinued operations	—	(2,256)	(10,620)	(948)	—	(13,824)
Effect on movements in exchange rates	—	(67)	(330)	(33)	—	(430)
At 31 December 2024, 1 January 2025 and 31 December 2025	—	—	—	22	—	22
<u>Net carrying amount</u>						
At 31 December 2025	—	—	—	—	—	—
At 31 December 2024	—	—	—	—	—	—

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

3 Property, plant and equipment (Cont'd)

Depreciation

Depreciation for the year is charged to the accounts stated as follows:

The Group	2025 \$'000	2024 \$'000
Biological assets	–	1,157
Inventories	–	87
Administrative expenses	–	16
	–	1,260

4 Right-of-use assets / lease liabilities

Right-of-use assets

The Group	Land plots \$'000	Agricultural equipment \$'000	Total \$'000
2024			
At 1 January	3,190	10	3,200
Depreciation	(383)	–	(383)
Additions to right-of-use assets	–	215	215
Modification of right-of-use assets	21	–	21
Disposal of discontinued operations (Note 23)	(2,725)	(225)	(2,950)
Effect on movements in exchange rates	(103)	–	(103)
At 31 December 2024, 1 January 2025 and 31 December 2025	–	–	–

Depreciation for the year is charged to the accounts stated as follows:

The Group	2025 \$'000	2024 \$'000
Biological assets	–	278
Inventories	–	71
Cost of sales	–	34
	–	383

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

4 Right-of-use assets / lease liabilities (Cont'd)

Lease liabilities

Amounts recognised in statement of cash flows

	2025	2024
The Group	\$'000	\$'000
Repayment of lease liabilities and interest	–	256
Payment of short-term leases	30	291
	30	547

Amounts recognised in profit or loss

	2025	2024
The Group	\$'000	\$'000
Interest expense on lease liabilities	–	(209)
Income from remeasurement and modification of lease liabilities	–	3
	–	(206)

5 Investments in subsidiaries

At the reporting date, the subsidiaries of the Group are as follows:

Name of subsidiaries	Principal place of business	Effective interests held by the Group		Principal activities
		2025	2024	
		%	%	
Tetra JSC	Russia	100.0	100.0	Holding company
Happy Cow LLC	Russia	100.0	100.0	Dormant

The subsidiaries of the Group are audited by Beterra JSC (Russia) for the purpose of consolidation.

In accordance with Catalist Rules 715 and 716 of the SGX-ST Listing Manual, the Audit and Risk Committee and Board of Directors of the Company confirmed that they are satisfied that the appointment of different auditor for its significant foreign incorporated subsidiaries, would not compromise the standard and effectiveness of the audit of the Company. For this purpose, a subsidiary is considered significant as defined under the Catalist Rules if the Group's share of its net tangible assets represents 20% or more of the Group's consolidated net tangible assets, or if the Group's share of its pre-tax profits accounts for 20% or more of the Group's consolidated pre-tax profits.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

6 Goodwill

	2025	2024
The Group	\$'000	\$'000
Balance at 1 January	–	436
Disposal of discontinued operations (Note 23)	–	(422)
Effect on movements in exchange rates	–	(14)
Balance at 31 December	–	–

7 Biological assets

(a) Biological assets - livestock

Changes in biological assets - livestock balances are disclosed below:

	2025	2024
The Group	\$'000	\$'000
Balance at 1 January	–	8,375
Increase due to cost on growth	–	3,673
Disposal due to mortality	–	(12)
Decrease due to sales of livestock	–	(786)
Decrease due to sales of milk	–	(2,723)
Loss from changes in fair value of biological assets	–	(2,061)
Disposal of discontinued operations (Note 23)	–	(6,195)
Effect on movements in exchange rates	–	(271)
Balance at 31 December	–	–

(b) Biological assets - permanent grass

Changes in biological assets - permanent grass balances are disclosed below:

	2025	2024
The Group	\$'000	\$'000
Balance at 1 January	–	601
Increase due to costs on growing crops	–	555
Decrease of crops due to harvest	–	(258)
Disposal of discontinued operations (Note 23)	–	(879)
Effect on movements in exchange rates	–	(19)
Balance at 31 December	–	–

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

7 Biological assets (Cont'd)

(c) Biological assets - crops

Changes in biological assets - crops balances are disclosed below:

The Group	2025 \$'000	2024 \$'000
Balance at 1 January	–	8,474
Increase due to costs on growing crops	–	9,974
Loss arising from changes in fair value of biological assets	–	(7,740)
Decrease of crops due to harvest	–	(1,646)
Disposal of discontinued operations (Note 23)	–	(8,789)
Effect on movements in exchange rates	–	(273)
Balance at 31 December	–	–

Risk management strategy related to agriculture activities

The Group is exposed to the following risks related to its crops and livestock:

Regulatory and environmental risks

The Group had established environmental policies and procedures aimed at compliance with local environmental and other laws. Management performed regular reviews to identify environmental risks and to ensure that the systems are in place to manage those risks.

Supply and demand risk

The Group was exposed to risks arising from fluctuations in the prices and sales volume of crops and milk products. Whenever possible, the Group managed this risk by aligning its production volume to market supply and demand. Management performed regular industry trend analyses to ensure that the Group's pricing structure is in line with the market and to ensure that the projected harvest and milk volumes are consistent with expected demand.

Climate and other risks

The Group's crops were exposed to the risk of damage from climatic changes and diseases. The Group had processes in place aimed at monitoring and mitigating those risks. The Group does not insure itself against failure of crops.

Measurement of fair values

Fair value hierarchy

The fair value measurements for the crops and livestock have been categorised as Level 3 fair values based on the inputs to the valuation techniques used.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

7 Biological assets (Cont'd)

Measurement of fair values (Cont'd)

Level 3 fair value

The following table shows a breakdown of the total losses recognised in respect of Level 3 fair values.

The Group	2025 \$'000	2024 \$'000
Loss from changes in fair value of biological assets		
- Changes in fair value (unrealised)	–	(9,801)
	–	(9,801)
Loss included in other comprehensive income		
Effect of movements in exchange rates	–	(563)

8 Other investments

The Group	2025 \$'000	2024 \$'000
Unquoted equity investments at fair value through profit or loss		
Balance at 1 January	385	–
Additions	–	457
Changes in fair value	141	–
Effect on movements in exchange rates	136	(72)
Balance at 31 December	662	385

Other investments represented the 1% of equity interest in 812 Capital LLC, acquired by the Group as disclosed in Note 30.

Information about the Group's and the Company's fair value measurement is included in Note 29.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

9 Other receivables

	The Group		The Company	
	2025	2024	2025	2024
	\$'000	\$'000	\$'000	\$'000
Other receivables	–	8	–	7
Loans due from:				
- A third party	1,220	1,207	–	–
- 812 Capital LLC and CIMT LLC	4,915	–	–	–
- A subsidiary	–	–	218	–
Interest receivables due from:				
- A third party	1,141	309	–	–
- A subsidiary	–	–	668	625
Dividends receivable from a subsidiary	–	–	1,645	1,213
Deferred consideration receivable	–	3,017	–	–
Financial assets at amortised cost	7,276	4,541	2,531	1,845
Advance payments for proposed acquisition of 812 Capital LLC and Center for Innovative Medical Technologies LLC (“CIMT LLC”)	36,099	–	–	–
Prepayments	253	214	97	67
VAT receivables	98	8	–	–
	43,726	4,763	2,628	1,912

Loan due from a third party

At the reporting date, the loan due from a third party amounting to \$1,220,000 (RUB 75 million) (2024: \$1,207,000 (RUB 100 million)) is unsecured and bears interest on the outstanding principal amount of the loan at the key rate the Central Bank of Russia plus 3% per annum. The loan has a maturity date on 31 August 2026 (2024: 31 August 2025).

Loans due from 812 Capital LLC and CIMT LLC

At the reporting date, the loans due from 812 Capital LLC and CIMT LLC comprised:

- A loan of \$3,838,000 (RUB 236 million) granted to 812 Capital LLC in May 2025 for its acquisition of Uni Medica LLC and The Group of Companies Uni Clinic Ltd (“Uni Medica Group”). The loan is unsecured and only subject to interest at the key rate of the Central Bank of Russia plus 3% per annum if the proposed acquisition of 812 Capital LLC and CIMT LLC (“Proposed Acquisition”) by the Group is not completed by 28 February 2026; and
- Loans of \$1,077,000 (RUB 66.2 million) granted to CIMT LLC for its working capital purpose, which are unsecured, interest-free and have maturity dates ranging from 10 April 2026 to 20 June 2026.

Loan due from a subsidiary

At the reporting date, the loan due from a subsidiary amounting to \$218,000 is unsecured, bears interest at 7% per annum and is repayable no later than 30 September 2026.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

9 Other receivables (Cont'd)

Deferred consideration receivable

As at 31 December 2024, the deferred consideration receivable of \$3,017,000 (RUB 250 million) represented the final cash consideration in relation to the disposal of discontinued operations, which were received in January 2025 and February 2025.

Advance payments for proposed acquisition of 812 Capital LLC and CIMT LLC

At the reporting date, the advance payment amounting to \$36,099,000 (RUB 2,220 million) represented payments made by the Group to the vendors of 812 Capital LLC and CIMT LLC for the Proposed Acquisition in accordance with the contract terms entered with these vendors.

The Group's and the Company's exposure to credit and foreign currency risks are disclosed in Note 28.

10 Cash and bank balances

	The Group		The Company	
	2025	2024	2025	2024
	\$'000	\$'000	\$'000	\$'000
Bank balances	4,353	9,030	153	38
Short-term bank deposits with maturities of three months or less	20,326	12,067	—	—
Restricted deposits	—	26,789	—	—
	24,679	47,886	153	38
Less: Restricted deposits	—	(26,789)		
Cash and cash equivalents included in consolidated statement of cash flows	24,679	21,097		

During the year, interest rates relating to short-term bank deposits with maturities of three months or less with financial institutions range from 12.30% to 22.00% (2024: 12.39% to 22.00%).

As at 31 December 2024, the restricted deposits of \$26.8 million (RUB 2,220,000 million) represented advance payments for the shares in 812 Capital LLC and CIMT LLC in the form of letters of credits issued by PJSC Sberbank Moscow, which was subject to the approval by the SGX-ST on the Company's waiver application in relation to the escrow requirements under Catalist Rule 1017(1)(a). The Group obtained approval from SGX-ST on 17 January 2025.

The Group's and the Company's exposure to credit and foreign currency risks are disclosed in Note 28.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

11 Share capital

	No. of shares		The Group		The Company	
	2025	2024	2025	2024	2025	2024
			\$'000	\$'000	\$'000	\$'000
Issued and fully paid:						
At beginning of year						
and at end of year	150,272,700	150,272,700	40,667	40,667	40,911	40,911

In arriving at the share capital of the Group, listing expenses incurred in 2020 by the subsidiaries, amounting to \$244,000, have been capitalised against the share capital of the Company in accordance with SFRS(I) 1-32 *Financial Instruments: Presentation*.

The holders of ordinary shares are entitled to receive dividends as declared from time to time and are entitled to one vote per share at meetings of the Company. All shares rank equally with regard to the Company's residual assets.

Capital management

As a consequence of the disposal of discontinued operations of the Group (see Note 23), the Group does not have any operating businesses following the completion of the disposal and the Company has become a cash company on 8 July 2024, as defined under Rule 1017 of the Catalist Rules.

On 9 February 2026, the Group completed the acquisition of healthcare business in Russian Federation and ceased to be a cash company.

The Group and the Company manage its capital to ensure that entities in the Group will be able to continue as a going concern while maximising the returns to stakeholders through optimisation of debt and equity balances. The Group considers the amount of equity attributable to the owners of the Company as capital. To maintain or adjust the capital structure, the Company may issue new shares.

The Group monitors capital on the basis of net debt to earnings before interest, tax, depreciation and amortisation ("EBITDA") ratio. Net debt is calculated as total borrowings (including current and non-current loans, borrowings and lease liabilities as shown in the consolidated statement of financial position) less cash and bank balances.

As at 31 December 2025 and 2024, the Group does not have any debt and therefore, the net debt to EBITDA ratio is not presented.

The Group and the Company are not subjected to any externally imposed capital requirements during the financial years ended 31 December 2025 and 2024, respectively.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

12 Reserves

		The Group		The Company	
		2025	2024	2025	2024
		\$'000	\$'000	\$'000	\$'000
Capital reserve	(a)	(10,450)	(10,450)	(21,270)	(21,270)
Foreign currency translation reserve	(b)	10,268	(6,730)	–	–
		(182)	(17,180)	(21,270)	(21,270)

(a) Capital reserve

Capital reserves mainly relates to the merger reserve recognised in connection with the execution of the share swap agreement between the Company and Vallerd Investments Limited as a result of the Restructuring Exercise (Note 1.2) and transactions with former shareholders, which has been accounted for as a transaction with shareholders in their capacity as shareholders in accordance with SFRS(I) 1-1 – *Presentation of Financial Statements*.

(b) Foreign currency translation reserve

The foreign currency translation reserve records exchange differences arising from the translation of the financial statements of foreign operations whose functional currencies are different from that of the Group's presentation currency.

13 Deferred tax liabilities

The movements in the deferred tax account are as follows:

The Group	2025	2024
	\$'000	\$'000
At 1 January	–	5,045
Revaluation of property, plant and equipment	–	959
Disposal of discontinued operations (Note 23)	–	(5,841)
Effect on movements in exchange rates	–	(163)
At 31 December	–	–

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

14 Other payables

	The Group		The Company	
	2025	2024	2025	2024
	\$'000	\$'000	\$'000	\$'000
Other payables	1,383	666	1,316	475
Loan to a subsidiary	–	–	70	70
Interest payable to a subsidiary	–	–	27	23
Dividends payable	171	171	171	171
Financial liabilities at amortised cost	1,554	837	1,584	739
Unified Social Tax (“UST”) payables	15	11	–	–
Other taxes payables	3	2	–	–
	1,572	850	1,584	739

The loan to a subsidiary is unsecured, bears interest at 6.10% per annum and is payable no later than 30 June 2026.

The Group’s and the Company’s exposure to liquidity and foreign currency risks are disclosed in Note 28.

15 Provisions

Provisions were created mainly for employees’ unused vacation. The unused vacation provisions are expected to be utilised within the next 12 months.

The Group	2025	2024
	\$'000	\$'000
At 1 January	380	619
Provision made for unutilised annual leave (Note 22)	160	626
Reversal of unutilised annual leave no longer required (Note 19)	(288)	(39)
Provision made, net	(128)	587
Provision utilised during the year	(334)	(252)
Disposal of discontinued operations (Note 23)	–	(484)
Effect on movements in exchange rates	121	(90)
At 31 December	39	380

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

16 Revenue

The Group	2025 \$'000	2024 \$'000
Discontinued operations		
Revenue from sale of crop production	–	7,011
Revenue from sale of livestock and milk	–	4,593
Revenue from sale of flour production	–	574
Revenue from services provided	–	69
	–	12,247

The following table provides information about the nature and timing of the satisfaction of performance obligations in contracts with customers, including significant payment terms, and the related revenue recognition policies:

Nature of goods or services	The Group is growing, processing and distributing agricultural and dairy products, mainly grain and milk at farms and produces and distributes flour.
When revenue is recognised	Revenue is recognised at a point in time, when the crops, livestock, milk and flour are collected by the customer or delivered to the customer's premises.
Significant payment terms	Invoices are issued when the products are delivered. Payment for these products is due within period of 10 days. Advance payment is collected from most of the customers upon confirmation of orders. Payment of the outstanding amounts is due within period of 10 days from the date of the products are delivered to the customer. The Group applied the practical expedient not to recognise any financing element as the contracts are typically completed within a year.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

17 Cost of sales

The Group	2025 \$'000	2024 \$'000
Discontinued operations		
Cost of inventories sold	–	6,201
Wages and salaries	–	2,323
Depreciation of property, plant and equipment and right-of-use assets	–	1,031
Short-term leases expenses	–	251
Growing and harvesting services	–	807
Energy utilities	–	174
Other taxes	–	44
Write-down of inventories	–	22
Repair and maintenance	–	120
Others	–	587
	–	11,560

18 Administrative expenses

The Group	Continuing operations \$'000	Discontinued operations \$'000	Total \$'000
2025			
Employee benefits expense (Note 22)	937	–	937
Information, consulting and other professional services	4,986	–	4,986
Short-term lease expenses	30	–	30
Business travel expenses	130	–	130
Others	18	–	18
	6,101	–	6,101
2024			
Employee benefits expense (Note 22)	3,585	380	3,965
Depreciation of property, plant and equipment (Note 3)	–	16	16
Information, consulting and other professional services	3,059	45	3,104
Short-term leases expenses	29	11	40
Repair costs	–	10	10
Business travel expenses	65	93	158
Other material expenses	–	30	30
Others	54	105	159
	6,792	690	7,482

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

19 Other operating income/(expenses)

The Group	Continuing operations \$'000	Discontinued operations \$'000	Total \$'000
2025			
Government grants received	2	–	2
Reversal of unutilised annual leave no longer required (Note 15)	288	–	288
Changes in fair value of other investments (Note 8)	141	–	141
Other income	431	–	431
Bank services	(13)	–	(13)
Penalties	(84)	–	(84)
Directors' fees	(220)	–	(220)
Executive Chairman's salaries	(195)	–	(195)
Others	(113)	–	(113)
Other operating expenses	(625)	–	(625)
	(194)	–	(194)
2024			
Gain on disposal of property, plant and equipment	–	88	88
Government grants received	2	38	40
Reversal of provision for inventory obsolescence	–	272	272
Reversal of unutilised annual leave no longer required (Note 15)	–	39	39
Sales of own feeds and scrap metal	–	195	195
Others	–	26	26
Other income	2	658	660
Bank services	(81)	(25)	(106)
Penalties	–	(9)	(9)
Other tax expenses	(139)	(81)	(220)
Directors' fees	(133)	–	(133)
Executive Chairman's salaries	(168)	–	(168)
Other operating expenses	(521)	(115)	(636)
	(519)	543	24

In 2024, the Group, as an agricultural producer, recognised government grants amounting to \$257,000, to subsidise growing and production cost of the Group's biological assets. There were no unfulfilled conditions nor other contingencies attached to these grants, nor significant decreases expected in the level of government grants.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

19 Other operating income/(expenses) (Cont'd)

The government grants recognised during the year are attributable to:

	2025	2024
The Group	\$'000	\$'000
Operational activities - other operating income	–	40
Financing activities – Government grants compensating finance cost (Note 20)	–	217
	–	257

20 Finance income and finance costs

	Continuing operations \$'000	Discontinued operations \$'000	Total \$'000
The Group			
2025			
Interest income from:			
- Bank deposits	3,472	–	3,472
- Loan due from a third party	591	–	591
Unwinding interest income from loans due from CIMIT LLC	117	–	117
	4,180	–	4,180
Foreign exchange gains, net	942	–	942
Finance income	5,122	–	5,122
Net losses from difference in the fair value of loans due from CIMIT LLC at initial recognition and its transaction price	(195)	–	(195)
Finance costs	(195)	–	(195)
Net finance income	4,927	–	4,927

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

20 Finance income and finance costs (Cont'd)

The Group	Continuing operations \$'000	Discontinued operations \$'000	Total \$'000
2024			
Interest income from:			
- Bank deposits	283	–	283
- A loan due from a third party	3,095	43	3,138
- Remeasurement and modification of lease liabilities (Note 4)	–	3	3
Finance income	3,378	46	3,424
Interest expense:			
- Loans and borrowings	–	(785)	(785)
- Lease liabilities (Note 4)	–	(209)	(209)
Government grants compensating finance cost (Note 19)	–	217	217
	–	(777)	(777)
Foreign exchange losses, net	(688)	–	(688)
Finance costs	(688)	(777)	(1,465)
Net finance costs	2,690	(731)	1,959

21 Tax expense

The Group	2025 \$'000	2024 \$'000
Current year tax expense		
- Continuing operations	–	–
- Discontinued operations	–	62
	–	62

Reconciliation of effective tax rate

The Group	2025 \$'000	2024 \$'000
Loss before tax from continuing operations	(1,368)	(4,621)
Loss before tax from discontinuing operations	–	(18,040)
	(1,368)	(22,661)
Tax at the domestic rates applicable in the respective jurisdiction	(186)	(4,532)
Tax effect of income of agricultural subsidiaries taxed at Nil%	–	3,629
Tax effect of non-deductible expenses	162	1,799
Change in unrecognised temporary differences	24	(834)
	–	62

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

21 Tax expense (Cont'd)

In 2024, the income tax rate applicable to the majority of the Group's income is 0% as their activities were mainly related to agricultural production while other activities are taxed at 20%. In 2024, non-deductible expenses relate mainly to loss on disposal of discontinued operations.

Unrecognised deferred tax assets

	2025	2024
The Group	\$'000	\$'000
Tax losses	25,446	22,416

Due to amendments to the Russian tax legislation starting from 1 January 2017, tax losses carried forward do not expire but may be set off only against 50% of taxable profits. The deferred tax assets are not recognised as there is no evidence of probable future taxable profits related to the Group's non-core activities.

Unrecognised deferred tax liabilities

At the reporting date, deferred tax liabilities associated with the Group's investments in subsidiaries amounted to \$13,700,000 (2024: \$10,425,000). These have not been recognised as the Group is able to control the timing of reversal of the difference, and reversal is not expected in the foreseeable future.

22 Employee benefits expense

	Continuing operations	Discontinued operations	Total
The Group	\$'000	\$'000	\$'000
2025			
Salaries and related expenses	644	–	644
Contributions to defined contribution plans	133	–	133
Provision made for unutilised annual leave (Note 15)	160	–	160
	937	–	937
2024			
Salaries and related expenses	2,678	2,167	4,845
Contributions to defined contribution plans	461	715	1,176
Provision made for unutilised annual leave (Note 15)	446	180	626
	3,585	3,062	6,647

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

22 Employee benefits expense (Cont'd)

Employee benefits expense for the year are charged to the accounts stated as follows:

The Group	2025 \$'000	2024 \$'000
Biological assets	–	1,845
Inventories	–	509
Cost of sales	–	328
Administrative expenses (Note 18)	937	3,965
	937	6,647

23 Discontinued operations

In July 2024, the Group completed the disposal of the following subsidiaries for a cash consideration of \$64.3 million (RUB 4,500 million):

- 100% equity interests in Don Agro LLC;
- 100% equity interests in Don Agrarian Group JSC;
- 90% equity interests in Don Muchnov LLC; and
- 99.99% equity interests in Volgo-Agro LLC.

The above subsidiaries represented separate major line of business and met the definition of discontinued operations in accordance with SFRS(I) 5 *Non-current Assets Held for Sale and Discontinued Operations*. Accordingly, they are deconsolidated from the consolidated financial statements of the Group in the financial year ended 31 December 2024 and the financial statements were presented to reflect the presentation of discontinued operations.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

23 Discontinued operations (Cont'd)

Results of discontinued operations

	2024 \$'000
Revenue	12,247
Cost of sales	(11,560)
Loss from change in fair value of biological assets	(9,801)
Gross loss	(9,114)
Administrative expenses	(690)
Other operating income, net	543
Loss from operating activities	(9,261)
Finance income	46
Finance costs	(777)
Net finance costs	(731)
Loss before tax	(9,992)
Tax expense	(62)
Results from operating activities, net of tax	(10,054)
Loss on disposal of discontinued operations	(8,048)
Loss from discontinued operations, net of tax	(18,102)
Loss from discontinued operations, net of tax attributable to:	
Owners of the Company	(18,101)
Non-controlling interests	(1)
	(18,102)
Loss per share	
Basic and diluted loss per share from discontinued operations (cents)	(12.04)
Cash flows from/(used in) discontinued operations	
Net cash used in operating activities	(4,479)
Net cash used in investing activities	(204)
Net cash from financing activities	4,229
Net cash outflows for the year	(454)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

23 Discontinued operations (Cont'd)

Effect of disposal of discontinued operations of the Group

	2024 \$'000
Property, plant and equipment	43,427
Right-of-use assets (Note 4)	2,950
Goodwill (Note 6)	422
Biological assets – Livestock and permanent grass	7,074
Other non-current assets	12
Biological assets – Crops (Note 7c)	8,789
Inventories	7,417
Trade and other receivables	2,216
Cash and cash equivalents	126
Deferred tax liabilities (Note 13)	(5,841)
Deferred income	(114)
Lease liabilities	(4,150)
Loans and borrowings	(10,769)
Trade and other payables	(2,717)
Provisions (Note 15)	(484)
Current tax liabilities	(8)
	48,350
Non-controlling interests	(44)
	48,306
Foreign currency translation reserve reclassified to profit or loss upon disposal of discontinued operations	24,033
Loss on disposal of discontinued operations	(8,048)
Proceeds from disposal of discontinued operations	64,291
Consideration received, satisfied in cash	64,291
Less: Deferred consideration	(3,572)
Less: Cash and cash equivalents disposed of	(126)
Net cash inflows	60,593

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

24 Loss per share

Basic loss per share is calculated by dividing the net loss attributable to equity holders of the Company by the weighted average number of ordinary shares outstanding during the financial year. The number of ordinary shares outstanding from the completion date to the end of the period is the weighted average number of ordinary shares of the Company outstanding during the period.

	Continuing operations	Discontinued operations	Total
2025			
Loss for the year attributable to owners of the Company (\$'000)	(1,368)	–	(1,368)
Basic and diluted loss per share (cents), calculated based on 150,272,700 weighted average number of ordinary shares	(0.91)	–	(0.91)
2024			
Loss for the year attributable to owners of the Company (\$'000)	(4,621)	(18,101)	(22,722)
Basic and diluted loss per share (cents), calculated based on 150,272,700 weighted average number of ordinary shares	(3.08)	(12.04)	(15.12)

Diluted loss per share is the same as basic loss per share because there were no potential dilutive ordinary shares existing during the respective periods.

25 Related party transactions

Key management personnel compensation

Key management personnel of the Group are those persons having authority and responsibility for planning, directing and controlling the activities of the Group.

Key management received the following remuneration during the year, which is included in employee benefits expense:

	2025 \$'000	2024 \$'000
The Group		
Salaries and related expenses	823	2,759
Contributions to defined contribution plans	154	471
	977	3,230

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

26 Contingencies and commitments

Insurance

The insurance industry in the Russian Federation is in a developing state and many forms of insurance protection common in other parts of the world are not yet generally available. The Group does not have full coverage for its plant facilities, biological assets, business interruption, or third-party liability in respect of property or environmental damage arising from accidents on the Group's property or relating to the Group's operations. Until the Group obtains adequate insurance coverage, there is a risk that the loss or destruction of certain assets could have a material adverse effect on the Group's operations and financial position.

Taxation

The taxation system in the Russian Federation continues to evolve and is characterised by frequent changes in legislation, official pronouncements and court decisions, which are sometimes contradictory and subject to varying interpretation by different tax authorities.

The tax authorities have the power to impose fines and penalties for tax arrears. A tax year is generally open for review by the tax authorities during three subsequent calendar years. Currently, the tax authorities are taking a more assertive and substance-based approach to their interpretation and enforcement of tax legislation in the Russian Federation.

In addition, changes aimed at regulating tax consequences of transactions with foreign companies have been introduced, such as concept of beneficial ownership of income, taxation of controlled foreign companies, tax residency rules, etc. These changes may potentially impact the Group's tax position and create additional tax risks.

All these circumstances may create tax risks in the Russian Federation that are substantially more significant than in other countries. Management believes that it has provided adequately for tax liabilities based on its interpretations of applicable Russian tax legislation, official pronouncements and court decisions. However, the interpretations of the tax authorities and courts could differ and the effect on these consolidated financial statements, if the authorities are successful in enforcing their interpretations, could be significant.

27 Operating segments

Basis of segmentation

In 2024, the Group had the following two strategic divisions, which were its reportable segments. These divisions offered different products and are managed separately because they required different technology and marketing strategies.

The following summary described the operations in each of the Group's reportable segment.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

27 Operating segments (Cont'd)

Reportable segments	Operations
Crops	It includes production and sale of agriculture produce in the Russian Federation, mainly winter wheat, sunflower, corn and other crops.
Livestock	It includes the breeding of dairy cows for milk production and sale of livestock.

The Group's Chief Executive Officer reviewed the internal management reports of each division regularly.

Other operations included other non-significant segments but none of these segments met the quantitative thresholds for reportable segments in 2024.

There were varying levels of integration between the Crops segment and Livestock segment. This integration included transfer of harvested crops for production of feed for dairy cow consumption. Inter-segment pricing was determined on an arm's length basis.

Information about reportable segments

As a consequence of the disposal of discontinued operations of the Group, the Group does not have any operating businesses and reportable segment. Therefore, the information about reportable segments is not presented in 2025.

In 2024, the information related to each reportable segment is set out below. Segment loss before tax is used to measure performance because management believes that such information is the most relevant in evaluating the results of the respective segments relative to other entities that operate in the same industries.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

27 Operating segments (Cont'd)

	Discontinued operations				Continuing operations		
	Crops \$'000	Livestock \$'000	Others \$'000	Eliminations \$'000	Total \$'000	Others \$'000	Total \$'000
2024							
External revenue	7,011	4,593	643	–	12,247	–	12,247
Inter-segment revenue	1,061	–	–	(1,061)	–	–	–
Segment revenue	8,072	4,593	643	(1,061)	12,247	–	12,247
Segment loss before tax	(5,332)	(4,237)	(423)	–	(9,992)	(4,621)	(14,613)
Other operating income/(expenses)	316	198	29	–	543	(519)	24
Finance income	27	17	2	–	46	3,378	3,424
Finance costs	(554)	(197)	(26)	–	(777)	(688)	(1,465)
Depreciation	(891)	(133)	(23)	–	(1,047)	–	(1,047)
Segment assets	–	–	–	–	–	53,034	53,034
Capital expenditure	375	53	11	–	439	–	439
Segment liabilities	–	–	–	–	–	1,294	1,294

Geographical information

In 2024, external customers of the Group were located in the Russian Federation. The Group carried out its operations in the Russian Federation and all the Group's non-current assets were located in the Russian Federation.

Major customers

The following are major customers with revenue amounting to 10% or more of the Group's total revenue during the year ended 31 December 2024.

The Group	2024 \$'000
LLC Grain Service	1,277
JSC Voronezhsky Milk Combinat	3,804
JSC Aston	1,874
LLC Rubickon	3,441
	10,396

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

28 Financial risk management objectives and policies

Overview

The Group has exposure to the following risks from its use of financial instruments:

- credit risk
- liquidity risk
- market risk

The Group has a system of controls in place to create an acceptable balance between the cost of risks occurring and the cost of managing those risks. Management continually monitors the Group's risk management process to ensure that an appropriate balance between risk and control is achieved.

Credit risk

Credit risk is the potential financial loss resulting from the failure of a customer or a counter party to settle its financial and contractual obligations to the Group, as and when they fall due. Management has a credit policy in place which establishes credit limit for customers and monitors their balances on an ongoing basis.

Exposure to credit risk

The carrying amount of financial assets represents the maximum credit exposure. The maximum exposure to credit risk at the reporting date was:

	Note	The Group		The Company	
		2025 \$'000	2024 \$'000	2025 \$'000	2024 \$'000
Other receivables	9	7,276	4,541	2,531	1,845
Cash and bank balances	10	24,679	47,886	153	38
		31,955	52,427	2,684	1,883

The maximum exposure to credit risk for financial assets at the reporting date by customer type and geographical segment was:

	The Group		The Company	
	2025 \$'000	2024 \$'000	2025 \$'000	2024 \$'000
Corporation	7,276	4,541	2,531	1,845
Financial institutions	24,679	47,886	153	38
	31,955	52,427	2,684	1,883
Singapore	153	45	153	38
Russian Federation	31,802	52,382	2,531	1,845
	31,955	52,427	2,684	1,883

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

28 Financial risk management objectives and policies (Cont'd)

Other receivables – measured at 12-month ECL

The Group and the Company assessed the credit exposure of these receivables to be insignificant based on the historical default rates, taking into consideration for the future outlook of the industry in which these counterparties operate in.

At the reporting date, the Group and the Company considered that there has been no significant increase in the credit risk since the initial recognition and measured the ECL allowance based on 12-month expected loss basis, and the amount of the allowance is insignificant.

Movement in the allowance for ECL

The movement in the allowance for ECL in respect of trade and other receivables during the year was as follows:

	2025	2024
	\$'000	\$'000
The Group		
At 1 January	–	(19)
Disposal of discontinued operations	–	18
Effect on movements in exchange rates	–	1
At 31 December	–	–

Cash and bank balances

Cash and bank balances are placed with banks and financial institutions which are regulated. Impairment on cash and bank balances has been measured on the 12-month ECL basis and reflects the short maturities of the exposures. The Group considers that its cash and bank balances have low credit risk based on the external credit ratings of the counterparties and low credit risk of the exposures. The amount of loss allowance on cash and bank balances was negligible.

Liquidity risk

Liquidity or funding risk is the risk that an enterprise will encounter difficulty in raising funds to meet commitments associated with financial instruments. Liquidity risk may result from an inability to sell a financial asset quickly at close to its fair value.

The Group monitors its liquidity risk and maintains a level of cash and cash equivalents deemed adequate by management to finance the Group's operations and to mitigate the effects of fluctuations in cash flows. Management believes that the Group will have the continued support of its creditor-banks to renew its short-term loans as and when they fall due.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

28 Financial risk management objectives and policies (Cont'd)

The following are the expected contractual maturities of financial liabilities, including interest payments and excluding the impact of netting agreements:

		Contractual undiscounted cash flows			
	Note	Carrying amount \$'000	Total \$'000	Within 1 year \$'000	Within 1 to 5 years \$'000
The Group					
2025					
Non-derivative financial liabilities					
Other payables	14	1,554	(1,554)	(1,554)	–
2024					
Non-derivative financial liabilities					
Trade and other payables	14	837	(837)	(837)	–
The Company					
2025					
Non-derivative financial liabilities					
Other payables	14	1,584	(1,584)	(1,584)	–
2024					
Non-derivative financial liabilities					
Other payables	14	739	(739)	(739)	–

Market price risk

Market risk is the risk that changes in market prices, such as interest rates, foreign exchange rates and equity prices will affect the Group's income or the value of its holdings of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimising the return on risk.

Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of the Group's financial instruments will fluctuate because of changes in market interest rates.

The Group does not hedge its exposure to changes in interest rates on interest-bearing financial instruments.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

28 Financial risk management objectives and policies (Cont'd)

Interest rate risk (Cont'd)

At the reporting date, the interest rate profile of the Group's interest-bearing financial instruments was as follows:

	Nominal amount	
	2025	2024
The Group	\$'000	\$'000
Fixed rate instruments		
Bank deposits	20,326	38,856
	20,326	38,856
Variable rate instruments		
Loan due from a third party	1,220	1,207
	1,220	1,207

Sensitivity analysis for variable rate instruments

The variable rate instruments have interest rates that are re-set regularly at one, three or six month intervals. A change of 100 basis points in interest rates at the reporting date would have increased/(decreased) loss before tax by \$12,000 (2024: increased/(decreased) loss before tax by \$12,000). There is no impact on other components of equity. This analysis assumes that all other variables remain constant.

Foreign currency risk

Currency risk is the risk that the value of a financial instrument will fluctuate due to changes in foreign exchange rates. Currency risk arises when transactions are denominated in foreign currencies.

The Group has minimal exposure to foreign currency risks as transactions are mainly denominated in the respective functional currencies of the Group entities, except for certain minimal transactions are denominated in United States Dollar.

Sensitivity analysis for foreign currency risk

Sensitivity analysis is not prepared as the possible changes in the exchange rates at the reporting date would not significantly affect profit or loss of the Group.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

28 Financial risk management objectives and policies (Cont'd)

Equity price risk

The Group's exposure to equity price risk relates to equity investments classified as financial assets at fair value through other comprehensive income ("FVOCI"). The market values of these investments are affected by, amongst others, changes in market prices as a result of changes in the economic conditions, macro and micro economic factors affecting the business operations of the investee.

At the reporting date, the price risk profile of equity investments classified as financial assets at FVOCI was as follows:

	2025	2024
	\$'000	\$'000
The Group		
Other investments		
Unquoted equity investments (Note 8)	662	385

Sensitivity analysis for price risk

If movements in financial markets result in a 10% (2024: 10%) appreciation/depreciation in the value of the unquoted equity investments, all other variables being held constant, the Group's loss before tax would have been lower/higher by \$66,000 (2024: \$39,000).

29 Fair value of financial instruments

(a) Accounting classification and fair value

The carrying amounts and fair values of financial assets and financial liabilities, including their levels in the fair value hierarchy are as follows. It does not include fair value information for financial assets and financial liabilities not measured at fair value if the carrying amount is a reasonable approximation of fair value.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

29 Fair value of financial instruments (Cont'd)

(a) Accounting classification and fair value (Cont'd)

	Note	Equity investment at FVOCI \$'000	Amortised cost \$'000	Other financial liabilities \$'000	Total \$'000	Fair value – Level 3 S\$'000
The Group						
2025						
Financial assets not measured at fair value						
Other receivables	9	–	7,276	–	7,276	
Cash and bank balances	10	–	24,679	–	24,679	
		–	31,955	–	31,955	
Financial assets measured at fair value						
Other investments	8	662	–	–	662	662
		662	–	–	662	
Financial liabilities not measured at fair value						
Other payables	14	–	–	(1,554)	(1,554)	
		–	–	(1,554)	(1,554)	
2024						
Financial assets not measured at fair value						
Other receivables	9	–	4,541	–	4,541	
Cash and bank balances	10	–	47,886	–	47,886	
		–	52,427	–	52,427	
Financial assets measured at fair value						
Other investments	8	385	–	–	385	385
		385	–	–	385	
Financial liabilities not measured at fair value						
Trade and other payables	14	–	–	(837)	(837)	
		–	–	(837)	(837)	

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

29 Fair value of financial instruments (Cont'd)

(a) Accounting classification and fair value (Cont'd)

	Note	Amortised cost \$'000	Other financial liabilities \$'000	Total \$'000
The Company				
2025				
Financial assets not measured at fair value				
Other receivables	9	2,531	–	2,531
Cash and bank balances	10	153	–	153
		2,684	–	2,684
Financial liabilities not measured at fair value				
Other payables	14	–	(1,584)	(1,584)
		–	(1,584)	(1,584)
2024				
Financial assets not measured at fair value				
Other receivables	9	1,845	–	1,845
Cash and bank balances	10	38	–	38
		1,883	–	1,883
Financial liabilities not measured at fair value				
Other payables	14	–	(739)	(739)
		–	(739)	(739)

(b) Determination of fair values

A number of the Group's accounting policies and disclosures require the determination of fair value, for both financial and non-financial assets and liabilities. Fair values have been determined for measurement and/or disclosure purposes based on the following methods. Where applicable, further information about the assumptions made in determining fair values is disclosed in the notes specific to that asset or liability.

(c) Financial instruments measured at fair value

The following tables show the valuation techniques used in measuring Level 3 fair values, as well as the significant unobservable inputs used.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

29 Fair value of financial instruments (Cont'd)

(c) Financial instruments measured at fair value (Cont'd)

Type	Valuation technique	Significant unobservable inputs	Inter-relationship between key unobservable inputs and fair value measurement
Other investments – 2025	Discounted cash flows: The valuation model considers the present value of the expected cash inflows, discounted using a risk-adjusted discounted rate.	▪ EBIDTA growth rate of 4% per annum ▪ Risk-adjusted discount rate of 24.7%	The estimated fair value would increase (decrease) if: ▪ the expected EBIDTA growth rate is higher (lower); or ▪ the risk-adjusted discount rate is lower (higher).
Other investments – 2024	The Group applied paragraph of B5.2.3 of SFRS(I) 9 in assessing the carrying amounts of these investments to be a reasonable approximation of fair value at the reporting date because the initial investment made is near to the reporting date.	Not applicable	Not applicable

The following table shows a reconciliation from the opening balances to the ending balances for Level 3 fair values:

	2025	2024
The Group	\$'000	\$'000
Balance at 1 January	385	–
Additions	–	457
Changes in fair value	141	–
Effect on movements in exchange rates	136	(72)
Balance at 31 December	662	385

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

29 Fair value of financial instruments (Cont'd)

(d) Financial instruments not measured at fair value

Other financial assets and liabilities

The carrying amounts of financial assets and liabilities with a maturity of less than one year (including other receivables (excluding advance payments for proposed acquisition of 812 Capital LLC and CIMT LLC, prepayments and VAT receivables), cash and bank balances, and other payables (excluding UST payables and other taxes payables) are assumed to approximate their fair values because of the short period to maturity.

Transfer between the levels

There were no transfers between the levels during the financial years ended 31 December 2025 and 2024, respectively.

30. Significant and subsequent events

On 6 September 2024, the Group entered into various agreements for the proposed acquisitions of 99.99% of equity interests in 812 Capital LLC and 11.5% of equity interests in CIMT LLC (collectively, “**Target Group**”).

On 6 September 2024, the Group completed the acquisition of 1% of equity interests in 812 Capital LLC.

On 30 January 2026, the Company changed its name from Don Agro International Limited to UpHealth Group Limited.

On 9 February 2026, the Group completed the acquisition of the Target Group, which comprise the following:

- Euroonco operates a network of expert oncology clinics across three major cities, focusing on the treatment of advanced-stage cancer. The clinics include inpatient facilities, intensive care units and operating rooms, with total inpatient capacity exceeding 60 beds.
- Uni Medica operates a large multifunctional medical facility with a gross floor area of approximately 7,000 square metres. Uni Medica combines outpatient and inpatient services and currently operates around 30 inpatient beds, intensive care units, operating rooms and an outpatient infrastructure comprising 70 fully equipped medical rooms.

Consequently, the Target Group became the subsidiaries of the Company.

31 Ongoing geopolitical uncertainties

Ongoing geopolitical tensions with Ukraine have resulted in sanctions introduced by the United States of America, the European Union, and some other countries. Sanctions and counter measures have increased the level of economic uncertainty in the Russian business environment and imposed limitations on capital movements across various jurisdictions.

ADDITIONAL INFORMATION ON DIRECTORS SEEKING RE-ELECTION

Pursuant to Rule 720(5) of the Catalist Rules, the information as set out in Appendix 7F to the Catalist Rules relating to the retiring directors is set out below and to be read in conjunction with their respective biographies under the section entitled “Board of Directors” in the Annual Report 2025:

Name of director	Gavin Mark McIntyre	Ravi Chidambaram
Date of Appointment	16 August 2023	28 June 2019
Date of last re-appointment (if applicable)	29 April 2024	29 April 2023
Age	60	62
Country of principal residence	Singapore	Singapore
The Board's comments on this appointment (including rationale, selection criteria, board diversity considerations, and the search and nomination process)	The Board having considered the Nominating Committee's recommendations, the qualifications and working experience of Mr. Gavin Mark McIntyre, is of the view that he has the requisite experience and capabilities and approved his re-election as an Independent Director of the Company.	The Board having considered the Nominating Committee's recommendations, the qualifications and working experience of Mr. Ravi Chidambaram, is of the view that he has the requisite experience and capabilities and approved his re-election as Independent Director of the Company.
Whether appointment is executive, and if so, the area of responsibility	Non-Executive	Non-Executive
Job Title (e.g. Lead ID, AC Chairman, AC Member etc.)	Independent Director, Chairman of the Audit and Risk Committee and Member of the Nominating Committee and Remuneration Committee.	Lead Independent Director, Chairman of the Remuneration Committee and Member of the Audit and Risk Committee and Nominating Committee.

ADDITIONAL INFORMATION ON DIRECTORS SEEKING RE-ELECTION

Professional qualifications	Bachelor of Business (Curtin University of Technology, Australia). Certified Practising Accountant (the Australian Society of Certificate Practising Accountants).	BA, HONOURS; MBA; MA
Working experience and occupation(s) during the past 10 years	1. June 2023 to May 2024 Waystron Pte. Ltd., Director ; 2. November 2021 to June 2024, Biolidics Limited, Director ; 3. October 2020 to Present Xihe Holdings Group of Companies (in Liquidation), Director ; 4. May 2018 to present: Aegis Interaktif Asia Pte. Ltd., Director ; 5. February 2017 to April 2024: VCPlus Limited (formerly known as Anchor Resources Limited), Director; 6. August 2016 to September 2023: Nico Steel Holdings Limited, Director; 7. December 2015 to Present Equitasasia Pte. Ltd., Director Equitasia Holdings Pte. Ltd., Director Equitas Financial Services Pte. Ltd., Director/	President, TC Capital Pte Ltd, Investment Banker
Shareholding interest in the listed issuer and its subsidiaries	Not Applicable	Not Applicable
Any relationship (including immediate family relationships) with any existing director, existing executive officer, the issuer and/or substantial shareholder of the listed issuer or of any of its principal subsidiaries	Not Applicable	Not Applicable

ADDITIONAL INFORMATION ON DIRECTORS SEEKING RE-ELECTION

Conflict of interest (including any competing business)	Not Applicable	Not Applicable
Undertaking (in the format set out in Appendix 7H) under Rule 720(1) has been submitted to the listed issuer	Yes	Yes
Other Principal Commitments* Including Directorships		
Past (for the last 5 years)	1. VCPlus Limited, Director. 2. Nico Steel Holdings Limited, Director. 3. Bromat Holdings Ltd, Director 4. Waystron Pte. Ltd., Director 5. Embracing Future Holdings Limited (fka Biolidics Ltd), Director	Director, Energyone Power Pte. Ltd. (struck off)
Present	1. Xihe Holdings Group of Companies (in Liquidation), Director 2. Aegis Interaktif Asia Pte. Ltd., Director 3. Equitasasia Pte. Ltd., Director 4. Equitasia Holdings Pte. Ltd., Director 5. Equitas Financial Services Pte. Ltd., Director	1. CeeSuite Pte. Ltd., Director 2. Datarama Pte. Ltd., Director 3. Datarama Technology Pte. Ltd, Director 4. Oneness Pte. Ltd., Director 5. TCVN IT Pte. Ltd., Director 6. TC Capital Pte. Ltd., Director 7. Watershed Holdings Pte. Ltd., Director 8. TC Capital Advisory Ltd., Director 9. TC Capital Partners Ltd, Director 10. Zen Capital Ltd, Director 11. Rimm Sustainability Pte Ltd, Director 12. Ecosphere Partners Ptd Ltd, Director 13. TNGA Pte Ltd, Director

ADDITIONAL INFORMATION ON DIRECTORS SEEKING RE-ELECTION

		14. Amar Terrace Pte Ltd, Director 15. Atom8ai Pte Ltd, Director.
Disclose the following matters concerning an appointment of director, chief executive officer, chief financial officer, chief operating officer, general manager or other officer of equivalent rank. If the answer to any question is “yes”, full details must be given.		
(a) Whether at any time during the last 10 years, an application or a petition under any bankruptcy law of any jurisdiction was filed against him or against a partnership of which he was a partner at the time when he was a partner or at any time within 2 years from the date he ceased to be a partner?	No	No
(b) Whether at any time during the last 10 years, an application or a petition under any law of any jurisdiction was filed against an entity (not being a partnership) of which he was a director or an equivalent person or a key executive, at the time when he was a director or an equivalent person or a key executive of that entity or at any time within 2 years from the date he ceased to be a director or an	Yes, in 2020, I was appointed a director in various Xihe Holdings Group subsidiaries by the Judicial Managers (JM). Xihe Holdings Group is part of the Hin Leong Group. My appointment in the Xihe Holdings Group subsidiaries by the JMs was specifically to facilitate the disposal of assets (ships) for eventual account to the creditors. Several of these Xihe Holdings Group subsidiaries are now being liquidated following the cessation of the JM. I was not a	No

ADDITIONAL INFORMATION ON DIRECTORS SEEKING RE-ELECTION

equivalent person or a key executive of that entity, for the winding up or dissolution of that entity or, where that entity is the trustee of a business trust, that business trust, on the ground of insolvency?	Director, nor was I involved in any executive function, of the Xihe Holdings Group subsidiaries prior to the appointment of the JMs in 2020.	
(c) Whether there is any unsatisfied judgment against him?	No	No
(d) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving fraud or dishonesty which is punishable with imprisonment, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such purpose?	No	No
(e) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such breach?	No	No
(f) Whether at any time during the last 10 years, judgment has been entered against	No	No

ADDITIONAL INFORMATION ON DIRECTORS SEEKING RE-ELECTION

him in any civil proceedings in Singapore or elsewhere involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or a finding of fraud, misrepresentation or dishonesty on his part, or he has been the subject of any civil proceedings (including any pending civil proceedings of which he is aware) involving an allegation of fraud, misrepresentation or dishonesty on his part?		
(g) Whether he has ever been convicted in Singapore or elsewhere of any offence in connection with the formation or management of any entity or business trust?	No	No
(h) Whether he has ever been disqualified from acting as a director or an equivalent person of any entity (including the trustee of a business trust), or from taking part directly or indirectly in the management of any entity or business trust?	No	No
(i) Whether he has ever been the subject of any order, judgment or ruling of any court,	No	No

ADDITIONAL INFORMATION ON DIRECTORS SEEKING RE-ELECTION

tribunal or governmental body, permanently or temporarily enjoining him from engaging in any type of business practice or activity?		
(j) Whether he has ever, to his knowledge, been concerned with the management or conduct, in Singapore or elsewhere, of the affairs of:- (i) any corporation which has been investigated for a breach of any law or regulatory requirement governing corporations in Singapore or elsewhere; or (ii) any entity (not being a corporation) which has been investigated for a breach of any law or regulatory requirement governing such entities in Singapore or elsewhere; or (iii) any business trust which has been investigated for a breach of any law or regulatory requirement governing business trusts in Singapore or elsewhere; or (iv) any entity or business trust which has been investigated for a breach of any law or regulatory	No No No No	No No No No

ADDITIONAL INFORMATION ON DIRECTORS SEEKING RE-ELECTION

requirement that relates to the securities or futures industry in Singapore or elsewhere, in connection with any matter occurring or arising during that period when he was so concerned with the entity or business trust?		
(k) Whether he has been the subject of any current or past investigation or disciplinary proceedings, or has been reprimanded or issued any warning, by the Monetary Authority of Singapore or any other regulatory authority, exchange, professional body or government agency, whether in Singapore or elsewhere?	No	No
Disclosure applicable to the appointment of Director only		
Any prior experience as a director of an issuer listed on the Exchange? If yes, please provide details of prior experience. If no, please state if the director has attended or will be attending training on the roles and responsibilities of a director of a listed issuer as prescribed by the Exchange. Please provide details of relevant experience and the nominating committee's reasons for not requiring the director to undergo training	N/A. This is a re-election of a Director.	N/A. This is a re-election of a Director.

***ADDITIONAL INFORMATION ON DIRECTORS SEEKING
RE-ELECTION***

as prescribed by the Exchange (if applicable).		
---	--	--

SHAREHOLDINGS STATISTICS

AS AT 23 MARCH 2026

Issued and fully paid-up share capital	: S\$41,301,100
Class of shares	: Ordinary shares
Number of shares issued	: 150,272,700
Voting rights	: One (1) vote per ordinary share (excluding treasury shares and subsidiary holdings)
Number of treasury shares and percentage	: Nil
Number of subsidiary holdings and percentage	: Nil

DISTRIBUTION OF SHAREHOLDERS BY SIZE OF SHAREHOLDINGS

Size of Shareholdings	No. of Shareholders	% of Shareholdings	No. of Shares	% of Shareholdings
1 – 99	1	0.81	99	0.00
100 – 1000	14	11.38	9,000	0.01
1,001 – 10,000	37	30.08	242,000	0.16
10,001-1,000,000	66	53.66	5,456,701	3.63
1,000,001 and above	5	4.07	144,564,900	96.20
Grand Total	130	100.00	150,272,700	100.00

SHAREHOLDINGS STATISTICS

AS AT 23 MARCH 2026

LIST OF 20 LARGEST REGISTERED SHAREHOLDERS

(as shown in the Register of Members)

No	Name of Shareholder	No. of Shares	% of Shareholdings
1.	EVGENY TUGOLUKOV	117,500,000	78.19
2.	UOB KAY HIAN PRIVATE LIMITED	11,033,500	7.34
3.	HSBC (SINGAPORE) NOMINEES PTE LTD	7,608,200	5.06
4.	DBS NOMINEES (PRIVATE) LIMITED	7,048,800	4.69
5.	PHILLIP SECURITIES PTE LTD	1,374,400	0.91
6.	MOOMOO FINANCIAL SINGAPORE PTE. LTD.	414,600	0.28
7.	TUNG ING HUAT	400,000	0.27
8.	ABN AMRO CLEARING BANK N.V.	343,600	0.23
9.	MAYBANK SECURITIES PTE. LTD.	289,400	0.19
10.	RAFFLES NOMINEES (PTE.) LIMITED	265,200	0.18
11.	CITIBANK NOMINEES SINGAPORE PTE LTD	263,200	0.18
12.	CGS INTERNATIONAL SECURITIES SINGAPORE PTE. LTD.	180,200	0.12
13.	OCBC SECURITIES PRIVATE LIMITED	178,200	0.12
14.	NG SOON HOCK (HUANG SHUNFU)	174,900	0.12
15.	TIGER BROKERS (SINGAPORE) PTE. LTD.	167,800	0.11
16.	ONG EE HAR	160,000	0.11
17.	WU CHUNG SHOU	142,800	0.10
18.	BIN BOON KIM	137,300	0.09
19.	ROSLI LIM BIN ABDULLAH@LIM HUI SEONG	136,200	0.09
20.	ANGELA CHOONG CHIEW FOONG	136,000	0.09
Total		147,954,300	98.47

Based on the information available to the Company as at 23 March 2026, approximately 20.28% of the issued ordinary shares of the Company are held by the public and therefore, Rule 723 of the Catalist Rules has been complied with.

LIST OF SUBSTANTIAL SHAREHOLDERS

(As recorded in the Register of Substantial Shareholders)

Name of Substantial Shareholders	Direct Interest	%	Deemed Interest	%
EVGENY TUGOLUKOV	117,500,000	78.19	6,585,000	4.38

NOTICE OF ANNUAL GENERAL MEETING (“AGM”)

NOTICE IS HEREBY GIVEN that an AGM of UpHealth Group Limited (“**Company**”) will be held at 1 North Bridge Road, #13-06, High Street Centre, Singapore 179094 on 29 April 2026 at 3:00 p.m. (Singapore time) for the following purposes:

As Ordinary Business

1. To receive and adopt the Directors’ Statement and Audited Financial Statements for the financial year ended 31 December 2025, together with the Auditors’ Report thereon. **(Resolution 1)**
2. To re-elect Mr. Gavin Mark McIntyre, retiring by rotation under regulation 94 of the Company’s Constitution. **(Resolution 2)**
- (See Explanatory Note 1)
3. To re-elect Mr. Ravi Chidambaram, retiring by rotation under regulation 94 of the Company’s Constitution. **(Resolution 3)**
- (See Explanatory Note 2)
4. To approve Directors’ fees of \$180,000 for the financial year ending 31 December 2026, payable by the Company in arrears not later than 31 December 2026. **(Resolution 4)**
5. To re-appoint Foo Kon Tan LLP as auditors of the Company for the financial year ending 31 December 2026 and to authorise the Directors of the Company to fix their remuneration. **(Resolution 5)**
6. To transact any other ordinary business that may properly be transacted at an AGM.

As Special Business

To consider and, if thought fit, to pass, with or without modifications, the following resolutions as Ordinary Resolutions:

7. Authority to allot and issue shares

“THAT, pursuant to section 161 of the Companies Act 1967 (“**Companies Act**”) and Rule 806 of the Listing Manual Section B: Rules of Catalist (“**Catalist Rules**”) of the Singapore Exchange Securities Trading Limited (“**SGX-ST**”), authority be and is hereby given to the Directors of the Company to:

- (a) (i) allot and issue shares in the capital of the Company (“**Shares**”) (whether by way of rights, bonus or otherwise); and/or
- (ii) make or grant offers, agreements or options (collectively, “**Instruments**”) that might or would require Shares to be issued, including but not limited to the creation and issue of (as well as adjustments to) warrants, debentures or other instruments convertible or exchangeable into Shares.

NOTICE OF ANNUAL GENERAL MEETING (“AGM”)

- (b) (notwithstanding the authority conferred by this Resolution may have ceased to be in force) issue Shares in pursuance of any Instruments made or granted by the Directors of the Company while this Resolution was in force, provided that:
- (1) the aggregate number of Shares (including Shares to be issued in pursuance of Instruments made or granted pursuant to this Resolution) to be issued pursuant to this Resolution does not exceed 100% of the total number of issued Shares (excluding treasury shares and subsidiary holdings, if any) in the capital of the Company (as calculated in accordance with sub-paragraph (2) below), of which the aggregate number of Shares to be issued other than on a pro-rata basis to shareholders of the Company (including Shares to be issued in pursuance of Instruments made or granted pursuant to this Resolution) does not exceed 50% of the Company’s total number of issued Shares (excluding treasury shares and subsidiary holdings, if any) (as calculated in accordance with sub-paragraph (2) below);
 - (2) (subject to such manner of calculation and adjustments as may be prescribed by SGX-ST), for the purpose of determining the aggregate number of Shares that may be issued under sub-paragraph (1) above, the percentage of issued Shares shall be calculated based on the total number of issued Shares (excluding treasury shares and subsidiary holdings, if any) at the time of the passing of this Resolution, after adjusting for:
 - (a) new Shares arising from the conversion or exercise of any convertible securities;
 - (b) new Shares arising from the exercise of share options or vesting of share awards, provided the options or awards were granted in compliance with Part VIII of Chapter 8 of the Catalist Rules; and
 - (c) any subsequent bonus issue, consolidation or subdivision of Shares.

Adjustments in accordance with sub-paragraph (2)(a) or sub-paragraph (2)(b) above are only to be made in respect of new shares arising from convertible securities, share options or share awards which were issued and outstanding or subsisting at the time of the passing of this Resolution.

- (3) in exercising the authority conferred by this Resolution, the Company shall comply with the provisions of the Catalist Rules for the time being in force (unless such compliance has been waived by the SGX-ST), all legal requirements under the Companies Act and the Constitution for the time being of the Company; and
- (4) (unless revoked or varied by the Company in a general meeting), the authority conferred by this Resolution shall continue in force until the conclusion of the next AGM of the Company or the date by which the next AGM of the Company is required by law to be held or such authority is varied or revoked by the Company in general meeting, whichever is the earlier.”

(See Explanatory Note 3)

(Resolution 6)

NOTICE OF ANNUAL GENERAL MEETING (“AGM”)

8. **Authority to grant options and issue Shares under the Company’s Employee Share Option Scheme**

“THAT pursuant to Section 161 of the Companies Act, the Directors be and are hereby authorised and empowered to grant options, and to allot and issue from time to time such number of Shares as may be required to be issued pursuant to the exercise of options granted under the Company’s Employee Share Option Scheme (“ESOS”) provided always that the aggregate number of Shares in respect of which such options may be granted and which may be issued pursuant to the ESOS, when added to the aggregate number of Shares issued and issuable pursuant to all other share schemes of the Company, shall not exceed fifteen per cent (15%) of the issued share capital of the Company from time to time, and in this resolution, “subsidiary holdings” has the same meaning ascribed to it in the Catalist Rules.”

(See Explanatory Note 4)

(Resolution 7)

BY ORDER OF THE BOARD

CHEN CHUANJIAN, JASON

TAN CHING CHING

Company Secretaries
Singapore

14 April 2026

Explanatory Notes:

1. **Resolution 2**

Mr. Gavin Mark McIntyre, upon re-election, will remain as the Chairman of the Audit and Risk Committee and the member of the Remuneration Committee and the Nominating Committee of the Company. He is considered an Independent Director pursuant to Rule 704(7) of the Catalist Rules of the SGX-ST.

2. **Resolution 3**

Mr. Ravi Chidambaram, upon re-election, will remain as the Chairman of the Remuneration Committee and the member of the Audit and Risk Committee and the Nominating Committee of the Company. He is considered an Independent Director pursuant to Rule 704(7) of the Catalist Rules of the SGX-ST.

Detailed information of these Directors (including information as set out in Appendix 7F of the Catalist Rules of the SGX-ST) can be found in the Section “Additional Information on Directors Seeking Re-election” of the Company’s Annual Report 2025.

NOTICE OF ANNUAL GENERAL MEETING (“AGM”)

3. Resolution 6

The proposed Resolution 6, if passed, will empower the Directors, from the date of the AGM until the next AGM of the Company, to issue Shares and/or Instruments up to an aggregate number not exceeding 100% of the total number of issued Shares excluding treasury shares and subsidiary holdings if any, with a sub-limit of 50% for Shares other than on a pro rata basis to shareholders. For the purpose of determining the aggregate number of Shares that may be issued, the percentage of the total number of issued Shares excluding subsidiary holdings (as defined in the Rules of Catalist) and treasury Shares of the Company will be calculated based on the total number of issued Shares excluding subsidiary holdings (as defined in the Rules of Catalist) and treasury Shares of the Company at the time of the passing of resolution 6, after adjusting for new shares arising from the conversion or exercise of any convertible securities or share options or vesting of share awards, provided the options or awards were granted in compliance with Part VIII of Chapter 8 of the Rules of Catalist and provided further that such adjustments are only to be made in respect of new shares arising from convertible securities, share options or share awards which were issued and outstanding or subsisting at the time of the passing of the resolution; and any subsequent bonus issue, consolidation or subdivision of shares.

4. Resolution 7

The proposed Resolution 7, if passed, will empower the Directors of the Company, to grant options and to allot and issue Shares upon the exercise of such options in accordance with the provisions of the ESOS and pursuant to Section 161 of the Companies Act, to allot, issue and/or deliver from time to time such number of fully paid-up new Shares as may be required to be delivered pursuant to the exercise of the Options granted by the Directors under the ESOS; and (b) subject to the same being allowed by law, apply any Shares purchased under any share purchase mandate and to allot, issue and/or deliver such existing Shares (including treasury Shares) towards the satisfaction of Options granted under the Scheme, provided always that the aggregate number of Shares to be allotted, issued and/or transferred pursuant to the Options under the Scheme on any date, when aggregated with the number of Shares over which options or awards are granted under any other share option schemes or share schemes of the Company, shall not exceed fifteen per cent. (15%) of the total number of issued Shares of the Company excluding subsidiary holdings (as defined in the Rules of Catalist) and treasury Shares on the day preceding that date.

NOTICE OF ANNUAL GENERAL MEETING (“AGM”)
IMPORTANT NOTICE TO SHAREHOLDERS IN RELATION TO THE CONDUCT
AND PROCEEDINGS OF THE COMPANY’S AGM ON 29 APRIL 2026 AT 3:00 P.M.
(SINGAPORE TIME)

Shareholders should take note of the following arrangements for the conduct of the AGM on 29 April 2026.

(a) Attendance:

The AGM is being convened, and will be held, in a wholly physical format in Singapore at 1 North Bridge Road, #13-06 High Street Centre, Singapore 179094 on 29 April 2026 at 3:00 p.m. Members, including CPF Investors and SRS Investors, and, where applicable, duly appointed proxy(ies) and representatives will be able to ask questions and vote at the AGM by attending the AGM in person and they should bring along their NRIC/passport so as to enable the Company to verify their identity. There will be no option for members to participate virtually.

(b) Appointment of Proxies

A member who is not a relevant intermediary is entitled to appoint not more than two (2) proxies. Where such member’s instrument appointing a proxy(ies) appoints more than one (1) proxy, the proportion of the shareholding concerned to be represented by each proxy shall be specified in the instrument.

A member who is a relevant intermediary is entitled to appoint more than two (2) proxies, but each proxy must be appointed to exercise the rights attached to a different share or shares held by such member. Where such member’s instrument appointing a proxy(ies) appoints more than two (2) proxies, the number and class of shares in relation to which each proxy has been appointed shall be specified in the instrument.

“**Relevant intermediary**” has the meaning ascribed to it in Section 181 of the Companies Act 1967 of Singapore.

A proxy need not be a member of the Company.

Duly completed Proxy Forms must be submitted in the following manner:

- (i) if submitted by post, be deposited at the registered office of the Company’s Share Registrar at:

Boardroom Corporate & Advisory Services Pte. Ltd.
1 Harbourfront Avenue
#14-07 Keppel Bay Tower
Singapore 098632

or

- (ii) if submitted electronically, be submitted via email to the Company’s Share Registrar at srs.proxy@boardroomlimited.com.

in each case, not less than 72 hours before the time appointed for holding the AGM, i.e. no later than 3:00 p.m. on 26 April 2026.

NOTICE OF ANNUAL GENERAL MEETING (“AGM”)

A member who wishes to submit an instrument of proxy must complete and sign the Proxy Form, before submitting it by post to the address provided above, or before scanning and sending it by email to the email address provided above. Members are encouraged to submit completed Proxy Forms electronically via email.

A printed copy of the Proxy Form has been despatched to members together with this Notice of AGM, and also published on the SGXNet and the Company’s corporate website at the URL: <http://www.donagroint.com>. In completing the Proxy Form, a member should specifically direct the proxy on how he/she is to vote for or vote against or abstain from voting on the resolutions to be tabled at the AGM.

(c) Questions Relating to the Agenda of the AGM:

Members can submit questions in advance of the AGM or ask questions during the AGM. Members are encouraged to submit questions related to the resolutions to be tabled for approval at the AGM in advance of the AGM.

(i) Submitting questions in advance of the AGM

Members can submit questions relating to the agenda of the AGM in advance of the AGM via electronic mail to: anazaryan@donagroint.com and vnovikov@donagroint.com.

All questions submitted in advance of the AGM via any of the above must be received by 3:00 p.m. on 22 April 2026.

Members who submit questions in advance of the AGM should identify themselves by stating (i) his/her/its full name as it appears on his/her/its CDP/CPF/SRS shares records, (ii) NRIC/Passport/Company registration number and (iii) state the manner in which he/she/it holds his/her/its shares in the Company (e.g. via CDP, CPF or SRS) for verification purposes. The Company will only address relevant and substantive questions (as may be determined by the Company in its sole discretion) received from members. The Company will endeavour to publish its response(s) to relevant and substantive questions received from members prior to the AGM by 3:00 p.m. on 24 April 2026 and/or during the AGM proceedings. Such questions from members and responses from the Company will be published on the Company’s corporate website and the website of the SGX-ST.

(ii) Submitting questions during the AGM

Members and proxyholders attending the AGM will be able to ask questions relating to the agenda of the AGM in person at the AGM venue.

(iii) Where there are substantially similar questions for the AGM, the Company will consolidate such questions. Consequently, not all questions may be individually addressed.

(d) Voting:

Live voting will be conducted during the AGM for members and proxyholders attending the AGM. It is important for members and proxyholders to bring their own web-browser enabled devices for voting at the AGM. For optimal experience, users should update their devices’ operating system and browsers to the latest available versions.

Members and proxyholders will be required to log-in via the e-mail address or unique QR code provided at the AGM.

NOTICE OF ANNUAL GENERAL MEETING (“AGM”)

- i) **Live Voting:** members and proxyholders may cast their votes in real time for the resolutions to be tabled at the AGM. Members and proxyholders will have the opportunity to cast their votes via the live voting feature.

As specified in paragraph (e) below, CPF/SRS Investors who have used their CPF/SRS monies to buy the Company’s share should instead approach their respective relevant intermediary as soon as possible to specify voting instructions.

- ii) **Voting via appointing Chairman as Proxy:** As an alternative to the above, members and proxyholders may also vote at the AGM by appointing the Chairman as proxy to vote on their behalf.

(e) CPF/SRS Investors:

CPF/SRS Investors who have used their CPF/SRS monies to buy the Company’s shares should not make use of the Proxy Form and should instead approach their respective relevant intermediary as soon as possible if they wish to attend the AGM in person or if they wish to appoint the Chairman of the AGM to vote on their behalf. CPF/SRS investors who wish to vote should approach their respective CPF Agent Bank/SRS Operator at least seven (7) working days before the AGM (i.e. by 3:00 p.m. on 17 April 2026), in order to allow sufficient time for their respective CPF Agent Bank/SRS Operator to in turn submit the Proxy Forms no later than the Proxy Deadline.

(f) Access to documents or information relating to the AGM:

All the documents (including the Annual Report 2025, the Proxy Form and the Notice of AGM) or information relating to the business of the AGM have been published and available for download or online viewing by members at the Company’s corporate website at the URL: <http://www.donagroint.com> and the SGX-ST’s website at the URL: <https://www.sgx.com/securities/company-announcements>.

A printed copy of the Annual Report 2025 will not be mailed to members.

For members who wish to receive a printed copy of the Annual Report 2025, please complete the Request Form and submit via email to the Company’s Share Registrar at srs.requestform@boardroomlimited.com by 5:00 p.m. on 22 April 2026.

Notwithstanding the above, printed copies of the following documents will be despatched to members:

- (i) Notice of AGM;
- (ii) Proxy Form for the AGM; and
- (iii) Request Form.

(g) Filming and Photography

When a member or proxyholder attends, speaks and votes at the AGM, he/she consents to his/her videos and/or photographs being taken for the purpose of publication on the Company’s corporate website and publicity materials without further notification.

NOTICE OF ANNUAL GENERAL MEETING (“AGM”)

Notes:

1. A member being a depositor whose name appears in the depository register wishes to attend and vote at the AGM, should complete the Proxy Form and deposit the duly completed Proxy Form in the manner set out under the section titled “IMPORTANT NOTICE TO SHAREHOLDERS IN RELATION TO THE CONDUCT AND PROCEEDINGS OF THE AGM”.

A depositor’s name must appear on the depository register maintained by The Central Depository (Pte) Limited as at 72 hours before the time fixed for holding the AGM in order for the depositor to be entitled to attend and vote at the AGM.

2. The instrument appointing a proxy must be signed by the appointer or his/her attorney duly authorised in writing. Where the instrument appointing a proxy is executed by a corporation, it must be executed either under its common seal or under the hand of any officer or attorney duly authorised. The power of attorney or other authority, if any, under which the instrument of proxy is signed on behalf of the member or duly certified copy of that power of attorney or other authority (failing previous registration with the Company) shall be attached to the instrument of proxy, failing which the instrument may be treated as invalid.

Personal Data Privacy:

Where a member of the Company submits an instrument appointing a proxy(ies) and/or representative(s) to attend, speak and vote at the AGM and/or any adjournment thereof, a member of the Company (i) consents to the collection, use and disclosure of the member’s personal data by the Company (or its agents) for the purpose of the processing and administration by the Company (or its agents) of proxies and representatives appointed for the AGM (including any adjournment thereof) and the preparation and compilation of the attendance lists, proxy lists, minutes and other documents relating to the AGM (including any adjournment thereof), and in order for the Company (or its agents) to comply with any applicable laws, listing rules, regulations and/or guidelines (collectively, the “**Purposes**”); (ii) warrants that where the member discloses the personal data of the member’s proxy(ies) and/or representative(s) to the Company (or its agents), the member has obtained the prior consent of such proxy(ies) and/or representative(s) for the collection, use and disclosure by the Company (or its agents) of the personal data of such proxy(ies) and/or representative(s) for the Purposes.

The member of the Company agrees that he/she/it will indemnify the Company in respect of any penalties, liabilities, claims, demands, losses and damages as a result of his/her/its breach of such warranty.

The member’s personal data and its proxy’s and/or representative’s personal data may be disclosed or transferred by the Company to its subsidiaries, its share registrar and/or other agents or bodies for any of the abovementioned purposes and retained for such period as may be necessary for the Company’s verification and record purpose.

Annual Report 2025
UpHealth Group Limited
(Formerly known as Don Agro International Limited)

PROXY FORM
PROXY FORM

UPHEALTH GROUP LIMITED
(formerly known as DON AGRO INTERNATIONAL LIMITED)
Company Registration No. 201835258H
(Incorporated in the Republic of Singapore)

ANNUAL GENERAL MEETING

PROXY FORM

IMPORTANT

1. The Annual General Meeting (“AGM”) of UpHealth Group Limited (“Company”) is being convened, and will be held at 1 North Bridge Road, #13-06, High Street Centre, Singapore 179094 on Wednesday, 29 April 2026 at 3:00 p.m. (Singapore time). Printed copies of the Annual Report 2025 will NOT be sent to members. Instead, the Annual Report 2025 will be sent to members solely by electronic means via publication at the Company’s corporate website at the URL: <http://www.donagroint.com> and will also be available on the SGXNet at the URL <https://www.sgx.com/securities/company-announcements>.
2. Please read the notes overleaf which contain instructions on, inter alia, the appointment of a proxy(ies).
3. This proxy form is not valid for use and shall be ineffective for all intents and purposes if used or purported to be used by Central Provident Fund (“CPF”) Investors and Supplementary Retirement Scheme (“SRS”) Investors. CPF and SRS Investors (1) may vote at the AGM if they are appointed as proxies by their respective CPF Agent Banks or SRS Operators, and should contact their respective CPF Agent Banks or SRS Operators if they have any queries regarding their appointment as proxies; and (2) may appoint the Chairman of the AGM as proxy to vote on their behalf at the AGM, in which case they should approach their respective CPF Agent Banks or SRS Operators to submit their votes by 3:00 p.m. (Singapore time) on 17 April 2026.
4. By submitting an instrument appointing a proxy(ies), the member accepts and agrees to the personal data privacy terms set out in the Notice of AGM.

*I/We, _____ (name), *NRIC/Passport number/Company registration number
_____ of _____ (address)
being *a member/members of UPHEALTH GROUP LIMITED (the “Company”), hereby appoint:

Name	Email Address	NRIC/Passport No.	Proportion of Shareholdings	
			No. of shares	%

*and/or (delete as appropriate)

Name	Email Address	NRIC/Passport No.	Proportion of Shareholdings	
			No. of shares	%

or if no proxy is named, the Chairman of the AGM, as *my/our proxy to attend, speak and vote for *me/us on *my/our behalf at the AGM to be convened and held at 1 North Bridge Road, #13-06, High Street Centre, Singapore 179094 on

PROXY FORM

Wednesday, 29 April 2026 at 3:00 p.m. (Singapore time) and at any adjournment thereof. *I/We direct *my/our *proxy/proxies to vote for or against or abstain from the Resolutions to be proposed at the AGM as indicated hereunder. If no specific directions as to voting are given, the *proxy/proxies will vote or abstain from voting at *his/her/their discretion, as *he/she/they will on any other matter arising at the AGM. Where the Chairman of the AGM is appointed as proxy and the absence of specific directions as to voting, the appointment of Chairman of the AGM as your proxy for that resolution will be treated as invalid.

*** Delete accordingly**

No.	Resolutions	No. of votes for ⁽¹⁾	No. of votes against ⁽¹⁾	Abstain from voting ⁽¹⁾
Ordinary Business				
1.	To receive and adopt the Directors' Statement and Audited Financial Statements for the financial year ended 31 December 2025, together with the Auditors' Report thereon.			
2.	To re-elect Mr. Gavin Mark McIntyre, who is retiring by rotation under regulation 94 of the Company's Constitution.			
3.	To re-elect Mr. Ravi Chidambaram, who is retiring by rotation under regulation 94 of the Company's Constitution.			
4.	To approve Directors' fees of \$180,000 for the financial year ending 31 December 2026, payable by the Company in arrears not later than 31 December 2026.			
5.	To re-appoint Foo Kon Tan LLP as auditors of the Company and to authorise the Directors to fix their remuneration.			
Special Business				
6.	To authorise the Directors to issue and allot shares and/or instruments pursuant to Section 161 of the Companies Act 1967.			
7.	To authorise the Directors to grant options and issue shares under the Company's Employee Share Option Scheme.			

⁽¹⁾ If you wish to exercise all your votes "For" or "Against" or "Abstain", please indicate with a tick "✓" within the box provided. Alternatively, please indicate the number of votes as appropriate.

Dated this _____ day of _____ 2026.

Signature(s) of Member(s)/Common seal <u>IMPORTANT: PLEASE READ NOTES OVERLEAF.</u>	Total number of shares in:	Number of shares
	(a) CDP Register	
	(b) Register of Members	
	TOTAL	

Annual Report 2025
UpHealth Group Limited
(Formerly known as Don Agro International Limited)

PROXY FORM

Notes to Proxy Form

1. Please insert the total number of shares held by you. If you have shares entered against your name in the depository register (maintained by The Central Depository (Pte) Limited), you should insert that number of shares. If you have shares registered in your name in the Register of Members of the Company (maintained by or on behalf of the Company), you should insert that number of shares. If you have shares entered against your name in the depository register and shares registered in your name in the Register of Members, you should insert the aggregate number of shares. If no number is inserted, this form of proxy will be deemed to relate to all the shares held by you.
2. A member who is not a relevant intermediary is entitled to appoint not more than two proxies. Where such member's instrument appointing a proxy(ies) appoints more than one proxy, the proportion of the shareholding concerned to be represented by each proxy shall be specified in the instrument.
3. A member who is a relevant intermediary is entitled to appoint more than two proxies, but each proxy must be appointed to exercise the rights attached to a different share or shares held by such member. Where such member's instrument appointing a proxy(ies) appoints more than two proxies, the number and class of shares in relation to which each proxy has been appointed shall be specified in the instrument.

"Relevant intermediary" has the meaning ascribed to it in Section 181 of the Companies Act 1967.

4. A proxy need not be a member of the Company.
5. This Proxy Form may be accessed at the Company's corporate website at the URL: <http://www.donagroint.com> and will also be made available on the SGXNet at the URL: <https://www.sgx.com/securities/company-announcements>.
6. Investors who hold shares through relevant intermediaries, including investors who buy shares using CPF monies ("CPF Investor") or SRS monies ("SRS Investor"), and who wish to appoint the Chairman of the AGM to act as their proxy should approach their respective relevant intermediaries, including CPF Agent Banks or SRS Operators, to submit their votes at least seven (7) working days before the AGM and in any case, no later than 3:00 p.m. (Singapore time) on 17 April 2026.
7. The Proxy Form must be under the hand of the appointor or his attorney duly authorised in writing. Where the Proxy Form is executed by a corporation, it must be executed under its common seal or under the hand of its attorney duly authorised. Where the Proxy Form is signed on behalf of the appointor by an attorney, the letter or power of attorney or a duly certified copy thereof must (failing previous registration with the Company), if the Proxy Form is submitted by post, be lodged with the Proxy Form, or if the Proxy Form is submitted electronically via email, be emailed with the Proxy Form, failing which the Proxy Form may be treated as invalid.
8. The Proxy Form, together with the power of attorney or other authority, (if any) under which it is signed, or a notarial certified copy, must be submitted to the Company in the following manner:
 - (a) if submitted by post, be deposited at the registered office of the Company's Share Registrar at Boardroom Corporate & Advisory Services Pte. Ltd. at 1 Harbourfront Avenue, #14-07 Keppel Bay Tower, Singapore 098632; or
 - (b) if submitted electronically, be submitted via email to the Company's Share Registrar at srs.proxy@boardroomlimited.com,

in either case, not less than 72 hours before the time appointed for holding the AGM, i.e. no later than 3:00 p.m. (Singapore time) on 26 April 2026.

A member who wishes to submit the Proxy Form must first download, complete and sign the Proxy Form, before submitting it by post to the address provided above, or before scanning and sending it by email to the email address provided above.

9. A depositor shall not be regarded as a member of the Company entitled to attend the AGM and to vote thereat unless his name appears on the depository register as at 72 hours before the time appointed for holding the AGM.
10. Completion and return of an instrument appointing a proxy(ies) shall not preclude a member from attending, speaking and voting in person at the AGM. Any appointment of proxy(ies) shall be deemed to be revoked if a member attends the AGM in person, and in such event, the Company reserves the right to refuse to admit any person or persons appointed under the relevant instrument appointing a proxy(ies) to the AGM.
11. The Company shall be entitled to reject the Proxy Form if it is incomplete, improperly completed or illegible or where the true intentions of the appointor are not ascertainable from the instructions of the appointor specified in the Proxy Form. In addition, in the case of members of the Company whose shares are entered against their names in the depository register, the Company may reject any Proxy Form lodged if such members are not shown to have shares entered against their names in the depository register as at 72 hours before the time appointed for holding the AGM as certified by The Central Depository (Pte) Limited to the Company.

Personal Data Privacy:

By submitting this Proxy Form, the member accepts and agrees to the personal data privacy terms set out in the Notice of AGM dated 14 April 2026.